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 Peripheral T-cell lymphoma (PTCL) encompasses a heterogenous group of tumors 
derived from neoplastic T-cells that affect the peripheral lymphoid organs, most often the 
peripheral lymph nodes.  PTCL is a naturally-occurring disease in multiple species, including 
humans and dogs. This disease is poorly understood and associated with short overall survival 
times in both canine and human patients. PTCL is relatively more common in dogs, and 
therefore the dog provides a unique opportunity to serve as a naturally occurring model.  
Hypothesis: We hypothesize that canine PTCL and a subset of human PTCL have shared 
pathologic features and molecular drivers; therefore, the dog will provide a useful translational 
model to aid in the discovery of novel, targeted therapies.  We test this hypothesis by 1) 
characterizing tumor heterogeneity, biologic behavior, and gene expression profile of canine 
PTCL 2) comparing the molecular features of canine PTCL to those previously identified in 
human PTCL 3) identifying the normal immunological counterpart(s) of canine PTCL and 4) 
discovering oncogenic molecular pathways and driving genetic alterations including fusion 
genes.  
Aim 1: Characterization of the histomorphology, clinical features, and gene 
expression profile of canine PTCL. Our understanding of the biologic and molecular subtypes 
of lymphoproliferative diseases in dogs is scarce compared to what is known about similar 
diseases in humans. Within the T-cell lymphoma (TCL) group, tumors can be categorized by 
expression of the surface antigen molecules CD4 and CD8, with the majority of TCL cases in 
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dogs expressing CD4. CD4+ TCL has been previously associated with a poor prognosis and short 
overall survival times. Tumors expressing CD8 or lacking expression of CD4 or CD8 are 
considered rare. In an effort to better characterize these TCL phenotypes we evaluated a large 
number of cases with paired flow cytometry and biopsy samples to determine if tumors 
diagnosed as TCL by flow cytometry identified distinct lymphoma subtypes with consistent 
histologic and molecular features. All evaluated tumors diagnosed as CD4+ TCL had a histologic 
pattern and cellular morphology consistent with PTCL. RNA-seq was performed on a small 
group of CD4+ PTCL cases compared to sorted non-neoplastic CD4+ lymphocytes. The gene 
expression pattern of CD4+ TCL was similar between all cases, regardless of dog breed. We then 
focused on the less common CD8+ and CD4-CD8- subgroups. A small subset of CD8+ and CD4-
CD8- tumors were evaluated histologically or cytologically. Tumor morphology was consistent 
with PTCL, but exhibited increased variation in cytologic appearance with some cases displaying 
marked atypia. We then evaluated the presenting clinical signs, flow cytometry, and clinical 
outcomes of a large group of dogs diagnosed with either CD8+ or CD4-CD8- TCLs. Dogs with 
either CD8+ or CD4-CD8- TCLs had aggressive clinical disease with short overall survival times. 
Skin lesions present at the time of diagnosis were more commonly observed in the CD8+ TCL 
group. Mediastinal enlargement and/or hypercalcemia, clinical features previously associated 
with CD4+ TCL, were more commonly present in patients with CD4-CD8- TCL. Shared 
diagnostic and clinical features identified in both CD4-CD8- and CD4+ TCLs suggested a 
common pathogenesis. Conversely, CD8+ TCLs exhibited unique clinical features and prognostic 
indicators suggesting that these tumors may have a different pathobiology.   
Aim 2: Evaluation of canine PTCL as a model for human PTCL-NOS. In humans, 
peripheral T-cell lymphoma (PTCL), not-otherwise specified (NOS) is the most common PTCL 
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subgroup. Recent studies using human patient samples have identified molecular subtypes of 
PTCL-NOS, including PTCL-GATA3 and PTCL-TBX21. PTCL-GATA3 is associated with a 
worse prognosis and frequent alterations in the CDKN2A/TP53 and PTEN-PI3K signaling 
pathways. We identified molecular similarity to human PTCL-NOS by evaluating the gene 
expression profiles of a large number of canine PTCL cases by RNA-seq. We show that canine 
PTCL is most similar to the PTCL-GATA3 subgroup, with strong expression of GATA3 and 
gene enrichment for the PI3K-AKT-MTOR pathway. In vitro cell culture studies established a 
functional role for PI3K signaling in canine PTCL. Inhibition of PI3K resulted in impaired 
proliferation of a canine T-cell lymphoma cell line and reduced survival of primary patient-
derived PTCL cells. We show that the dog may provide a unique opportunity to further 
investigate the pathogenesis of the PTCL-GATA3 subgroup.  
Aim 3:  Evaluation of canine PTCL cell of origin. Classification of hematopoietic 
neoplasms is in part reliant upon identification of the cell of origin, which can provide insights 
into the underlying pathogenesis and can have prognostic and therapeutic impact. We evaluated 
surface protein expression and changes in gene expression in canine PTCL to identify the normal 
immunological counterpart. We demonstrated that CD4+ PTCL appears to be derived from a 
naïve single positive T-cell. This conclusion is supported by lack of expression of markers of 
activation (MHC class II, CD25, and T-cell receptor signaling molecules) as well as lack of 
upregulation of markers associated with T helper subsets. CD4-CD8- tumors were enriched for 
gene signatures associated with a more immature T-cell phenotype, and therefore are thought to 
most likely develop from an immature, double negative, thymic precursor cell.  CD8+ TCLs 
upregulated molecules associated with activated cytotoxic T-cells, suggesting that at least a 
subset of CD8+ TCLs may originate from a mature CD8+ effector cell.  
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Aim 4: Discovery of fusion gene candidates in canine PTCL. Chromosome aberrations 
and rearrangements resulting in the formation of fusion genes are common in a wide variety of 
cancers. Fusion genes are particularly common drivers of hematologic malignancies (e.g., AML) 
and serve as useful diagnostic markers as well as therapeutic targets. We aimed to discover 
fusion gene candidates in canine PTCL using FusionCatcher, an RNA-seq based discovery 
pipeline. We identified 11 recurrent fusion genes of interest and evaluated the structural fusion 
events in these cases. Recurrent fusion genes involving DGKZ-MDK and LMO4 with several 5’ 
fusion partners were particularly interesting due to their oncogenic potential. This study 
identifies a list of potential fusion gene candidates in canine PTCL, and lays the groundwork for 
future efforts to validate these targets.  Identification of these potential driving fusion genes is 
critical for both improving diagnosis, as well as the development of targeted and personalized 
therapeutics.  
Conclusions: This dissertation improves mechanistic understanding of the molecular and 
genetic drivers of canine PTCL and correlates these findings to the human counterpart of the 
disease. In so doing, we provide essential supporting evidence that the dog may serve as a useful 
and relevant, naturally occurring, translational model of hematopoietic neoplasia. In a broader 
sense, this work supports a comparative approach to understanding cancer biology and treatment 
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T-cell Development and the Classification of Lymphoid Neoplasms  
Overview 
Lymphoma is a broad term used to describe clonal tumors of mature and immature B-
cells, T-cells, and NK cells at various stages of differentiation. Classification of lymphoma is 
reliant on a number of diagnostic features including cellular morphology, immunophenotype, 
genetic abnormalities, and clinical presentation. Neoplastic cells often appear to recapitulate 
stages of normal B-cell or T-cell development, and therefore classification is often based, at least 
in part, according to the corresponding normal counterpart.  
T-cells are key effectors of cell-mediated immunity and their development and 
differentiation involves a complex and tightly regulated series of events. T-cells are highly 
specialized to combat microbial pathogens, mediate immune surveillance against tumor cells, 
and coordinate antigen-driven responses. These cells originate from hematopoietic precursors 
which migrate to the thymus, differentiate, undergo selection, and eventually mature into 
functional T-lymphocytes (Figure 1.1).1  
Thymic Development 
T-cells arise from bone marrow progenitor cells that emigrate to the thymus to mature 
and undergo gene rearrangements to produce their antigen receptors.2As multipotent progenitors 
leave the bone marrow and travel to the thymus, they become progressively more restricted in 
their fate options.3 Progenitor cells can be identified by expression of cell-surface markers that 
characterize stem cells such as CD34, and lack of the characteristic cell-surface glycoproteins of 
mature T-cells.4–7 Following emigration to the thymus and interaction with thymic stromal cells, 
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these cells are signaled to divide and differentiate. IL-7 is secreted by thymic stromal cells and 
binds to the IL-7 receptor on thymocytes.4,8–10 This interaction is critical for T-cell development. 
Knockdown of the IL-7 receptor experimentally or within patients who have inherited two 
defective IL-7R alleles results in the absence of T-cells and subsequent immunodeficiency.8,11–13  
Thymic stromal cells are also important in promoting activation of the Notch1 pathway, a 
major regulator of T-cell development.14 Notch1 is a cell-surface receptor that is expressed on 
the surface of thymocytes and interacts with the ligands present on thymic epithelial cells.15–17 
Notch1 is vital for T-cell commitment and inhibition of B-cell differentiation.18,19 The critical 
role of Notch1 is highlighted by studies in which mice that are reconstituted with bone-marrow 
precursors expressing a constitutively active form of Notch completely lack B-cell development. 
Instead, these mice develop CD4+CD8+ double positive (DP) cells in the bone marrow.19  
Furthermore, Notch-1 deficient mice exhibit a block of T-cell development and concurrent 
development of B-cells within the thymus.18 
T-lymphoblastic leukemia/lymphoma is derived from T-cell progenitors within the bone 
marrow and early thymic T-cell progenitors. These precursor neoplasms are typically identified 
by the expression markers of immaturity including: CD34, TdT, CD1a, and CD99.20–22 
Activating mutations of the NOTCH1 gene are present in greater than 50% of T-ALL patients, 
demonstrating deregulation of normal thymic development in these patients.23,24 
 Differentiation of progenitor cells is dependent upon temporally coordinated expression 
of cell surface proteins, including CD4, CD8, CD44, and CD25 on the thymocytes.25 Progenitor 
cells entering the thymus do not express CD4 or CD8 and are therefore termed double-negative 
(DN) thymocytes.26 DN thymocytes progress through DN1 (CD44+CD25-), DN2 
(CD44+CD25+), DN3 (CD44-CD25+) and DN4 (CD44-CD25-)stages.1,2,27 At this stage, 
 3 
rearrangement of the T-cell receptor (TCR) g, d, and b loci can occur and DN thymocytes give 
rise to two distinct lineages of T-cells, distinguished by the expression of an a:b or g:d T-cell 
receptor (TCR).28–30 This process is termed b-selection. 
Commitment to a a:b or g:d T-cell lineage is determined by productive or non-productive 
rearrangements of TCR genes. TCR gene rearrangement is analogous to immunoglobulin gene 
rearrangements undergone during B-cell development. The b and d chains contain V,D, and J 
segments. The first rearrangement for a b or d chain joins D to J and the second rearrangement 
Figure 1.1 Overview of thymic T-cell development. Bone marrow derived hematopoietic progenitors migrate 
to the thymus. Early thymic precursors lack expression of T-cell receptor (TCR), CD4 and CD8, and are termed 
double-negative (DN) thymocytes. DN thymocytes undergo four stages of differentiation (DN1, CD44+CD25−; 
DN2, CD44+CD25+; DN3, CD44−CD25+; and DN4, CD44−CD25−). As cells progress through the DN stages, 
they undergo TCR gene rearrangement and B-selection, resulting in formation of the pre-TCR. Successful 
formation of a pre-TCR results in cell proliferation and expression of CD4 and CD8, termed double positive 
(DP) thymocytes. The pre-TCR α-chain is then replaced with a newly rearranged TCR α-chain, resulting in a 
complete αβ TCR. DP thymocytes undergo positive selection by interacting with cortical epithelial cells that 
express MHC class I and class II molecules and present self-peptides. A weak interaction results in apoptosis. 
Thymocytes that express TCRs that bind to MHC class I molecules become single positive (SP) CD8+ T-cells 
and those with TCRs that bind to MHC class II molecules become SP CD4+ T-cells. Cells further undergo 
negative selection, which results in removal of cells that interact too strongly with self-peptides on 
hematopoietic antigen presenting cells. Commitment to the CD4+ lineage is dependent upon key transcription 
factors ThPOK, GATA3, TOX, and Ikaros whereas commitment to the CD8+ lineage is dependent on the 
transcription factor Runx3. 
 
 4 
joins V to DJ. The a and g chains contain only V and J segments and therefore, a single 
rearrangement joins the V and J.31 The process of gene rearrangement is regulated by the genes 
RAG1 and RAG2 (recombination-activating genes), and involves the enzyme TdT which inserts 
the N nucleotides.32,33 Both a:b and g:d T-cells begin rearranging the g,d, and b TCR loci at the 
DN stage. If an individual thymocyte is able to make a successful g:d receptor prior to a 
functional b chain, then the cell commits to become a g:d T-cell.28,34 Conversely, if a functional b 
chain is created first this receptor chain is incorporated into a pre-TCR. The pre-TCR is formed 
by binding of the b chain to an invariant polypeptide termed pTa to form a superdimer.35,36 
 This pre-TCR is a rigorous test of the b chain conformation and its potential to bind the 
a chain to form a functional TCR. The a:b lineage is favored because the a:b lineage only 
requires one productive rearrangement, whereas g:d lineage requires two productive 
rearrangements.37 Following formation of a pre-TCR, gene rearrangements are halted by 
suppression of RAG1 and RAG2, proliferation is induced, and the thymocytes gains expression of 
the CD4 and CD8 co-receptors and are then termed double-positive (DP) thymocytes.38–40 Upon 
progression into the DP stage, cells are allowed to continue with TCR chain rearrangement 
including a-chain genes and continued g and d gene rearrangements. At this stage, if a DP 
thymocyte creates an a:b receptor prior to a g:d receptor it will commit to a:b lineage. 
Alternatively, if a g:d receptor is created first than it will commit to the g:d lineage.41 Cells with 
functional g:d rearrangements then assemble with the CD3 signaling complex and leave the 
thymus to enter circulation and migrate to peripheral tissues.42  If the thymocyte fails to create a 
functional TCR gene rearrangement, then the cell will undergo apoptosis and be phagocytosed 
by thymic cortical macrophages.43,44 Peripheral g:d cytotoxic T-cells of the splenic pool are 
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believed to be the cell-of-origin of hepatosplenic T-cell lymphomas (HSTL)45.  A smaller 
fraction of HSTL, are believed to be derived from a:b cytotoxic T-cells.20,46 
The process of TCR gene rearrangement produces a highly diverse repertoire of TCRs 
that can interact with MHC class I and class II isoforms. However, the TCR genes of an 
individual are not specific for the forms of MHC molecules expressed by that same individual. 
Therefore, positive selection is a necessary process that occurs to select only the thymocytes that  
can recognize the self-MHC complexes expressed on thymic cortical epithelial cells.47,48 
Following positive selection, DP thymocytes differentiate into single-positive (SP) CD4 or CD8 
T-cells. When a DP thymocyte interacts with an MHC class I molecule, CD8 molecules are 
recruited. Conversely, when a DP thymocyte interacts with an MHC class II molecule, CD4 
molecules are selected.49,50 This stage of T-cell development is highly regulated by changes in 
gene expression and defined by detectable cell-surface phenotypes.  In particular, the T-helper-
inducing POZ/Krueppel-like factor (Th-POK), GATA3, TOX, and Ikaros are key regulatory 
transcription factors that drive the development of SP CD4 thymocytes from DP 
thymocytes.47,51–56 Conversely, Runx3 directs commitment to the CD8 lineage.57,58  
Following commitment to a SP lineage, T-cells undergo the process of negative selection. 
This process removes cells whose antigen receptor binds too strongly to the complexes of self-
peptides and self-MHC molecules presented by cells within the thymus, including bone marrow 
derived dendritic cells and macrophages. This process of negative selection is critical for the 
elimination of potentially autoreactive T-cells and prevention of subsequent autoimmune 
disease.25,59,60  
a:b T-cells that survive the processes of positive and negative selection and commit to 
CD4 or CD8 single positive lymphocytes, are able to leave the thymus as naïve T-cells. These 
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cells enter the circulation and travel to secondary lymphoid tissues. Within secondary lymphoid 
tissues, naïve T-cells can interact with specific antigens and become activated. Antigen-exposure 
triggers proliferation and further differentiation into the effector T-cell subsets.  
T-cell Activation 
 Adaptive immune responses are coordinated to maximize exposure of lymphocytes to 
potential antigens. Essential to this process, are myeloid dendritic cells (DCs), which capture 
antigens at the site of infection and then travel to secondary lymphoid tissues to present to naïve 
T-cells. The dendritic cells express pathogen-derived peptides on MHC molecules. Binding of 
the T-cell to the dendritic cell involves binding of the T-cell LFA-1 to ICAM-1 and ICAM-2 on 
the DC, as well as binding of the DC LFA-1 to ICAM-3 expressed on the T-cell.61 ICAM-3 also 
binds to the adhesion molecule DC-SIGN, which is uniquely expressed on activated DCs.62,63 
These cell surface interactions promote binding of the antigen receptor to the peptide-MHC 
complexes on the surface of a DC. The binding of the TCR and co-receptor (CD4 or CD8) with 
the MHC complex is necessary, but not sufficient, for T-cell activation. A co-stimulatory signal 
is also required and is induced by binding of the co-stimulatory receptor CD28 on T-cells to its 
ligand B7 on DCs.64,65  
 Upon organization of the molecules on the T-cell membrane and formation of the 
immunological synapse, cytoplasmic protein tyrosine kinases are activated to phosphorylate 
tyrosine residues in the cytoplasmic tails of the CD3 cell-surface proteins and the associated  z 
chain (CD247). The phosphorylated residues are a component of the immunoreceptor tyrosine-
based activation motifs (ITAMs). One of the molecules that phosphorylates the CD3 ITAMs is 
Lck.66 Lck also actives ZAP-70, another protein kinase, which is necessary for the initiation of 
the major pathways of T-cell activation and signaling.67 ZAP-70 initiates cell signaling pathways 
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including nuclear factor of activated T-cells (NFAT), activating protein-1 (AP-1), and NFkB 
which ultimately result in transcription of genes that promote T-cell proliferation, differentiation, 
and effector function.68,69 Particularly important for T-cell proliferation is the cytokine IL-2. IL-2 
works in an autocrine manner to trigger cell division.70  
 A number of T-cell neoplasms are derived from activated T-cells. Skin-homing activated 
T-cells are believed to be the normal counterpart to cutaneous lymphoma syndromes including 
mycosis fungoides, primary cutaneous CD30-positive T-cell lymphoproliferative disorders, and 
primary cutaneous anaplastic large cell lymphoma.20,71 
Differentiation of Activated T-cell Subsets 
Differentiation of activated T-cells is dependent upon the antigen to which they are 
responding.  CD8 T-cells, which interact with MHC class I molecules, are particularly important 
for defense against intracellular pathogens, such as viruses and bacteria, as well as for tumor 
surveillance.72 CD8 T-cells are considered cytotoxic and can release cytotoxins including 
perforin, granzymes, and granulysin to trigger cell-death via apoptosis.73  
T-cell large granular lymphocytic leukemias (T-LGLs) are believed to be derived from a 
subset of CD8+ a:b T-cells. A smaller portion of LGL leukemias are derived from natural killer 
cell lineage.74,75 T-LGLs can express the cytotoxic effector proteins including perforin, TIA1, 
granzyme B, and granzyme M.20 This neoplasm is thought to be driven by an initial exposure to 
an unknown antigen which results in oligoclonal LGL expansion.76 Chronic and persistent 
antigen exposure results in STAT3 activation and the development of a dominant clone. This 
proposed pathogenesis is supported by serial studies of T-cell repertoire utilization.77  
Effector CD4 T-cells, on the other hand, do not directly attack pathogens but rather help 
other cells of the immune system to perform their necessary functions and coordinate an 
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appropriate immune response. CD4 T-cells are therefore, termed T-helper cells. CD4 T-helper 
cells are highly heterogenous in their functions, cell-surface marker expression, and cytokine 
secretion. Classification of CD4 T-helper cell subsets is a continually evolving field with new 
subtypes being identified and overlapping features amongst existing subtypes. Nevertheless, 
there are five major T-helper subtypes identified: Th1, Th2, Th17, T follicular helper cells (Tfh), 
and regulatory T-cells (Treg).  
Th1 cells aid in macrophage responses to intracellular bacterial and viral infections. 
Differentiation of Th1 cells is induced by the cytokines IL-12 and INF-g to activate the defining 
transcription factor T-bet (TBX21). TBX21 regulates expression of INF-g and can repress Th2 
cytokines, Il-4 and IL-5.78 Activated Th1 cells secrete IL-12 and INF-g to further promote Th1 
differentiation.  
Th2 cells aid in the response to parasitic infections mediated by eosinophils, basophils, 
and mast cells. In addition, Th2 lymphocytes play a role in the repair and recovery of tissues 
injured by inflammatory processes.  Th2 cell differentiation is induced by secretion of IL-4 
which activates the major transcription factor GATA3.79–81 GATA3 activation then promotes 
upregulation and secretion of IL-4 and IL-5. The balance between Th1 and Th2 T-cell subsets 
plays a role in determining the susceptibility to disease states, where an improper skew of Th2 
cells can lead to allergy and asthma and an overactive Th1 response can result in 
autoimmunity.82 
Th17 cells work to promote neutrophil-mediated responses to extracellular bacterial and 
fungal infections.83–85 Th17 cell differentiation is induced by IL-6, TGF-!, Il-21, and IL-23, 
which promote transcription of RORgT.86  RORgT is the master regulator of the Th17 subgroup 
and works to induce transcription of genes encoding IL-17 and IL-17F in naïve CD4+ T helper 
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cells.86  Th17 cells then secrete IL-17 and IL-6. IL-17 aids in recruiting neutrophils to sites of 
infection.87  
Tfh cells interact with naïve B-cells to promote the antibody-mediated response to 
infection. The cytokine IL-6 promotes Tfh cell differentiation and induces expression of Bcl6, 
the master regulator of this subgroup.88–91 Bcl6 is required for Tfh cells to express CXCR5, the 
receptor for the CXCL13 chemokine produced by the stromal cells of the B-cell follicle. The 
CXCR5-CXCL13 interaction allows Tfh cells to leave the T-cell areas of the secondary 
lymphoid tissue and migrate to the B-cell follicles.92 Tfh cells secrete IL-21 and IL-4 which aid 
in class-switching, as well as formation and maintenance of the germinal center.93,94 
Angioimmunoblastic T-cell lymphomas (AITL) are derived from Tfh cells and express 
the key markers BCL6, CXCR5, CD10, and CXCL13.95–98 Patients with AITL often present with 
autoimmune phenomena including circulating immune complexes, cold agglutinins, hemolytic 
anemia, rheumatoid factor and anti-smooth muscle antibodies. Additionally, approximately half 
of patients have a concurrent polyclonal hypergammaglobulinemia, consistent with secondary 
disruption of normal B-cell physiology.99,100  
Treg cells are unique in that they work to dampen the immune response.  Tregs are 
induced by TGF-! in the absence of IL-6 and other pro-inflammatory cytokines.101 Tregs 
express the master transcription factor FoxP3 as well as the cell-surface molecule CD25.102 
Activated Tregs secrete TGF-! and IL-10, which are important inhibitors of inflammation and 
immune responses.103 Adult T-cell leukemia/lymphoma (ATLL) is postulated to be derived from 
CD4+ CD25+ FoxP3+ Tregs104 and patients with ATLL characteristically exhibit T-cell 
immunodeficiency and frequent opportunistic infections20,105–107.  
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Peripheral T-cell Lymphomas  
Overview 
Peripheral T-cell lymphomas (PTCL) encompass a heterogenous group of aggressive T-
cell neoplasms. These neoplasms are uncommon, comprising 5-20% of all non-Hodgkin 
lymphomas (NHL).20,108 This group of neoplasms includes tumors classified as 
angioimmunoblastic T-cell lymphoma, ALK+ anaplastic large cell lymphoma, ALK- anaplastic 
large cell lymphoma, adult T-cell leukemia/lymphoma (ATLL) and extranodal NK/T cell 
lymphoma of nasal type. Approximately 30-50% of PTCL cases do not correspond specifically 
to defined T-cell entities in the World Health Organization classification and are therefore 
categorized as PTCL, not otherwise specified (NOS).20,109,110 Advances in the understanding of 
the underlying pathobiology of PTCL-NOS and development of targeted treatments have been 
limited by the disease heterogeneity, rarity, and lack of appropriate animal model systems.111  
 PTCL-NOS affects older patients with a median age of 60 years at the time of 
presentation and more commonly affects males, with a reported 2:1 male-to-female ratio.109 
Patients most often exhibit peripheral lymph node involvement. Advanced disease stages are 
common at the time of presentation.  Patients typically exhibit poor overall responses to 
anthracycline-based chemotherapeutic protocols such as combination cyclophosphamide, 
doxorubicin hydrochloride, vincristine sulfate, and prednisone (CHOP) chemotherapy, which is 
considered the standard of care.110  
Molecular Classification of PTCL-NOS 
Because PTCL-NOS encompasses a group of tumors that do not correspond to other 
defined entities defined by the World Health Organization classification, cases can exhibit a 
broad spectrum of cytologic, histologic, and molecular features. Recent gene expression profiling 
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studies have improved the ability to further classify these cases. Firstly, genetic profiling studies 
have identified a small subset of cases previously classified as PTCL-NOS that exhibit features 
of Tfh cell origin, leading to the development of new distinction within the WHO classification 
termed follicular T-cell lymphoma (PTCL-Tfh). These cases exhibit some morphological, 
immunophenotypic, genetic, and clinical overlap with AITL but also have a number of unique, 
distinctive features precluding inclusion in the AITL phenotype.20,112 Overlapping features 
between AITL and PTCL-Tfh include genetic alterations associated with Tfh origin such as 
TET2, RHOA, DNMT3A, IDH2 mutations113–116 as well as expression of Tfh cell phenotypic 
markers CD4, CD10, CXCL13, and BCL6.  
The PTCL-NOS cases that cannot be reclassified as Tfh cell origin can be classified into 
two major subgroups based on GATA3 or TBX21 molecular signatures, termed PTCL-GATA3 
and PTCL-TBX21.117–119 PTCL-GATA3 is associated with a worse prognosis and a 5-year OS of 
19% compared to PTCL-TBX21, which has a 5-year OS of 38%. The majority of cases within 
the PTCL-GATA3 group exhibit a CD4+CD8- immunophenotype.120 Histologically, PTCL-
GATA3 group displays a monotonous pattern of intermediate to large cells with a minimal 
inflammatory background.120 The GATA3 phenotype is enriched in gene signatures related to 
cell proliferation including MYC, PI3K-ATK-MTOR, and b-catenin. PTCL-GATA3 also 
exhibits increased genetic abnormalities including frequent loss or mutation of tumor suppressor 
genes involving the CDKN2A, TP53, RB1 and PTEN-PI3K pathways. Co-occurrence of 
impaired TP53 signaling and loss of PTEN are significantly associated with PTCL-GATA3. This 
combination of tumor suppressor gene aberrations is infrequent in other PTCL-NOS subtypes 
and other T-cell NHLs.119 Simultaneous amplifications of STAT3 and MYC were also identified 
in a subset of PTCL-GATA3 cases.119 Similarly, recurrent gene fusions and alterations involving 
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components of the T-cell receptor signaling pathways including VAV1, ITK, SYK, PTPRC, 
PLCGI or proliferation pathways including TP63, CDKN2A, PTEN, and TP53 have been 
described by multiple groups in a proportion of PTCL-NOS cases.119,121–124  
Alternatively, PTCL-TBX21 exhibits a more heterogenous immunophenotype with half 
of cases being CD4+CD8- immunophenotype, approximately a third of cases being CD8+CD4-, 
and fewer CD4-CD8- or CD4+CD8+ cases.120 These tumors are exhibit by a polymorphous 
histologic appearance characterized by variably-sized neoplastic cells admixed with high 
numbers of inflammatory cells including small lymphocytes, eosinophils, plasma cells, and 
histiocytes. A portion of PTCL-TBX21 cases have a lymphohistioyctic pattern comprised of 
atypical small neoplastic cells admixed with aggregates of epithelioid histiocytes.120 The TBX21 
phenotype is enriched in the INF-g and NF-kB gene signatures.  PTCL-TBX21 generally 
exhibits fewer genetic aberrations, and those present primarily involve cytotoxic effector genes 
or regulators of DNA methylation.119 A higher proportion of cases within the TBX21 subgroup 
also exhibit upregulation of transcripts associated with cytotoxic T-cells as well expression of T-
cell restricted intracellular antigen-1 (TIA-1) and/or granzyme B by immunohistochemistry.120  
Novel Therapies for PTCL-NOS 
 Conventional treatment for PTCL-NOS involves anthracycline based chemotherapy, like 
CHOP. CHOP-based protocols, however, typically do not result in durable remission and relapse 
or refractory disease is common.110 Targeted and personalized therapies are therefore an 
important and emerging field for improved outcomes for patients with PTCL-NOS.  
 Platelet-derived growth factor receptors (PDGFRs) are tyrosine kinase receptors critical 
for regulation of a number of cellular processes including cellular proliferation, development, 
differentiation, and inflammatory responses.125 Aberrant PDGFR has been identified in a number 
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of cancers and receptor tyrosine kinase (RTK) inhibitors have been developed as a targeted 
therapeutic approach.125,126 PDGFRs activation can result in stimulation of multiple signaling 
cascades including MAPK, PI3K, and PLCg pathways.127  PTCL-NOS has been shown to 
overexpress PDGFRa and PDGFR activity has been shown to promote neoplastic cell 
proliferation.128,129 The PDGFR inhibitor, imatinib mesylate, was shown to effectively inhibit 
growth of PTCL-NOS primary cells. In a small clinical trial involving 12 patients with refractory 
or relapsed PTCL, however, treatment with imatinib, a tyrosine kinase inhibitor that targets 
PDGFR, resulted in no clinical improvement with short overall survival and progression-free 
survival times. Targeted treatment of PDGFRs via imatinib, therefore, is considered not effective 
for the treatment of PTCL-NOS.130 
 The PI3K-AKT-MTOR pathway is an important pathway involved in cell growth, 
survival, and proliferation.131,132 Activation of this pathway controls many hallmarks of cancer 
including cell cycle, metabolism, motility and genomic instability.133 PI3K signaling can also 
contribute to alterations in the microenvironment that promotes tumor growth including 
angiogenesis.134–136 The PI3K pathway has been shown to be among the most frequently altered 
pathways in human tumors, with frequent mutations in PIK3CA and PTEN, a negative regulator 
of PI3K-AKT.137  Alteration of this pathway has been shown to be involved in PTCL-NOS 
pathogenesis, particularly within the PTCL-GATA3 subgroup.117,119 Duvelisib (IPI-145) is an 
oral inhibitor of PI3K. Treatment of patients with refractory or relapsed PTCL with duvelisib 
resulted in a 50% response rate and 3 complete responses.138 Duvelisib is also a potent inducer of 
cell death within 4 TCL lines with constitutively phosphorylated AKT (pAKT). In a patient-
xenograft mouse model, administration of duvelisib resulted in shifting of tumor-associated 
macrophages from the immunosuppressive M2-phenotype to the inflammatory M1-phenotype. 
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Duvelisib and other combination therapies that target the PI3K-AKT-MTOR axis are therefore 
considered promising new therapeutics for patients with PTCL-NOS.138  
 Subsets of PTCL including AITL and PTCL-Tfh have been shown to exhibit mutations in 
epigenetic regulators, including TET, DNMT2, and IDH. Drugs targeting epigenetic regulators, 
particularly histone deacetylase (HDAC) inhibitors, are therefore of interest to treat these 
subtypes of PTCL. Patients receiving HDAC inhibitors such as romidepsin and belinostat have 
exhibited strong response rates.139 HDAC inhibitors, particularly as part of a combination 
therapy protocol, are therefore of interest in patients with T-cell neoplasms that exhibit altered 
epigenetic regulation.  
 Another therapeutic target of interest in the treatment of PTCL is CD30. CD30 is a 
transmembrane glycoprotein receptor that is a member of the tumor necrosis factor 
superfamily.140 CD30 promotes cell growth and survival primarily through NFkB signaling 
pathways.141  CD30 is expressed by a wide variety of lymphomas, to varying degrees. Anaplastic 
large cell lymphoma (ALCL) and the Reed-Sternberg cells found in classic Hodgkin lymphoma 
exhibit marked upregulation of CD30.20,140  A subset of PTCL-NOS have been shown to express 
the CD30 antigen.142 A novel CD30 antibody-drug conjugate, brentuximab vedotin, has 
undergone several clinical trials enrolling patients with ALCL, AITL, or PTCL-NOS with 
variable levels of surface and soluble CD30 expression.143–145 Targeted CD30 treatment resulted 
in strong response rates ranging from 33-86% with the highest overall response rates seen in 
patients with ALCL. The duration of responses, however, were variable and there was no 
apparent correlation between response and CD30 expression. Discrepancies in response rates and 
CD30 expression has been attributed to the sensitivity of the diagnostically available 
immunohistochemistry and contributions of activated T-cells within the microenvironment.139 
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Further investigation into the role of CD30 in TCL pathobiology and mechanisms in which 
CD30-targeted immunotherapy may alter disease progression are needed to better understand the 
potential impact of this method of treatment.  
 PTCL-NOS remains a highly aggressive disease with poor outcomes in patients receiving 
traditional CHOP chemotherapy. While there have been advances in our understanding of the 
molecular drivers of these tumors and development of new therapies, significant improvement in 
treatment and survival of patients still trails that of other lymphoproliferative diseases. Further 
understanding of the pathogenesis and response to treatment of this diverse group of neoplasms 
is therefore needed.   
Canine T-cell Lymphomas 
Overview 
 Lymphoma is among the most common types of cancer affecting dogs, comprising 
approximately 6% of all neoplasms and approximately 90% of all hematopoietic tumors.146,147 
The estimated incidence of canine lymphoma is between 20-107 cases per 100,000148–150 which 
is higher than that report in humans (19.6 cases per 100,000).151 Canine NHLs can be classified 
using a modified WHO classification152 and there is strong evidence that specific dog breeds 
have distinct predispositions for the development of unique subtypes of non-Hodgkin’s 
lymphomas (NHLs).150,153–155 The current classification of canine NHLs relies heavily on 
histomorphologic and cytologic features. Characterization of the molecular and genetic 
phenotypes and elucidation of the underlying pathogenesis of these canine lymphoma subtypes is 
therefore needed for more accurate tumor classification, development and utilization of targeted 
therapies, and better evaluation of the potential for a naturally occurring canine model of NHL.  
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 Similar to humans, B-cell lymphomas are the more common than T-cell lymphomas in 
dogs and diffuse large B-cell lymphoma is the most common subtype in both species. In dogs 
however, the next most common subtypes are PTCL, nodal marginal zone lymphoma, and T-
zone lymphoma.156 Because of the relative increased incidence of PTCL in dogs compared to 
humans, the dog may serve as a valuable and naturally occurring translational model for this 
uncommon but highly aggressive disease.  
Canine Peripheral T-cell Lymphoma 
PTCL is among the most common subtypes of naturally-occurring NHL in dogs, 
comprising approximately 15% of all NHLs in this species.156–159 The majority of PTCL cases in 
dogs fall within the category of PTCL-NOS160, with rare reports of other PTCL subtypes, 
including anaplastic large cell lymphoma.158,161,162 Dogs affected by PTCL-NOS exhibit similar 
clinical and diagnostic features to human patients. Dogs are typically diagnosed at middle to 
older age with a slight male predominance.109,159,163 Canine patients often present in advanced 
stages with multicentric peripheral lymph node involvement, although any organ can be affected. 
In dogs, mediastinal involvement is seen in 30-40% of cases and patients often present with 
concurrent paraneoplastic hypercalcemia.163 The Boxer breed is among the most common breeds 
affected by PTCL-NOS, comprising 19-26% of cases.158,163,164  
PTCL-NOS is an aggressive disease in dogs with median overall survival times ranging 
from 159-162 days.153,163,165 Dogs are typically treated with anthracycline-containing regimens, 
most often comprised of CHOP based protocols with variable initial response and poor overall 
prognosis.163  
The diagnosis of PTCL-NOS can be made based on a combination of histology, flow 
cytometry, and PCR for antigen receptor rearrangement (PARR) assay. Similar to PTCL-NOS in 
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humans, canine tumors exhibit clonal T-cell receptor (TCR) gene rearrangement. Using flow 
cytometry, the majority of PTCL-NOS cases are characterized by a homogenous expansion of 
intermediate to large sized T-cells identified by expression of T-cell markers CD3 and/or CD5 
and lack of expression of B-cell marker CD21. The majority of PTCL-NOS cases express the T-
cell subset antigen CD4 with fewer cases being CD8+ or CD4-CD8-. Loss of CD5 expression and 
low expression of MHC class II are common features of this neoplasm.163 Histologically, these 
tumors are comprised of intermediate to large cells that are arranged in diffuse sheets that efface 
normal nodal architecture. Nuclei are of the neoplastic population can be irregular with variable 
chromatin pattern, prominent nucleoli, and variable mitotic rates.152,156,163,166 
The molecular and genetic features of PTCL-NOS in dogs are not well-understood. 
Exome sequencing of Boxer dogs with TCL identified frequent mutations in the PTEN-mTOR 
pathways.167 Interestingly, the PTEN-PI3k-AKT-MTOR pathway has been shown to be a driving 
pathway of human PTCL-GATA3, and frequent mutations of PTEN has also been identified in 
human PTCL.119 Further investigation of the molecular drivers of canine PTCL-NOS is needed 
to better understand the pathogenesis underlying this aggressive disease in both human and 
canine patients.  
A Canine Model of Naturally Occurring Cancers 
Murine models are the mainstay animal model for cancer research and provide an 
invaluable tool for elucidating the mechanisms of cancer biology and oncogenesis. However, 
many novel therapeutics which exhibit strong results in rodent models fail in human patients. In 
fact, the success rate of oncologic clinical trials has been reported to be as low as 3.4%.168 The 
variable results in mice versus human patients may be due, at least in part, to the lack of tumor 
and microenvironmental heterogeneity, genomic instability, immune surveillance, and recurrence 
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and/or metastasis within the conventional mouse models.169 Therefore, a more relevant animal 
model that better represents human disease would be of tremendous value in effectively 
translating novel therapies into human patients.  
The dog has been proposed as a naturally occurring model for a number of human tumors 
based on shared clinical, diagnostic, and molecular features.170 Dogs provide a unique model for 
cancer research since tumors are able to grow over a long time period and in the presence of an 
in-tact immune system. Canine tumors additionally exhibit heterogeneity between individuals, as 
well as within the same individual. Furthermore, affected dogs can develop resistant or recurrent 
disease and exhibit variable responses to therapeutic agents.170 Companion dogs also share daily 
environmental and lifestyle exposures with their owners. Together, these features make the 
canine translational model an attractive one, as they offer an opportunity to better recapitulate 
natural disease than genetically-induced rodent models. 
Logistically, clinical trials in dogs are feasible, particularly within veterinary teaching 
hospitals that benefit from large caseloads and clinical researchers on staff. The establishment of 
inter-institutional and multidisciplinary consortiums and working groups, such as the Canine 
Comparative Oncology Trials Consortium,169 represents exciting possibilities for development of 
large-scale trials that limit the biases of geographic, socioeconomic, and institutional factors. The 
lack of gold-standard veterinary treatments allows for the unique design of trials to evaluate early 
implementation of novel therapies. This may provide an advantage over human clinical trials in 
which patients have already failed standard treatment protocols.  
The dog offers a naturally occurring model for a number of cancer subtypes including 
lymphoma, osteosarcoma, melanoma, prostate carcinoma, lung carcinoma, mammary carcinoma, 
and soft tissue sarcoma.170 Among the most studied and accepted models is canine 
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osteosarcoma.171 Osteosarcoma is a bone tumor that affects adolescent children as well as older, 
large-breed dogs. Similar to PTCL-NOS, osteosarcoma is a relatively uncommon, but highly 
aggressive tumor in people. Both osteosarcoma and PTCL-NOS occur relatively more frequently 
in the dog, and therefore offer a unique canine patient population to study these diseases. Recent 
studies have identified a novel agent, Losartan, to suppress pulmonary metastases in canine 
patients with osteosarcoma leading to combined clinical trials in canine and human patients 
(NCT03900793).172,173  
Further development and implementation of the dog as a naturally occurring disease 
model is dependent on molecular studies to evaluate mechanistic similarities between canine and 
human tumors. Through the identification of shared molecular drivers and oncogenic signaling 
pathways, we may foster a unique opportunity to evaluate targeted therapies in the dog at an 
earlier clinical timepoint than would be otherwise possible in typical trials involving human 
patients. This opportunity may facilitate faster and more efficient identification of promising 
treatment options and thereby allow more effective translation into human patients.  
Conclusions 
In this thesis we aim to characterize the clinical and molecular features of PTCL in dogs. 
In so doing, we seek to determine if this naturally occurring disease in dogs may provide a useful 
model to study PTCL-NOS in people. Specific goals of this work include:  1) characterization of 
the histomorphology, clinical features, and gene expression pattern of canine PTCL 2) evaluation 
of the molecular similarities between canine and human PTCL-NOS 3) investigation into the cell 
of origin of canine PTCL and 4) identification of genetic drivers of canine PTCL-NOS, including 
novel fusion gene candidates.  
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CHAPTER 2 – CHARACTERIZATION OF THE HISTOMORPHOLOGY, CLINICAL 




T-cell lymphomas (TCL) are a diverse group of neoplasms with variable diagnostic 
features, pathophysiology, therapeutic responses, and clinical outcomes. In dogs, TCL includes 
indolent and aggressive tumors such as T-zone lymphoma (TZL) and peripheral T-cell 
lymphoma (PTCL), respectively. TCL phenotypes can be categorized by expression of the 
surface antigen molecules CD4 and CD8, identified by flow cytometry. The majority of TCL 
cases are CD4+, with far fewer cases being CD8+ or CD4-CD8-. The clinical features of CD4+ 
TCLs have been previously described. The histomorphology and gene expression profile of 
tumors classified as CD4+ TCL, however, has not been well characterized and it remains 
uncertain if this group of tumors represents a uniform population or encompasses a more 
heterogenous group of diseases. Furthermore, the less common TCL phenotypes are poorly 
understood with little to no information about histomorphology, clinical features, and prognosis. 
In this chapter, we aim to first determine if tumors diagnosed as CD4+ TCL by flow cytometry 
identify a distinct lymphoma subtype with consistent histologic and molecular features. Seventy-
three cases of nodal TCL with paired flow cytometry and histopathology were evaluated. The 
majority of cases (82.2%) were characterized as CD4+ TCL by flow cytometry. Fewer cases 
were classified as CD8+ TCL (6.8%) or CD4-CD8- TCL (11.0%). All cases, regardless of 
immunophenotype, exhibited conserved histologic features consistent with the WHO 
classification of PTCL. Histologic subsets of PTCL corresponding to immunophenotypic 
features were not identified. RNA-seq was then performed on a subset of CD4+ PTCL cases 
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(n=6) and compared with sorted control CD4+ T-cells. The gene expression pattern of CD4+ 
PTCL was similar between all cases regardless of breed. 
 Given the rarity of the CD8+ and CD4-CD8- PTCL cases, we then sought to evaluate a 
second cohort of patients to further characterize these less common PTCL phenotypes. We 
describe and correlate the presenting clinical signs, flow cytometry, and outcomes of 119 dogs 
diagnosed with nodal, non-TZL, CD8+ or CD4-CD8- TCL by flow cytometry. Skin lesions 
present at the time of diagnosis were more commonly observed in the CD8+ TCL group. 
Mediastinal enlargement and/or hypercalcemia were more commonly seen in the CD4-CD8- TCL 
group.  Dogs with either CD8+ or CD4-CD8- TCLs had aggressive clinical disease with median 
overall survival (OS) times of 198 days and 145 days, respectively. In both groups, neoplastic 
cell size determined by flow cytometry ranged from small to large, and large cell size was 
associated with shorter OS times. In this chapter, we first demonstrate the ability of flow 
cytometry to identify a subtype of T-cell lymphoma, CD4+ PTCL, with a uniform 
histomorphology and gene expression profile. We then show that CD4-CD8- TCLs share clinical 
and diagnostic features with the more common CD4+ TCLs, suggesting a mutual pathogenesis. 
CD8+ TCLs, on the other hand, exhibit unique clinical features and prognostic indicators 









Lymphoma is the most common hematopoietic malignancy in dogs and encompasses a 
broad spectrum of diseases with diverse mechanisms of oncogenesis, diagnostic criteria, and 
biologic behaviors.149,156 Flow cytometry is a powerful non-invasive tool used to differentiate 
clinically significant subtypes of lymphoma by objectively evaluating cell size, cell complexity, 
and the expression of multiple surface antigens. The utility of flow cytometry is particularly 
evidenced by T-zone lymphoma (TZL) which is routinely diagnosed by flow cytometry based on 
an expansion of small to intermediate sized CD3+CD5+ T-cells with characteristic loss of the 
pan-leukocyte marker CD45.160,174 Diagnosis of T-zone lymphoma by flow cytometry has been 
shown to reliably predict a distinct histologic pattern and cytomorphology consistent with the 
disease entity.160,174 T-zone lymphoma is an indolent T-cell lymphoma that is clinically 
important to distinguish from more aggressive types of peripheral T-cell lymphomas.163  
CD4+ TCL is the most common subtype of TCL in dogs.5 The clinical presentation and 
outcome of dogs diagnosed with CD4+ TCL by flow cytometry have been previously 
described.163 In this study, the most common immunophenotype of neoplastic cells was 
CD3+CD4+CD45+CD21- with low levels of MHC class II expression, and variable expression of 
CD5. This phenotype has been associated with poor clinical outcomes independent of the 
treatment protocol with a median progressive free interval (PFI) of 91-108 days and overall 
survival (OS) of 159-160 days.163,164 Clinically, patients with this immunophenotype often 
present with a mediastinal mass and/or hypercalcemia.163,164 Boxer dogs are overrepresented in 
the CD4+ PTCL population, comprising approximately 19-26% of cases.153,163,165 
In the current study we assessed the correlation between flow cytometry and 
histomorphology of a large group of nodal, non-TZL, TCL cases and then evaluated the gene 
 23 
expression pattern of the most common immunophenotype, CD4+ TCL. Currently in veterinary 
medicine, it is far more common to diagnose lymphoma by cytology and flow cytometry than 
biopsy, and therefore this study provides the unique opportunity to directly correlate the 
immunophenotype to histology. Understanding the spectrum of histologic changes associated 
with specific antigen expression may also provide insight into the disease process and lay the 
groundwork for future studies that rely on flow cytometry to identify lymphoma subtypes. 
The cytomorphology and histomorphology of CD4+ TCLs (excluding T-zone lymphoma) 
have been previously classified as peripheral T-cell lymphoma not-otherwise specified (PTCL-
NOS)156,163,165, lymphoblastic lymphoma163,165, pleomorphic mixed small, medium, and large 
cell166, or pleomorphic large cell type166. In these studies, a range of classification criteria (World 
Health Organization (WHO) classification, Kiel classification) and sample preparation (cytology, 
histology) were used.  
Nodal TCLs with other immunophenotypes, including CD8+ and CD4-CD8- lymphomas, 
are less common164,165 and not well characterized in dogs. Studies focused on histologic and 
cytologic characterization of canine lymphomas using a variety of classification schemes other 
than the contemporary WHO standard, have included small numbers of CD8+ and/or CD4-CD8-
TCLs. CD8+ TCLs involving the lymph node have been classified as mycosis fungoides, 
pleomorphic large cell, pleomorphic mixed cell, unclassifiable plasmacytoid, plasmacytoid, and 
unclassifiable high-grade.166,175,176 CD4-CD8- TCLs have been previously classified as 
lymphoblastic and PTCL.166 The clinical features and biologic behavior of these uncommon 
nodal CD8+ and CD4-CD8- TCL subtypes are poorly described and it remains uncertain if T-cell 
immunophenotype can be used to identify TCL subtypes with unique clinical presentations or 
survival times.  
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 The goals of this chapter were to 1) evaluate the heterogeneity of histomorphologies and 
gene expression within a group of tumors diagnosed as CD4+ TCL by flow cytometry 2) 
determine if less common TCL immunophenotypes can be reliably distinguished from CD4+ 
TCL by histology and 3) characterize the presenting clinical signs, flow cytometry profiles, and 
clinical outcomes associated with the rare TCL subtypes.  
Materials and Methods 
Case Selection for Flow Cytometry-Histopathology Correlation  
Cases with a T-cell phenotype (expression of the T-cell antigens CD3 or CD5, lack 
expression of the B-cell antigen CD21, and variable expression of the T-cell subset antigens, 
CD4 and CD8) were identified through Aratana Therapeutics T-CHOMP and T-LAB clinical 
studies. Samples used in this study were collected between 2014 and 2015 from dogs presenting 
to veterinary specialty clinics throughout the United States with suspicion of lymphoproliferative 
disease. Dogs were selected for this study in two phases. During the first phase, fine needle 
aspirates for flow cytometry were taken simultaneously with a biopsy for histopathologic 
evaluation. All samples were obtained from peripheral lymph nodes. During the second phase of 
the study, flow cytometry was performed first and dogs with an indolent lymphoma (TZL 
immunophenotype) and B-cell lymphoma were excluded. TZL lymphoma was identified based 
on a neoplastic population composed of small to intermediate cells which expressed CD3, CD5, 
and lost expression of CD45. Dogs with a non-TZL TCL were then entered into the clinical 
study and a pre-treatment lymph node biopsy was obtained.  Thus, the cases in this study 
represent the diversity of phenotypes and histologies that might be present in nodal TCL not 
classified as TZL. During the first phase of the trial, ten TZL cases were evaluated and 
independently diagnosed by both histomorphology and flow cytometry.  
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 Flow Cytometry 
  Routine diagnostic flow cytometry was performed by the Colorado State University 
Clinical Immunology Laboratory (CSU-CI) on all cases as previously described.160 Flow 
cytometry was reviewed for lymph node aspirates of 73 cases of TCL, and compared to lymph 
node aspirates from 20 healthy dogs utilized for IACUC approved surgical continuing education 
courses, and 20 cases of CD4+ T-zone lymphoma submitted to the CSU-CI for routine 
diagnostics. Cases of T-zone lymphoma were selected based on CD45-CD3+CD4+CD5+CD21hi 
immunophenotype.160,174 Although T-zone lymphomas can express CD4, CD8, neither or rarely 
both subset antigens, for this study CD4-expressing cases were examined. The following features 
of the neoplastic populations and control CD4+ and CD8+ T-lymphocytes were evaluated: cell 
size by forward scatter on a linear scale, MHC class II median mean fluorescence intensity 
(MFI), CD25 median MFI, and expression of CD5.  
 Histopathology 
  Two pathologists (Lauren J Harris, Kelly L Hughes) were blinded to the flow cytometry 
parameters and independently evaluated whole lymph node or lymph node core biopsies. 
Biopsies were subtyped according to the WHO classification for canine lymphoma and scored 
for histologic features (summarized in Table 2.1). Hematoxylin and eosin stain, CD3 
immunohistochemistry, and CD79a immunohistochemistry were reviewed in every case. WHO 
classification and scores of histologic features were compared between pathologists and in cases 











Table 2.1. Summary of Criteria for Histologic Characterization  
 RBC=diameter of a resident red blood cell  
Immunohistochemistry  
CD3 and CD79a expression were evaluated by immunohistochemistry in all biopsies 
included in the flow cytometry-histopathology correlation study. Three-micron sections of 
formalin fixed paraffin embedded tissues were mounted on positively charged slides along with 
positive control tissue. Slides were deparaffinized and hydrated through two changes of xylene, 
two changes of 100% alcohol, and one change of 95% alcohol to water. Heat induced epitope 
retrieval (HIER) was performed using citrate buffer, pH = 6, for 30 seconds at 125 C using a 
Dako Pascal pressure cooker. CD3 (courtesy of Dr. Moore, UC Davis) at 1:50 dilution or CD79a 
(Biocare, Pacheco, CA) at 1:100 were applied for 60 minutes at room temperature. After rinsing, 
Promark Mouse on Canine Polymer (Biocare, Pacheco, CA) was applied for 60 minutes. After 
rinsing, Betazoid DAB (Biocare, Pacheco, CA) was applied for 5 minutes. Slides were then 
rinsed thoroughly and counterstained using Mayer’s Hematoxylin for 30 seconds. Slides were 
dehydrated and cleared using graded alcohol and xylene and coverslipped with tape coverslips. 
Negative controls were incubated in diluent consisting of Tris-buffered saline with carrier protein 
Feature Criteria 
Size Small: 1.5x RBC Intermediate: 1.5-2x RBC  Large: >2x RBC 
Percent necrosis 0-10% 10-20% >20% 
Number of tingible 
body macrophages 
None Few  Many 
Fibrosis Mild Moderate Marked 
Neovascularization Mild  Moderate  Marked 
Nuclear Shape Round Indented Pleomorphic 
Chromatin Pattern Condensed Stippled Vesicular 
Nucleolar Prominence Unapparent Small and distinct Large and prominent 
Cytoplasm Color Eosinophilic Basophilic Amorphous 
Cytoplasm Character Smooth, even Scant Flocculent 
Mitotic Rate Mitoses per ten 400x fields 
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and homologous nonimmune sera.  All sequential steps of the immunostaining procedure were 
performed on negative controls following incubation.  
Flow Cytometry-Histology Correlation Statistical Analysis 
All statistical analyses were performed using GraphPad Prism version 5.0 for Windows 
(GraphPad Software, San Diego California, USA). Nonparametric Mann-Whitney U tests were 
used to compare flow cytometric parameters amongst samples. Nonparametric correlations 
between flow cytometry and histologic features were determined using Spearman’s correlation 
matrix.  
RNA-Seq 
Lymph node aspirates from 6 dogs submitted to the CSU-CI for routine diagnostics and 
diagnosed with CD4+ PTCL by flow cytometry were selected for RNA-seq. Patients were naïve 
to treatment at the time of sample submission. The 6 patient samples selected for RNA-seq were 
not enrolled in the above-mentioned T-LAB and T-CHOMP clinical studies, and were therefore 
not included in the group of samples evaluated for flow cytometry-histopathology correlation. 
Patient information is summarized in Table 2.3. Aspirates from selected cases had a purity of 
greater than 88% neoplastic cells. Control CD4+ T lymphocytes were harvested from lymph 
nodes of 6 healthy dogs utilized for IACUC approved surgical continuing education courses. 
CD4+ T lymphocytes were sorted using a MoFlo cell sorter (Beckman Coulter, Brea, CA). RNA 
was extracted from the 6 individual CD4+ PTCL cases. RNA from sorted CD4+ lymphocytes 
from six total dogs were pooled in groups of two to obtain three control samples. RNA extraction 
was performed using the Purelink RNA mini Kit (Thermo Fisher Scientific, Waltham, MA) and 
quality was measured with an Agilent 2100 Bioanalyzer System. All samples had a RIN value 
greater than 8.80. RNA was shipped to Novogene Corporation Inc (Sacramento, CA) where the 
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libraries were constructed and sequenced. Briefly, mRNA was enriched using oligo(dT) beads 
and randomly fragmented. Random hexamer primer and reverse transcriptase were used for first 
strand cDNA synthesis followed by second strand synthesis via custom synthesis buffer 
(Illumina, San Diego, CA), dNTPs, RNAse H, and Escherichia coli polymerase I. Double-
stranded cDNA fragments were purified and end-repaired by A-tailing and ligation of 
sequencing adapters. cDNA inserts were selected and enriched via PCR. Transcriptome 
sequencing was carried out on an Illumina Hiseq PE150 platform and generated 150bp paired-
end raw reads. Sequences were aligned to the CanFam3.1 genome using TopHat2.19 HTSeq20 
and DESeq221 software were used to quantify reads and normalize gene expression levels 
measured as fragments per kilobase of transcript sequence per millions of base pairs sequenced 
(FPKM). P-values were determined using a negative binomial distribution.  A Benjamini-
Hochberg procedure was used to correct p-values and padj<0.05 was considered the 
differentially expressed gene screening standard. The Broad Institute tool, Morpheus22, was used 
to perform hierarchical clustering (Euclidean, average linkage) and create heatmaps based on the 
differentially expressed genes. The RNA-seq data in this publication have been deposited in 
NCBI’s Gene Expression Omnibus25 and are accessible through GEO Series accession number 
GSE122347. 
Case Selection of CD8+ and CD4-CD8- TCLs 
To determine the distribution of nodal lymphoma subtypes diagnosed at the Colorado 
State University Clinical Immunology Laboratory (CSU-CI), the CSU-CI database was searched 
for canine lymph node aspirates submitted between 2012-2017. Cases with a final diagnosis of 
B-cell lymphoma, CD4+ TCL, CD8+ TCL, CD4-CD8- TCL, CD4+CD8+ TCL or T-zone 
lymphoma were selected. Duplicate samples from the same patient with consistent diagnoses 
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were eliminated, as were patients that were involved in studies that recruited dogs with specific 
lymphoma immunophenotypes.  
Subsequently, cases with a diagnosis of either CD8+ or CD4-CD8- TCL were chosen for 
further evaluation. T-cell lymphoma cases were identified by a discrete population of T-cells 
with a single phenotype which comprised the majority of the sample, or a population of T-cells 
which exhibited at least one feature of aberrancy including: loss of both CD4 and CD8 T-cell 
subset antigens, loss of CD5 expression, marked decrease in MHC class II expression, or large 
cell size (greater than or equal to 1.3 times the size of normal T-lymphocytes). CD8+ and CD4-
CD8- TCLs were characterized by CD3 and/or CD5 expression, lack of expression of CD21, and 
either CD8+CD4- or CD4-CD8- T-cell subset antigen expression patterns. Cases with morphology 
consistent with large granular lymphocytes (LGL-leukemia) and cases with a diagnosis of T-
zone lymphoma, identified by the characteristic loss of the pan-leukocyte marker CD45, were 
excluded from evaluation. Medical records for 120 of these cases were obtained for further 
evaluation. One case with a concurrent B-cell lymphoma was subsequently excluded from the 
case series, resulting in a total of 119 cases.  
Medical Record Evaluation 
Medical records from patients that met inclusion criteria were acquired from the referring 
veterinarians. The patient age, sex, breed, date of diagnosis, type of treatment (categorized as: no 
treatment, corticosteroid treatment only, single-agent chemotherapy, or multi-agent 
chemotherapy), and date of last contact/euthanasia/death were extracted from the medical 
records. Patients in which the treatment regime or intention to treat was not clear in the medical 
record (n=5) and patients who were enrolled in a novel immunotherapy clinical trial (n=5) were 
removed from the group used to evaluate the effect of treatment on overall survival. Patients who 
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received a single injection of L-asparaginase and then were treated with CCNU alone or 
prednisone alone were categorized as single agent or corticosteroid alone, respectively. The 
presence or absence of the following clinical signs was also evaluated at the time of initial flow 
cytometry diagnosis: peripheral lymphadenopathy, abdominal lymphadenopathy, hepatomegaly, 
splenomegaly/splenic nodules, gastrointestinal involvement (including gastrointestinal mass, 
thickened intestines, and/or clinical diagnosis of protein-losing enteropathy), skin lesions, cranial 
mediastinal enlargement/sternal lymphadenopathy, and hypercalcemia. Where applicable, the 
diagnostic method used to identify these clinical abnormalities was also recorded. In cases where 
the presence or absence of the clinical sign was unknown, the patient was excluded from analysis 
of that particular feature. The patient’s complete blood count (CBC) at the time closest to flow 
cytometry diagnosis was reviewed for hematologic abnormalities. Anemia was classified as mild 
(hematocrit (HCT) 30-36%), moderate (HCT 20-30%), or marked (HCT <20%). 
Thrombocytopenia was characterized as mild (100,000-175,000 platelets/uL), moderate (30,000-
100,000 platelets/uL), or marked (<30,000 platelets/uL) if there were no platelet clumps 
identified on blood smear review. Lymphocytosis was classified as mild (5,000-10,000 
lymphs/uL), moderate (10,000-30,000 lymphs/uL) or marked (>30,000 lymphs/uL).  
Cytology 
Of the 119 cases included the CD8+ and CD4-CD8- outcome study, only 4 cases (3 CD4-
CD8- TCL and 1 CD8+ TCL) had cytology samples available at the CSU Veterinary Diagnostic 
Laboratory. To obtain additional cases for cytologic review, the CSU-CI database was searched 
for cases with concurrent flow cytometry and cytology where the slides were available at the 
CSU Veterinary Diagnostic Laboratory. Ten cases of CD8+ TCL and 10 cases of CD4-CD8- TCL 
were randomly selected for evaluation. Cases were classified as CD8+ TCL and CD4-CD8- TCL 
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by flow cytometry using the same criteria described above. Fine needle aspirations from the 24 
total cases were evaluated by two clinical pathologists (EDR, PRA). Pathologists were blinded to 
the immunophenotype. Additionally, for cytologic comparison, ten CD4+ nodal TCL samples 
with concurrent flow cytometry and cytology were randomly selected and reviewed. 
Statistical Analysis-Retrospective outcome study  
All statistical analyses were performed using GraphPad Prism version 8.0 for Windows 
(GraphPad Software, San Diego California, USA) and R version 3.5.3. Fischer’s exact test was 
used to compare categorical parameters and non-parametric Wilcoxon rank-sum test was used to 
compare continuous parameters between TCL phenotypes. Overall survival (OS) was calculated 
in days from the time of diagnosis by flow cytometry until time of death or censor by Kaplan 
Meier method. Dogs still alive or lost to follow-up at the time of data analysis were censored at 
the last date of contact. The following potential clinical prognostic factors were evaluated: 
abdominal lymphadenopathy, sternal lymphadenopathy or mediastinal enlargement, cutaneous 
involvement, splenomegaly or splenic nodules, hepatomegaly, hypercalcemia, anemia, age and 
treatment (multi-agent chemotherapy, single-agent chemotherapy, corticosteroids alone or no 
therapy). All clinical parameters were categorized as present or absent at the time of diagnosis. 
To evaluate age, patients were divided into ‘old’ and ‘young’ categories, with ‘old’ defined as 
≥10 years of age at the time of diagnosis. The following flow cytometry features of the 
neoplastic population were also evaluated: cell size as determined by forward scatter, MHC class 
II expression (MFI), and CD5 expression. Cases with a median neoplastic cell size greater than 
or equal to 1.3 times the median size of control T-cells from normal dogs were considered large. 
Cases with a median cell size less than 1.3 times the median size of control T-cells from normal 
dogs were considered small. MHC class II expression was categorized as high (greater than or 
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equal to the median MFI of control T-cells from normal dogs) or low (less than the median MFI 
of control T-cell from normal dogs). Cases were categorized as CD5 positive or CD5 negative, 
as determined by complete loss of CD5 expression based on MFI and interpretation of the flow 
cytometry plots. The impact on survival was determined by log rank test (p-value) and Cox 
proportional hazard model (Hazard Ratio [HR] and 95% confidence interval [CI]). Multivariable 
analysis was not performed due to insufficient sample numbers available for evaluation. A p-
value less than 0.05 was considered significant.  
Results 
Flow cytometry-Histopathology Correlation  
Flow cytometry features of canine nodal TCL 
The 73 nodal TCL cases fell into 3 immunophenotypic categories: CD4+ TCL (82.3%), 
CD8+ TCL (6.9%), and CD4-CD8- TCL (11.0%). The demographics of TCL patients are 
summarized in Table 2.2.  


















Age (years)      
    Median (range) 7  (3-13) 11 (8-12) 6.5 (4-8) 1 (1-1) 10 (8-14) 
Sex       
    Male 3   (5%) 0 (0%) 0 (0%) 5 (25%) 1 (5%) 
    Neutered Male 34 (57%) 0 (0%) 4 (50%) 0 (0%) 8 (40%) 
    Female 2   (3%) 1 (20%) 0 (0%) 15 (75%) 0 (0%) 
    Female Spayed 21 (35%) 4 (80%) 4 (50%) 0 (0%) 11 (55%) 
Breed      
    Mixed breed 18 (30%) 0 (0%) 2 (25%) 10 (50%) 6 (30%) 
    Boxer 16 (27%) 2 (40%) 1 (13%) 0 (0%) 0 (0%) 
    Golden Retriever 8 (13%) 1 (20%) 2 (25%) 0 (0%) 8 (40%) 
    Lab 4   (7%) 0 (0%) 1 (13%) 0 (0%) 0 (0%) 
   Other 14 (23%) 2 (40%) 2 (25%) 10 (50%) 6 (30%) 
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CD4+ TCL cases had a CD3+CD4+CD8- phenotype consistent with that previously 
associated with aggressive clinical disease.163 By flow cytometry, cells with the CD4+ TCL 
phenotype were significantly larger based on forward scatter determined on a linear scale 
(median=530) compared to control CD4+ lymphocytes (median=375; p-value<0.0001), control 
CD8+ lymphocytes (median=379; p-value<0.0001) and CD4+ TZL cells (median=406; p-
value<0.0001) (Figure 2.1a). CD4+ TCL cells exhibited low MHC Class II expression (median 
MFI=0.80) compared to control CD4+ lymphocytes (median MFI=12.15; p-value<0.0001), 
control CD8+ lymphocytes (median MFI=17.03, p-value<0.0001) and CD4+ TZL cells (median 
MFI=26.48; p-value<0.0001) (Figure 2.1b). CD25 expression in CD4+ TCL (median MFI=0.1) 
was similar to that of control T-cell subsets, while CD25 expression was increased in CD4+ TZL 
cells (median MFI=0.56; p-value<0.001) (Figure 2.1c). Nineteen of the 60 CD4+ TCL cases 
(31.7%) exhibited complete loss of CD5 expression and 6 cases (10.0%) exhibited partial 
downregulation of CD5. Consistent with previous studies,163 dogs diagnosed with CD4+ TCL 
were a median age of 7 years and mixed breeds (30%), Boxers (27%), and Golden Retrievers 
(13%) were the most common breeds. Male dogs, the majority of which were neutered, 
composed 62% of the population (Table 2.2).   
CD8+ TCL cases expressed the T-cell antigen CD3, the T-cell subset marker CD8, and 
lacked expression of CD4 (CD3+CD4-CD8+). These tumors exhibited variable expression of 
CD5 (3 out of 5 CD5+; 2 out of 5 CD5-). CD8+ TCL cells did not differ significantly in size 
(median=524), MHC class II expression (median MFI=1.79) or CD25 expression (median 
MFI=0.1) from CD4+ TCL cases. CD8+ TCL cases were significantly older at the time of 
diagnosis with a median age of 11 years (p-value=0.005) and all 5 cases were female. Similar to 
CD4+ TCL, 2 of the 5 CD8+ TCL cases were Boxer dogs and 1 was a Golden Retriever.  
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CD4-CD8- cases lacked expression of CD4 or CD8 (CD4-CD8-) and the majority 
expressed CD3. One CD4-CD8- TCL case lacked CD3 expression but exhibited CD5 positivity, 
confirming T-cell origin. Within this group of TCLs there was variable expression of CD5 (4 out 
of 8 CD5+, 4 out of 8 CD5-). CD4-CD8- TCL cells did not differ significantly in cell size 
(median=495.51), CD25 expression (median MFI=0.105), or MHC class II expression (median 
MFI=0.605) compared to CD4+ TCL. The median age of patients diagnosed with CD4-CD8- 
PTCL was 6.5 years and was not significantly different from CD4+ TCL cases. Two of the 8 total 
CD4-CD8- TCL cases were mixed breed dogs, 1 was a Boxer dog, and 2 were Golden Retrievers. 
Control CD4+ and CD8+ lymphocytes were evaluated in healthy, young hound and 
mixed-breed dogs (Table 2). This population was uniformly 1 year of age, predominantly female 
(75%), and all dogs were intact.  Cases of TZL were significantly older than CD4+ PTCL (p-
value<0.001) and CD4-CD8- PTCL (p-value=0.004).  CD8+ PTCL cases did not differ 
significantly in age from TZL cases (p-value=0.83). Golden Retrievers comprised 40% of the 
TZL cases.  
 
Figure 2.1. Flow cytometry features of PTCL. CD4+ PTCL cells were significantly larger than control CD4+ 
T-cells, control CD8+ T-cells, and TZL cells. Cell size was determined by forward scatter on a linear scale (A). 
CD4+ TCL had low levels of MHC class II expression (median fluorescence intensity) compared to control 
CD4+ T-cells, control CD8+ T-cells, and CD4+ TZL cells (B). CD4+ TCL had low levels of CD25 expression 
(median fluorescence intensity) compared to CD4+ TZL cells (C). (Mean ± SD , **=p<0.001).  
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Correlations between flow cytometry phenotype and histomorphology   
 Of the 73 total cases, 70 tumors had diagnostic quality histologic preparations adequate 
for subtyping. The three tumors with insufficient sample were diagnosed as CD4-CD8- TCL by 
flow cytometry. All evaluated cases were classified as PTCL-NOS, regardless of 
immunophenotype. All tumors were characterized by sheets of intermediate to large lymphocytes 
that diffusely infiltrated and effaced the nodal architecture and often invaded the fibrous capsule 
and perinodal adipose tissue. Neoplastic cells had moderate amounts of eosinophilic cytoplasm. 
Nuclei were 2 to 3 times the size of the diameter of an erythrocyte and round to indented or 
pleomorphic in shape. Most cases had open chromatin with 1-3 small distinct nucleoli, and a 
high mitotic index (median 49.42; range 10-118 per ten 400x fields). Throughout all cases there 
were few to moderate scattered tingible body macrophages, low levels of tumor necrosis (less 
than 20% examined cross sectional area), and mild fibroplasia. Neovascularization was generally 
not a prominent feature of these neoplasms (Figure 2.2).  
Cases of CD8+ and CD4-CD8- TCL could not be reliably distinguished from CD4+ TCL 
by histology. In the single CD4-CD8- PTCL case that lost expression of CD3 based on flow 
cytometry, approximately 40% of neoplastic cells exhibited positive membranous 
immunoreactivity to the CD3 antibody with immunohistochemistry. This finding is interpreted as 
a result of the intracellular binding of the CD3 antibody used in immunohistochemistry 
compared to the cell-surface binding of the CD3 antibody used for flow cytometry.  Two of 5 
CD8+ TCL tumors had unique histologic features. In one case, cells had markedly expanded lacy 
to vacuolated cytoplasm. Cell size, nuclear characteristics, and tumor pattern of this neoplasm 
was still consistent with that previously described in other cases of PTCL-NOS. Another CD8+ 
PTCL case exhibited pronounced tumor-associated fibroplasia that multifocally dissected 
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between neoplastic lymphocytes. A diagnosis of angioimmunoblastic lymphoma was considered 
in this case, however, because neoplastic cellular morphology was consistent with other cases of 
PTCL, a consensus diagnosis of PTCL was agreed upon. Because of the small sample size of 
CD8+ TCLs (n=5), conclusions of whether these unique histologic features represent distinct 
entities or variations within the PTCL subgroup cannot be definitively determined. 
Based on the consistency of the categorically evaluated histologic features throughout all 
examined cases, statistical evaluation of the categorical features with flow cytometry parameters 
was not pursued. Spearman’s rank correlation coefficients did identify a weak to moderate 
correlation between neoplastic cell size as determined by forward scatter via flow cytometry and 
mitotic rate per ten 400x fields (ρ=0.418, p-value<0.001).   
RNA-seq 
Flow Cytometry Identifies a Consistent Gene Expression Profile  
RNA-seq was performed on lymph node aspirates from 6 dogs diagnosed with CD4+ 
TCL (CD4+CD8-CD5+/-ClassIIlo) based on flow cytometry and compared to sorted CD4+ T-cells 
from lymph nodes of young, healthy, hound dogs. The selected cases were representative of the 
Figure 2.2. Histomorphology of PTCL. Tumors diagnosed as PTCL exhibited consistent histologic 
features including sheets of intermediate to large size cells with round to indented to pleomorphic nuclei, 
open chromatin, 1-3 small discrete nucleoli, and high mitotic rates (arrows) (A-C). Tumors diagnosed as 
CD4+ PTCL (A), CD8+ PTCL (B), and CD4-CD8- PTCL(C) could not be classified into distinct histologic 
subgroups. Insets are CD3 immunohistochemistry demonstrating diffuse positive membranous 
immunoreactivity. A single CD4-CD8- PTCL exhibited loss of CD3 by flow cytometry. In this case 
approximately 40% of neoplastic T-cells were CD3-positive by immunohistochemistry (C). 400x 
magnification. 
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CD4+ TCL patient population based on clinical presentation and flow cytometric features. Three 
of the selected cases were Boxers and three cases were non-Boxer breeds (Cavalier King Charles 
Spaniel, Rhodesian Ridgeback, and a Collie dog). Two of the cases exhibited loss of CD5 
expression. One case had a mediastinal mass, one case was hypercalcemic, and one case had 
both a mediastinal mass and hypercalcemia (Table 2.3).  
Table 2.3. Summary of Patient Information for individuals with RNAseq analysis 
RNA extracted from lymph nodes from CNTRL dogs 1a and 1b were combined for a single CNTRL1 sample, 
CNTRL2a and 2b were combined for a single CNTRL2 sample, and CNTRL3a and 3b were combined for a single 
CNTRL3 sample. MC=male castrated; FS=female spayed; F=female. 
 
5011 genes were significantly differentially expressed (padj<0.05) when comparing 
CD4+ PTCL cases to control CD4+ lymphocytes (Figure 2.4a,b).  Surface protein expression 
characterized by flow cytometry correlated with gene expression including decreased expression 
of CD5, CD25, and MHC class II molecules (DLA DRA, DLA DRB1, DLA DQA1, DLA 
DQB1)29 as well as the MHC class II transactivator, CIITA (Figure 2.3a-e). Hypercalcemia is a 
common clinical presentation in dogs with CD4+ PTCL and this process is driven by 
Sample 
name 
Breed Age Sex Mediastinal 
Mass 
Hypercalcemia 
BOXER1 Boxer 6 MC No No 
BOXER2 Boxer 8 FS No No 
BOXER3 Boxer 6 MC Yes No 
OTHER1 Cavalier King 
Charles Spaniel 
3 FS No Yes 
OTHER2 Rhodesian 
Ridgeback 
4 FS Yes Yes 
OTHER3 Collie 11 MC No No 
CNTRL1a Hound 1 F No No 
CNTRL1b Hound 1 F No No 
CNTRL2a Hound 1 F No No 
CNTRL2b Hound 1 F No No 
CNTRL3a Hound 1 F No No 
CNTRL3b Hound 1 F No No 
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paraneoplastic production of parathyroid hormone-like hormone (PTHLH).30 PTHLH expression 
was increased in all cases regardless of presence of clinical hypercalcemia.   
Hierarchical clustering of samples resulted in distinct separation of control lymphocytes 
and PTCL cases with intermixing of PTCL from Boxer and non-Boxer dogs (Figure 2.4a). In 
fact, only 82 genes were significantly differentially expressed when comparing tumor samples 
from Boxers and non-Boxer dogs (Figure 2.4c). Interestingly, one of the most overexpressed 
genes in PTCL in all 3 Boxers compared to PTCL in non-Boxer dogs was ROS proto-oncogene 1 
(ROS1) (log(fold change)=4.15; padj= <0.001). ROS1 is a receptor tyrosine kinase oncogene 
that has been shown to undergo genetic rearrangements in a variety of human cancers.31 Overall, 
it does not appear that the gene expression profile of CD4+ PTCL in Boxer dogs is markedly 
different from that of CD4+ PTCL in other breeds, despite overrepresentation of Boxers within 
the patient population.  
Figure 2.3. Flow cytometry cell surface protein expression is consistent with gene expression. CD4+ PTCL 
is characterized by enlarged cell size determined by forward scatter (A), expression of the T-cell subset marker 
CD4 and frequent loss of T-cell marker CD5 (B). CD4+ PTCL exhibits low levels of MHC class II (C) and 
CD25 (D). RNAseq derived differential gene expression of PTCL cases compared to control CD4+ T-cells 
demonstrated that expression of CD5, CD25, and MHC class II molecules (DLA-DRA, DLA-DRB1, DLA-
DQA1, DLA-DQB1, and CIITA) corresponded with cell surface protein expression (E). Parathyroid hormone 
like hormone (PTHLH) expression was increased in all patients, regardless of presence of clinical hypercalcemia 
(Mean ± SD, *=Padj<0.05). 
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CD8+ and CD4-CD8- Outcome Study 
Given the low numbers of CD8+ and CD4-CD8- TCLs within the population evaluated in 
the flow cytometry:histopathology correlation study, we next sought to evaluate the flow 
cytometry and clinical features of a larger group of these uncommon phenotypes. We aimed to 
better determine if CD8+ and CD4-CD8- tumors represent distinct biological entities with unique 
pathogeneses and clinical behaviors or conversely, if these tumors are part of the larger single 
group of TCL neoplasms that includes CD4+ TCL.   
Figure 2.4. Gene expression profile of CD4+ PTCL. Hierarchical clustering (average Euclidean distance) of 
differentially expressed genes (Padj<0.05) identified distinct separation of control and PTCL case samples. 
There was intermixing of PTCL cases from Boxer dogs and other breeds (A). MA-plots showed global 
differential gene expression of all PTCL cases compared to CD4+ T-cell controls (B) and PTCL cases from 
Boxer dogs compared to PTCL cases from other dog breeds (C). Significantly differentially expressed genes 
(Padj<0.05) are highlighted in red. 
 40 
In dogs, CD8+ and CD4-CD8- TCLs involving the lymph node are rare (Figure 2.5). 
Between 2012 and 2017, a total of 11,746 unique cases of canine lymphoma involving the lymph 
node were diagnosed at the CSU-CI laboratory. Of this population, the majority of cases were 
diagnosed as B-cell lymphoma. CD4+ TCL was the next most common phenotype followed by 
T-zone lymphoma. CD4-CD8- TCL and CD8+ TCL comprised 2.6% and 2.3% of cases 
respectively.  
Patient Demographics:  
During this timeframe, a total of 561 cases met inclusion criteria for this study and 
medical records for 119 of these cases were obtained. Within this study group, 59 cases were 
categorized as CD4-CD8- TCL and 60 cases were categorized as CD8+ TCL. Patient 
demographics are summarized in Table 2.4. Significantly more patients diagnosed with CD8+ 
TCL were categorized as older (≥10 years) than those diagnosed with CD4-CD8- TCL 
(p=0.0130). There was a significantly different sex distribution between CD8+ TCL cases and 
CD4-CD8- TCL cases (p=0.0045), with CD4-CD8- TCL having a male (62.7%) predominance 
Figure 2.5. Immunophenotypic distribution of canine nodal lymphoid neoplasms. The 
immunophenotypic distribution of canine lymphoid neoplasia characterized by flow cytometry performed 
on lymph node aspirates between 2012-2017. B-cell lymphoma (BCL) is the most common 
immunophenotype, followed by CD4+ T-cell lymphoma (TCL) and T-zone lymphoma (TZL). CD8+ TCL, 
CD4-CD8- TCL, and CD4+ CD8+ TCL are uncommon phenotypes.  
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and CD8+ TCL having a female (63.3%) predominance. The most common breeds affected by 
CD4-CD8- or CD8+ TCLs were mixed breeds, Boxers, Golden Retrievers, and Labrador 
Retrievers. There was no difference in breed distribution between the two immunophenotypes 
(p=0.8557).  
 














Presenting clinical signs are summarized in Table 2.5. Most cases of CD4-CD8- and 
CD8+ TCLs in this study presented with peripheral lymphadenopathy, consistent with the 
inclusion criteria of lymph node sample. Abdominal lymphadenopathy was present in 81% of 
evaluated CD4-CD8- TCLs and 56% of evaluated CD8+ TCLs. Few cases demonstrated enlarged 
abdominal lymph nodes in the absence of reported peripheral lymph node involvement (1 CD8+ 
TCL and 4 CD4-CD8- TCLs). More commonly, dogs with peripheral lymphadenopathy had 
concurrent abdominal lymphadenopathy (17 CD8+ TCLs and 25 CD4-CD8- TCLs). Abdominal 
lymph node involvement was most often identified by abdominal ultrasound, with rare cases 
identified by abdominal radiographs (n=2). The presence of hepatomegaly was unknown in 
about half of the evaluated dogs and of those where is was evaluated, 50% (n=18) of cases in the 
Immunophenotype CD4-CD8- TCL CD8+ TCL 
Age, yrs (median; range) 8 (3-15) 10 (1-15) 
Sex (number; percent)   
       Female Spayed  22 (37%) 36 (60%) 
       Female Intact 0 (0%) 2 (3%) 
       Male Castrated 32 (54%) 19 (32%) 
       Male Intact 5 (8%) 3 (5%) 
Breed (number; percent)   
      Mixed Breed 13 (22%) 12 (20%) 
      Golden Retriever 10 (17%) 7 (12%) 
      Boxer 7 (12%) 7 (12%) 
      Labrador Retriever 5 (8%) 8 (13%) 
      Other 24 (41%) 26 (43%) 
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CD8+ group and 47% (n=16) of cases in the CD4-CD8- TCL group were affected. Similarly, 
splenomegaly and/or splenic nodules affected 52% (n=17) and 53% (n=18) of evaluated cases in 
the CD8+ and CD4-CD8- TCL groups, respectively. Hepatomegaly and/or splenic changes were 
most often identified by abdominal ultrasound with fewer cases identified by abdominal 
radiographs (n=6), computed tomography (n=1), or abdominal palpation (n=2). The cause of 
liver or splenic enlargement was not definitively determined by cytology or histology. 
Gastrointestinal involvement was uncommon among both TCL groups (n=6) and included the 
presence of a gastrointestinal mass (n=2), thickened intestines (n=3), or clinical diagnosis of 
protein-losing enteropathy (n=1).  
Table 2.5. Summary of patient clinical signs and laboratory abnormalities  

















Peripheral Lymph Nodes 93% 55 59 98% 59 60 0.2068 
Abdominal Lymph Nodes 81% 29 36 56% 18 32 0.0380 
Hepatomegaly 47% 16 34 50% 18 36 0.8161 
Splenomegaly 53% 18 34 52% 17 33 0.9999 
Gastrointestinal 14% 4 28 8% 2 26 0.6702 
Skin/Mucocutaneous  10% 6 59 43% 26 60 <0.0001 
Sternal LN/Mediastinum              60% 21 35 13% 5 40 <0.0001 
Hypercalcemia 29% 16 55 4% 2 54 0.0005 
Complete Blood Count       
Mild anemia 11% 5 44 10% 4 41  
0.9999++ Moderate anemia 14% 6 44 15% 6 41 
Severe anemia 0% 0 44 0% 0 41 
Mild thrombocytopenia 27% 12 44 7% 3 41  
0.0323++ Mod. thrombocytopenia 11% 5 44 10% 4 41 
Severe thrombocytopenia 0% 0 44 0% 0 41 
Mild lymphocytosis 11% 5 44 15% 6 41  
0.4188++ Mod. lymphocytosis 2% 1 44 2% 1 41 
Severe lymphocytosis 2% 1 44 7% 3 41 
+Wilcoxon rank-sum test was performed to compare clinical features between CD4-CD8- TCLs and CD8+ TCLs. 
++Complete blood count parameters were grouped to compare all cases with anemia, thrombocytopenia, or 
lymphocytosis.  
 
Skin lesions were significantly more common in CD8+ TCL patients, with 43% (n=26) of 
the CD8+ TCL cohort exhibiting skin lesions clinically suspicious for cutaneous lymphoma. 
Within the CD8+ TCL group, 73% (n=19) of the patients with skin lesions had mucocutaneous 
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involvement. Thirteen of the 26 cases of CD8+ TCL with cutaneous lesions were confirmed to be 
cutaneous lymphoma by cytology or histology. Nine of those cases were described specifically 
as epitheliotropic, 1 case was described as non-epitheliotropic, and epitheliotropism was 
unknown in the remaining cases. In contrast, only 10% (n=6) of cases classified as CD4-CD8- 
TCL presented with concurrent cutaneous involvement. Of these 6 total CD4-CD8- TCL patients 
with cutaneous involvement, 1 dog had gingival involvement and the other 5 had generalized 
lesions. Two of the 6 cases within the CD4-CD8- TCL group were confirmed to be cutaneous 
lymphoma by cytology or histology. Epitheliotropism was unknown in all the CD4-CD8- TCL 
cases with cutaneous lesions. The presence of skin lesions was not significantly associated with 
cell size (p=0.6785), expression of MHC class II (p=0.6841), or CD5 expression (p=0.8287) 
evaluated by flow cytometry.  
Cranial mediastinal enlargement and/or sternal lymphadenopathy was seen significantly 
more commonly in CD4-CD8- TCLs, affecting 60% (n=21) of evaluated cases. Mediastinal 
enlargement or sternal lymphadenopathy were diagnosed by thoracic radiographs in all cases, 
with no additional diagnostics performed. Similarly, hypercalcemia affected 29% (n=16) of CD4-
CD8- TCL cases and was more frequently present at the time of diagnosis than in CD8+ TCLs.  
Complete blood counts (CBC) were available for review in 85 total cases (41 CD8+ TCLs 
and 44 CD4-CD8- TCLs) (Table 2.5). In general, CBC abnormalities were uncommon at the time 
of diagnosis. The most common changes included a mild to moderate anemia, mild to moderate 
thrombocytopenia, and mild lymphocytosis (5,000-10,000 lymphs/uL). Cases with mild to 
moderate neutrophilia in conjunction with mild to absent lymphopenia were common and 
interpreted as most consistent with a stress leukogram and not further evaluated. Two patients 
with CD4-CD8- TCL were mildly neutropenic (1,920 and 1,940 neutrophils/uL) and this finding 
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was not further explored. Moderate to marked lymphocytosis (>10,000 lymphs/uL), consistent 
with neoplastic involvement of the blood, was seen in 3 CD8+ TCLs and 1 CD4-CD8- TCL. 
Flow Cytometry 
 All cases were evaluated for relative cell size based on median forward light scatter, MFI 
of MHC class II, and expression of CD5 (Figure 2.6, Table 2.6). There was no significant 
difference in cell size between CD8+ TCLs and CD4-CD8- TCLs (p=0.3862), and neoplastic cell 
size ranged from small (less than 1.3 times the size of normal T-cells) to large (greater than or 
equal to 1.3 times the size of normal T-cells). The expression level of MHC class II was 
significantly lower in CD4-CD8- TCLs, compared to CD8+ TCLs (p=0.0470). The number of 
CD4-CD8- cases that were classified as low MHC expression (MFI less than normal T-cells), 
however, was not significantly different from CD8+ cases (p=0.0674). Loss of CD5 expression 
was observed significantly more often in CD4-CD8- tumors compared to CD8+ tumors 
(p=0.0188).  
Table 2.6. Summary of flow cytometry features  
Immunophenotype Size MHC class II Loss of CD5 Expression 
 Median IQR+ Median IQR+ Number Percentage 
CD4-CD8- TCL 478 424-567 2.16 0.60-9.41 25 42% 
CD8+ TCL 463 412-529 5.60 1.40-17.16 13 22% 






 Lymph node aspirates from eleven patients diagnosed with CD8+ TCL by flow cytometry 
and thirteen patients diagnosed with CD4-CD8- TCL by flow cytometry were independently and 
blindly evaluated by two clinical pathologists (Emily D. Rout, Paul R. Avery) and compared to 
cytology from ten cases of CD4+ PTCL (representative examples in Figure 2.7). The ten 
randomly-selected CD4+ PTCL cases were morphologically similar and samples contained an 
expanded population of intermediate-sized lymphocytes with round to oval, occasionally 
indented nuclei, fine chromatin, absent to rarely one faint nucleolus, and moderate amounts of 
Figure 2.6. Flow cytometric features of CD8+ and CD4-CD8- TCLs. (A) The median neoplastic cell size as 
determined by forward scatter is depicted for each case. There is no significant difference in neoplastic cell size 
between CD8+ and CD4-CD8- TCLs. The median cell size of normal T-cells is represented by the dotted line. (B) 
The MHC class II median fluorescence intensity (MFI) on neoplastic T-cells is depicted for each case. There is 
variable expression of MHC class II expression in both CD8+ and CD4-CD8- TCLs, with some cases exhibiting 
very low expression and others with higher levels compared to normal T-cells (dotted line). (C) The percent of 
cases within each immunophenotypic group that have lost expression of CD5 is provided. Loss of CD5 
expression was more commonly seen in CD4-CD8- TCLs (p-value=0.0188).  
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pale blue cytoplasm (Figure 2.7a). In comparison, CD8+ and CD4-CD8- TCLs were highly 
variable and there were no apparent trends in cytomorphology that correlated to 
immunophenotype. Approximately half of the CD8+ and CD4-CD8- TCL cases had similar 
morphology to CD4+ PTCL cases, but remaining cases were variable and often displayed more 
cellular pleomorphism. These cases tended to have round to indented nuclei and moderate 
amounts of cytoplasm similar to CD4+ PTCL, but the nuclear chromatin was often coarser to 
irregularly clumped with more prominent nucleoli and the cytoplasm could become quite 
basophilic. Five cases had marked anisocytosis and anisokaryosis. In a small number of cases, 
neoplastic cells had one to a few, small, clear, discrete cytoplasmic vacuoles. Four CD8+ TCLs 
and 3 CD4-CD8- TCLs had rare to small numbers of neoplastic lymphocytes with few fine 
azurophilic cytoplasmic granules.    
Figure 2.7. Cytomorphology of canine CD4+, CD8+ and CD4-CD8- T-cell lymphoma (TCL). Direct smears 
of fine-needle lymph node aspirates from a representative CD4+ peripheral TCL case (A) and CD8+ (B, D) and 
CD4-CD8- (C, E, F) TCL cases with variable cytomorphology are shown; Wright Giemsa stain, 50Χ. (A) Ten 
CD4+ peripheral TCLs were reviewed for comparison to CD8+ and CD4-CD8- TCLs and an example is shown 
here. The cells were intermediate sized with round to indented nuclei, fine chromatin, rare faint nucleoli and 
moderate amounts of pale blue cytoplasm. A subset of CD8+ and CD4-CD8- TCL cases had similar morphology 
to CD4+ peripheral TCL (B), while remaining cases were more variable (C-F). These cases demonstrated more 
anisocytosis with some lymphocytes exceeding 20 µm in diameter, frequently coarser to irregularly clumped 
chromatin, and increased cytoplasmic basophilia. Small numbers of cells had small clear cytoplasmic vacuoles 




 Of the 119 cases evaluated, 9 cases died, 47 were humanely euthanized, and 63 cases 
were lost to follow up (median follow-up time: 64 days). All 9 cases that died had progressive 
disease and were interpreted as a lymphoma-related death. Of the 47 cases that were humanely 
euthanized, 42 cases were euthanized due to progressive disease and declining quality of life. 
Four CD8+ cases were euthanized with clinical signs of unconfirmed etiologies including: 
hemoabdomen (n=1), pleural effusion (n=1), pulmonary nodules (n=1), and renal failure (n=1). 
A single CD4-CD8- case was euthanized with renal failure.  
CD8+ TCLs and CD4-CD8- TCLs were associated with poor clinical outcomes, with a 
median overall survival (OS) of 198 days (range 1-471 days) and 145 days (range 1-770 days), 
respectively (Figure 2.8a). Significant differences in survival between patients with tumors 
classified as CD8+ TCLs versus CD4-CD8- TCLs were not identified.  
Log-rank and Cox proportional hazards univariable analyses were performed 
independently for both tumor subtypes and the results are summarized in Tables 2.7 and 2.8. For 
both subtypes, large cell size (≥1.3 times normal T-cells) determined by forward scatter was 
associated with shorter overall survival. Combined, cases with large cell size had a median OS of 
61 days (range 1-541 days) versus 257 days (range 1-770) for those with small cell size 
(p=0.0002; Figure 2.8b). Neither MHC class II or CD5 expression levels had significant impact 




Among dogs with CD8+ TCL, the presence of hepatomegaly, anemia, or abdominal 
lymphadenopathy at the time of diagnosis were associated with a shorter OS (Table 2.7). 
Abdominal lymphadenopathy, hepatomegaly, or anemia did not significantly impact survival in 
the CD4-CD8- TCL group (Table 2.8) or the combined group of CD8+ and CD4-CD8- TCLs. The 
presence of cranial mediastinal enlargement/sternal lymphadenopathy, skin lesions, 
splenomegaly, hypercalcemia or age of the patient did not impact overall survival in CD8+ and 
CD4-CD8- TCLs.  
Chemotherapeutic regimes used to treat the dogs in this retrospective study were widely 
variable in the combination of agents used, dosages, and frequency of administration. 
Consequently, to evaluate the impact of chemotherapy on survival, treatment protocols were 
assigned to the following broad categories: no treatment, corticosteroid therapy only, single-
agent therapy, or multi-agent therapy. Corticosteroid therapy included treatment with prednisone, 
Figure 2.8. Overall survival of patients with CD8+ and CD4-CD8- TCLs. (A) Kaplan Meier curves depicting 
overall survival from time of flow cytometry diagnosis for each immunophenotypic group are provided. There is 
no significant difference in overall survival between patients with CD8+ and CD4-CD8- TCLs. The median 
survival times were 198 days and 145 days for CD8+ and CD4-CD8- cases, respectively. (B) Neoplastic cell size 
measured by forward scatter by flow cytometry is associated with a shorter overall survival in patients with 
CD8+ and CD4-CD8- TCLs (p=0.0002). The median survival time for cases classified as large cell was 61 days, 
while those classified as small cell was 257 days.  
 
 49 
prednisolone, and/or dexamethasone only. Single-agent therapy included a single 
chemotherapeutic agent with or without concurrent corticosteroid therapy. Single agents used 
included CCNU and chlorambucil. Multi-agent therapy included two or more chemotherapeutic 
agents with or without corticosteroid therapy. Five patients were enrolled in a double-blinded 
clinical trial evaluating a monoclonal antibody and may have additionally received this novel 
therapeutic. All dogs enrolled in this immunotherapy trial (n=5) and patients in which the 
therapeutic protocol was unclear in the medical record (n=5) were removed from this outcome 
evaluation. 
Within both TCL subgroups, dogs treated with chemotherapy (single-agent or multi-
agent) had a significantly prolonged survival compared to those receiving no treatment or 
corticosteroids alone. (Table 2.7 and 2.8). No significant difference in overall survival was 













Table 2.7. Summary of survival analysis for selected clinical and immunophenotypic 




















A Absent (n=14) 198 
0.076 2.92 1.02-8.42 




A Absent (n=35) 103 
0.717 1.80 0.23-14.39 
B Present (n=5) Undefined 
Cutaneous 
involvement 
A Absent (n=34) 80 
0.251 0.70 0.33-1.49 
B Present (n=26) 198 
Splenic 
changes 
A Absent (n=16) 55 
0.351 0.86 0.26-2.89 
B Present (n=17) 107 
Hepatomegaly 
A Absent (n=18) 257 
0.018 5.82 1.46-23.51 
B Present (n=18) 65 
Hypercalcemia 
A Absent (n=52) 107 
0.376 Undefined Undefined 




A Multi/Single (n=45) 237 
0.002 6.92 2.09-22.87 
B Steroids/None (n=12) 19 
Treatment - 
Single vs Multi 
A Multi-agent (n=34) 237 
0.324 0.60 0.21-1.67 
B Single-agent (n=11) 257 
Anemia 
A Absent (n=31) 237 
0.001 6.64 2.13-20.69 
B Present (n=10) 54 
Age 
A Years >10 (n=35) 198 
0.243 1.60 0.72-3.57 
B Years <10 (n=25) 80 
Cell Size 
A Small (n=40) 237 
0.002 3.54 1.52-8.26 
B Large (n=20) 54 
CD5 Loss 
A CD5+ (n=47) 147 
0.761 0.87 0.36-2.07 
B CD5- (n=13) 237 
Class II MHC 
A High (n=30) 352 
0.562 0.80 0.37-1.72 
B Low (n=30) 147 
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Table 2.8. Summary of survival analysis for selected clinical and immunophenotypic 
characteristics of CD4-CD8- TCLs.  
Variable Condition MST (d) p-value Hazard ratio (B/A) CI, hazard ratio 
Abdominal LN A Absent (n=7) 145 
0.867 2.03 0.57-7.25 




A Absent (n=14) 229 
0.179 0.38 0.13-1.11 
B Present (n=21) 469 
Cutaneous 
involvement  
A Absent (n=23) 135 
0.769 1.51 0.51-4.44 
B Present (n=6) 115 
Splenic changes A Absent (n=16) 145 
0.707 0.73 0.25-2.15 
B Present (n=18) 263 
Hepatomegaly A Absent (n=18) 263 
0.648 1.05 0.36-3.01 
B Present (n=16) 195 
Hypercalcemia A Absent (n=39) 145 
0.686 0.76 0.30-1.89 
B Present (n=16) 229 
Treatment:  
Chemo vs none 
A Multi/Single (n=40) 145 
0.050 3.09 1.00-9.54 
B Steroids/None (12) 56 
Treatment:  
Multi vs Single 
A Multi (n=37) 195 
0.937 0.92 0.12-6.99 
B Single (n=3) 145 
Anemia A Absent (n=33) 469 
0.847 1.14 0.31-4.16 
B Present (n=10) 195 
Age A Old (n=21) 126 
0.351 0.70 0.32-1.50 
B Young (n=38) 229 
Cell Size A Small (n=34) 469 
0.005 2.96 1.34-6.55 
B Large (n=25) 119 
CD5 Loss A CD5+ (n=34) 127 
0.351 1.43 0.67-3.04 
B CD5- (n=25) 469 
Class II MHC A High (n=24) 126 
0.712 0.87 0.40-1.87 
B Low (n=35) 229 
 
Discussion 
In this study we first investigated the correlations between immunophenotype by flow 
cytometry and histomorphology of nodal TCLs. Within this cohort of nodal TCL patients with 
paired histology and flow cytometry, approximately 80% were categorized as CD4+ PTCL and 
the remaining cases were classified as CD8+ PTCL or CD4-CD8- PTCL. The study population 
was representative of dogs with non-TZL TCL lymphoma presenting to specialty veterinary 
hospitals with enlarged peripheral lymph nodes. The less common T-cell phenotypes (CD8+, 
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CD4-CD8-) could not be reliably differentiated from CD4+ PTCL based on histomorphology 
alone. All tumors within the evaluated cohort were characterized by a diffuse infiltration of 
intermediate to large cells with pleomorphic nuclei and high mitotic rates. This finding may 
suggest that these tumors are part of the same disease entity regardless of immunophenotype. 
Alternatively, this finding may indicate that histomorphology alone is not a sensitive and reliable 
test to delineate biologically significant subtypes of nodal TCLs. Flow cytometry may be used to 
further divide this histologic entity into different immunophenotypic subtypes of PTCL.  
A histologic diagnosis of lymphoblastic lymphoma (LBL) was considered in few cases, but 
ultimately these tumors were classified as PTCL based on cell size, pleomorphic nuclear shape, 
and intertumoral variation in chromatin staining and nucleolar prominence. Lymphoblastic is a 
loosely defined term in veterinary medicine with variable interpretations by both clinical and 
anatomic pathologists.152 Histologically, LBL and PTCL exhibit overlapping morphologic 
features including intermediate cell size, variably round to oval to irregularly indented nuclei, 
and high mitotic rates.152 Differentiation between the histomorphology of these neoplasms has 
been reliant on nucleolar prominence and number and conspicuousness of mitotic figures.152 
Because there was  moderate to marked variation of these histologic features within an individual 
tumor sample, the authors felt that these features could not be used to reliably differentiate 
morphologically distinct subtypes and were consistent with the morphologic features described 
for PTCL-NOS by the WHO classification system in both dogs and humans. According to the 
WHO classification, LBL is a precursor T-lymphocyte neoplasm which typically expresses TdT 
and CD3420, markers of immature lymphoblasts. Cases of PTCL do not express CD34163, a 
commonly used marker of acute leukemias in dogs.177 Evaluation of TdT expression has not yet 
been optimized for canine diagnostics by flow cytometry or immunohistochemistry. Further 
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development of markers of immaturity for canine lymphocytes would be useful to more reliably 
differentiate tumors of precursor versus mature lymphocyte origins.  
We next performed gene expression profiling focused on the most common 
immunophenotype of PTCL. CD4+ PTCL exhibited consistent changes in gene expression 
between tumor samples from different dogs. Homogeneity within the gene expression profile of 
PTCL from different patients is promising for investigation into novel therapeutics and clinical 
trial design. PTCL in Boxer dogs, who are overrepresented in the patient population, did not 
exhibit a distinct overall gene expression profile from PTCL in other breeds. However, one gene 
that was significantly differentially expressed in Boxer dogs was ROS1. ROS1 is a receptor 
tyrosine kinase often involved in chromosomal translocations and oncogenic fusion gene 
formation in human cancers.31 In a preliminary analysis, ROS1 fusion gene transcripts were not 
identified in canine CD4+ PTCL (data not shown).  
CD8+ and CD4-CD8- TCLs involving the lymph nodes are rare in dogs, comprising 2.3% and 
2.6% of all nodal lymphomas respectively. The distribution of nodal lymphoma 
immunophenotypes in dogs from the CSU-CI database described in this study closely mimics the 
distribution reported by Martini et al, demonstrating inter-institutional consistency.178 Because 
these lymphoma subtypes are uncommon, the clinical features and biologic behavior has not 
previously been well described. In the third part of this chapter, we performed a retrospective 
study to describe the clinical features of a large group of individuals diagnosed with CD8+ and 
CD4-CD8- TCLs by flow cytometry. In general, patients with either CD8+ or CD4-CD8- TCL had 
poor clinical outcomes with median overall survival times of 198 and 145 days, respectively. 
There was no significant difference in survival between patients diagnosed with CD8+ versus 
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CD4-CD8- TCLs and these survival times are similar to that previously reported for CD4+ TCLs 
(159-162 days).158,163,164  
 CD8+ and CD4-CD8- TCLs had widely variable cytomorphology, with inconsistent cell 
size, chromatin pattern, cytoplasmic basophilia and presence of nucleoli. Similarly, by flow 
cytometry both CD8+ and CD4-CD8- neoplastic cells ranged in size from small to large. Cell size 
determined by flow cytometry did have a prognostic impact, with tumors comprised of large 
cells measuring greater than or equal to 1.3 times the median size of normal T-cells having a 
shorter overall survival. Nevertheless, the median overall survival of patients with small cell size 
was 257 days. This overall survival time is still much shorter than that expected for an indolent 
disease,10,12 despite the small cell size. These results support the finding that cell size is 
prognostic only within specific subtypes of lymphoma163, but not as an indicator of indolent 
disease when the subtype is unknown. Therefore, these findings highlight the importance of 
ancillary diagnostics, specifically flow cytometry, to phenotype canine lymphoma cases in order 
to provide accurate prognostic information and inform treatment decisions.  
Concurrent skin lesions, suspicious for or confirmed to be cutaneous lymphoma were 
more commonly seen in CD8+ TCLs. This finding is consistent with previous reports 
demonstrating that canine cutaneous epitheliotropic lymphoma is most typically comprised of 
neoplastic CD8+ T-cells.178,179 Of the CD8+ TCL cases with skin involvement, 73% had 
mucocutaneous localization. Cases with skin lesions did not exhibit distinct trends in cell size, 
expression of MHC class II, or CD5 expression evaluated by flow cytometry.  
 The presence of hepatomegaly, anemia, or abdominal lymphadenopathy were associated 
with shorter overall survival times in cases of CD8+ TCL. In dogs, hepatosplenic lymphoma is a 
rare form of T-cell lymphoma characterized by infiltration of the liver and/or spleen in the 
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absence of peripheral lymph node involvement.20,180  Hepatosplenic lymphoma in dogs can be 
comprised of CD8+ or CD4-CD8- T-cells.180 Of the 18 CD8+ TCLs in this study with 
hepatomegaly, one patient had abdominal lymphadenopathy in the absence of peripheral 
lymphadenopathy. All other CD8+ TCLs and all cases of CD4-CD8- TCL with hepatomegaly in 
this study had concurrent peripheral lymphadenopathy, making a diagnosis of hepatosplenic 
lymphoma less likely.  
The few cases of CD8+ and CD4-CD8- included in the flow cytometry-histopathology 
correlation study were classified as PTCL-NOS by histology. Therefore, we hypothesize that the 
majority of cases within the larger cohort of patients would also fall with the histologic 
classification of PTCL-NOS. A subset of cases in the current study were classified as small to 
intermediate in size by flow cytometry. This feature could be also be consistent with a 
classification of lymphoblastic lymphoma. Both PTCL and lymphoblastic lymphoma carry poor 
prognoses in dogs6, consistent with the overall survival times of patients evaluated in this study.    
Presence of cranial mediastinal/sternal lymph node enlargement and/or hypercalcemia 
were more frequent in the CD4-CD8- TCL subgroup. These clinical features have been 
previously associated with CD4+ TCLs163, suggesting clinical similarity between these two 
entities. CD4-CD8- TCLs also exhibit flow cytometry features characteristic of CD4+ TCLs, 
including frequent low MHC class II expression and loss of CD5 expression.163 Furthermore, a 
subset of CD4-CD8- cases had cytomorphology similar to CD4+ TCL. It is possible that at least a 
subset of CD4-CD8- TCLs are part of the same, or closely related PTCL entity as CD4+ PTCL. 
We hypothesize that CD4-CD8- TCLs may arise from a thymic precursor prior to expression of 
CD4 and CD8, while CD4+ TCLs arise from a slightly more mature thymocyte or naïve single 
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positive T-cell that has committed to the CD4 lineage. Alternatively, CD4-CD8- TCLs may 
represent a variant of CD4+ TCL, that has lost expression of CD4.  
 In this study, approximately 63% of dogs with CD8+ TCL were female and 
approximately 63% of dogs with CD4-CD8- TCLs were male. CD4+ TCL in dogs also has a male 
predominance with 56-62% of affected patients being male.159,163 In human patients, PTCL-
NOS, which we hypothesize to be similar to canine CD4+ TCL, has a reported male to female 
ratio of 2:1.20 The pathobiology underlying this sex predilection is not yet understood. 
 Evaluation of the impact of treatment on overall survival is limited by the retrospective 
nature of this study. Within the patient group, a wide range in chemotherapy protocols were used 
with marked variations in drug combinations, dosages, and frequency of administration. 
Consequently, patients were divided into broad treatment categories (no treatment, 
corticosteroids only, single-agent, multi-agent) to evaluate impact of treatment on survival. 
Complicating the treatment evaluation, was inherent bias in treatment decisions based on disease 
severity at the time of presentation to the veterinarian, response to initial treatment, and/or 
financial and personal considerations of clients. With these limitations in mind, we did find that 
patients treated with single-agent or multi-agent chemotherapy protocols had a prolonged 
survival compared to those not receiving treatment or only receiving corticosteroid therapy. This 
finding was consistent in both CD8+ and CD4-CD8- TCL subgroups. A significant difference in 
survival was not observed between patients treated with multi-agent compared to single-agent 
chemotherapy regimens. The clinical significance of this finding is uncertain, given the limited 
power and sample size in this analysis.  In this group of patients, CCNU was the most frequently 
administered single-agent therapeutic, and this drug has been shown to improve outcome in 
canine patients with cutaneous lymphoma.28,29  
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 In human patients, PTCL is a heterogeneous disease with the majority of tumors 
classified into a ‘not-otherwise specified’ subgroup (PTCL-NOS) of uncertain pathobiology.30 
Similar to dogs, PTCL-NOS in people is an aggressive disease with poor responses to 
conventional chemotherapy and 5-year overall survival rates of only 32%.31 The majority of 
nodal PTCL-NOS in people are CD4+, however cases can also be CD8+, CD4-CD8-, or rarely 
CD4+CD8+.32 In people, CD8+ PTCL-NOS is more commonly associated with extranodal 
disease.33 Similarly, extranodal T-cell lymphoma in dogs is most commonly CD8+ or CD4-CD8-
.178 Gene expression profiling in human PTCL-NOS has identified subgroups with expression 
profiles similar to mature, activated CD4+ T-cells or less commonly, CD8+ T-cells. In this human 
study, however, the tumors classified as CD4+ ‘helper-like’ or CD8+ ‘cytotoxic-like’ subgroups 
did not correlate with protein expression of CD4 or CD8 as evaluated by 
immunohistochemistry.32 Consequently, the utility of classifying PTCL cases in humans based 
on surface expression of CD4 and CD8 molecules is uncertain.  
 In this chapter, we first describe the ability of flow cytometry to identify a distinct 
molecular and histologic entity: CD4+ PTCL. Less common immunophenotypes (CD8+, CD4-
CD8-) could not be distinguished histologically from CD4+. We then describe the clinical 
characteristics of two uncommon nodal TCL phenotypes in dogs. Due to the rarity of these TCL 
subtypes, previous reports of the clinical features and biologic behavior are limited, preventing 
accurate prognostication of patients diagnosed with these tumors. We demonstrate that CD8+ and 
CD4-CD8- nodal TCLs have an aggressive behavior with overall survival times similar to that of 
the more common CD4+ PTCL. Furthermore, based on similar presenting clinical signs, 
cytomorphology and flow cytometry features, we suggest that at least a subset of CD4-CD8- 
tumors may share a common pathogenesis to CD4+ PTCL. CD8+ TCLs exhibited more variable 
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cytomorphology, as well as differences in clinical presentations and prognostic features. These 
findings imply that this entity may have a different pathophysiology to the more common CD4+ 
TCL. Within both CD8+ and CD4-CD8- TCL groups, cell size was prognostic, and cases 
comprised of large cells determined by flow cytometry exhibited significantly decreased overall 
survival times. Importantly, however, even cases classified as small cell exhibited aggressive 
disease with shorter overall survival times than that reported for indolent lymphomas.10,12,34,35 
This study lays the groundwork for further investigation into the molecular pathways driving 
these aggressive neoplasms and highlights the utility of flow cytometry in identifying and 

































Peripheral T-cell lymphoma (PTCL), not-otherwise specified (NOS) is the most common 
PTCL subgroup and includes a heterogenous group of tumors derived from neoplastic T-cells. 
PTCL-NOS is a poorly understood and aggressive disease with grave clinical outcomes and 
limited therapeutic options. Molecular subtypes of PTCL-NOS including PTCL-GATA3 and 
PTCL-TBX21 have recently been identified. PTCL-GATA3 is associated with a worse prognosis 
and greater genomic complexity including frequent loss of tumor suppressor genes associated 
with the CDKN2A/TP53 and PTEN-PI3K pathways. Despite these advances, characterization of 
the underlying pathogenesis and identification of novel therapies trails that of other 
hematopoietic tumors. The dog presents a unique opportunity to study a naturally-occurring 
translational model of PTCL-NOS. PTCL is one of the most common subtypes of non-Hodgkin’s 
lymphoma in dogs. The clinical and diagnostic features of this canine neoplasm have been 
previously described; however, molecular characterization remains largely unexplored. In this 
chapter, we evaluate the gene expression prolife of canine PTCL by RNA-seq. We compare gene 
expression profiles of human and canine PTCL-NOS, and identify molecular similarities 
between the neoplasms in these two species. We show that canine PTCL is similar to the PTCL-
GATA3 subgroup with strong expression of GATA3 and enrichment for the PI3K-AKT-MTOR 
pathway.  We also demonstrate a functional role for PI3K signaling in canine PTCL by showing 
that inhibition of PI3K results in impaired proliferation in a canine T-cell lymphoma cell line as 
well diminished cell survival of primary patient-derived PTCL cells in short-term cell culture. 
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Results support the dog as a potentially valuable naturally-occurring model of PTCL-NOS to 
investigate the pathogenesis of the PTCL-GATA3 subgroup.  
Introduction 
Peripheral T-cell lymphomas (PTCL) encompass a heterogenous group of aggressive 
neoplasms derived from T-lymphocytes. These neoplasms are uncommon, comprising 5-20% of 
all non-Hodgkin lymphomas (NHL).20,108 At least 25% of PTCL cases do not correspond 
specifically to defined T-cell entities in the World Health Organization classification and are 
therefore categorized as PTCL, not otherwise specified (NOS).20,109,110 Advances in the 
understanding of the underlying pathobiology and development of targeted treatments have been 
limited by intrinsic disease heterogeneity, rarity, and lack of useful animal model systems.  
 In contrast to humans, PTCL is among the most common NHL subtypes in dogs, 
comprising approximately 15% of all naturally-occurring NHLs cases in this species.156–159 The 
majority of PTCL cases in dogs fall within the category of PTCL-NOS160, with rare reports of 
other PTCL subtypes, including anaplastic large cell lymphoma.158,161,162 Dogs affected by 
PTCL-NOS exhibit similar clinical and diagnostic features to human patients. Dogs are typically 
diagnosed at middle to older age, with an average age of approximately 7 years old. Similarly, 
PTCL-NOS most often affects adult patients, with a median age of presentation of 60 years.109 
There is a male predominance in both species.109,159,163 Both human and canine patients typically 
present in advanced stages with multicentric peripheral lymph node involvement, although any 
organ can be affected. Unlike in human patients, mediastinal involvement is seen in 30-40% of 
canine cases.163 Dogs and people with PTCL-NOS are typically treated with anthracycline-
containing regimens, most often comprised of cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP), with variable initial response and poor overall prognosis.109,163    
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Similar to PTCL-NOS in humans, canine tumors exhibit clonal T-cell receptor (TCR) 
gene rearrangement. The majority of PTCL-NOS cases are CD4+ with fewer cases being CD8+ 
or CD4-CD8-. Loss of CD5 expression is common in both species.163,181 Histologically, these 
tumors are comprised of sheets of intermediate to large cells which often efface normal tissue 
architecture. Neoplastic cells typically have cleaved or oval nuclei and the mitotic rate can be 
variable but most often is considered high.152 
Gene expression profiling has improved the understanding of PTCL-NOS in humans and 
has identified two major molecular subgroups: (1) the GATA3 subgroup, which is enriched for 
MYC, PI3K-ATK-MTOR, and ß-catenin gene signatures; and (2) the TBX21 subgroup which is 
enriched for INF-g and NF-kB signaling. The GATA3 signature is associated with a worse 
prognosis.117,118 Similar gene expression profiling experiments have not yet been performed in 
canine PTCL-NOS.  
In this study, we evaluate the gene expression profile of 33 canine PTCL cases compared 
to sorted control CD4 and CD8 T-cells from the lymph nodes of healthy dogs. We identify 
molecular similarities between human and canine PTCL-NOS. Canine PTCL-NOS is most 
similar to the GATA3 subgroup with upregulation of the GATA3-associated gene signature as 
well as enrichment of the PI3K-AKT-MTOR signaling axis. Shared molecular signatures 
between human and canine PTCL-NOS, suggests that the dog has potential as a valuable 
naturally-occurring translational model to further investigate the pathogenesis of PTCL-NOS. 
The dog may also serve as a unique model-system to evaluate responses to novel, targeted 




Materials and Methods 
Case selection for RNA-Seq 
Fine needle tissue aspirates from 33 dogs submitted to the Colorado State University-
Clinical Immunology laboratory for routine diagnostics and diagnosed with CD4+, CD4-CD8-, or 
CD8+ PTCL by flow cytometry were selected for RNA-seq. PTCL cases were identified by 
uniform expansion of T-cells characterized by expression of the pan-leukocyte marker CD45, the 
T-cell markers CD3 with or without CD5, and lack of expression of the B-cell marker CD21. 
Cases exhibited variable expression of T-cell subset antigens, CD4 and CD8. Median purity of 
neoplastic cells was 91.5% (range 63-99%). Prior studies from our laboratory have demonstrated 
that T-cell lymphomas with these flow cytometric features are histologically classified as PTCL 
NOS. 
Control CD4+ and CD8+ T lymphocytes were harvested from lymph nodes of healthy 
dogs utilized for IACUC approved surgical continuing education courses. T-cell subsets were 
sorted by a MoFlo cell sorter (Beckman Coulter, Brea, CA) using positive selection with anti-
CD4 (clone YKIX302.9) or anti-CD8 (clone YCATE55.9). Sorted populations were re-analyzed 
for purity and were used if greater than 90% of the cells were the desired population. 
RNA Extraction and Sequencing 
RNA extraction was performed using the Purelink RNA mini Kit (Thermo Fisher 
Scientific, Waltham, MA) and quality was measured with an Agilent 2100 Bioanalyzer System. 
All samples had a RIN value greater than 6.3 (median RIN 8.45; range 6.3-9.8). RNA was 
shipped to Novogene Corporation Inc (Sacramento, CA) where the libraries were constructed 
and sequenced using an Illumina Hiseq PE150 platform.  
Differential Gene Expression 
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Sequences were aligned to CanFam3.1 genome using HISAT2.182 HTseq183 and 
DESeq2184 were then used to quantify reads, normalize gene expression, and evaluate 
differentially expressed genes between tumor samples and controls. P-values were determined 
using a negative binomial distribution.  A Benjamini-Hochberg procedure was used to correct p-
values and padj<0.05 was considered the differentially expressed gene screening standard.  
Clustering 
Samples were clustered by FPKM using hierarchical clustering distance method with the 
function of heatmap, SOM (Self-organization mapping) and kmeans. Silhouette coefficient was 
used to adapt the optimal classification with default parameters in R. The Broad Institute tool, 
Morpheus185, was used to visualize heatmaps using one minus Pearson’s correlation and average 
linkage. 
Correlation of canine and human gene expression profiles 
 
 Differential gene expression between human PTCL-NOS samples and sorted CD4+ 
control human T-cells was evaluated using microarray analysis previously carried out by 
Piccagula et al (geo accession number GSE6338).128 Differential gene expression between 
human PTCL-NOS patient biopsies and sorted CD4+ T-cells was performed using GEO2R 
analysis software. The top 200 significantly upregulated and 200 significantly downregulated 
genes were selected for comparison. The log2foldchange(FC) of those selected genes were 
identified in both human and canine samples. Human genes which are not annotated in the 
canine genome were removed from the analysis. Comparison of the log2FC of the selected genes 
in human and canine samples was compared using a heatmap created by the Morpheus tool185 
and gene set enrichment analysis (GSEA).186 The gene set used for GSEA analysis was pre-
ranked based on the log2FC.  
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Pathway Enrichment Analysis 
Gene set enrichment analysis (GSEA)186 was used to compare canine PTCL gene 
expression profiles to various molecular signatures. The list of significantly differentially 
expressed genes in CD4+ PTCL compared to control CD4+ was ranked based on log2FC. The 
pre-ranked gene list was then compared to gene sets identified in the molecular signature 
database (MSigDB) v7.0.187 Gene sets with an FDR q-value <0.05 were considered significantly 
enriched.  
Immunohistochemistry  
Six PTCL cases were selected from submissions to the CSU Diagnostic Laboratory for 
biopsy or post-mortem examination. Cases were identified based on histomorphology consistent 
with PTCL-NOS and confirmed T-cell origin by flow cytometry, immunohistochemistry, and/or 
clonal T-cell receptor rearrangement. Normal canine lymph node was used as a positive control. 
A canine cutaneous mast cell tumor18 served as an additional positive control for the CD30 
antibody. HIER was performed on a Leica Bond-Max or Leica Bond III IHC stainer using Bond 
Epitope Retrieval Solution 2 (Bond Epitope Retrieval Solution 2, Leica Biosystems Newcastle 
Ltd, Newcastle Upon Tyne, United Kingdom) for 30 minutes.  The monoclonal anti-human 
CD30 antibody (clone Ber-H2, Dako North America Inc., Carpinteria, CA) at 1:20 dilution or 
monoclonal anti-mouse GATA3 antibody (clone 1A12-1d9, Invitrogen, Waltham, MA) at 1:500 
dilution was applied. Labeling was performed on an automated staining platform (Bond-Max, 
Leica Biosystems Newcastle Ltd, Newcastle Upon Tyne, United Kingdom). Fast Red (Fast Red 
Substrate System, Dako North America Inc., Carpinteria, CA) was used as a chromogen and 
slides were counterstained with hematoxylin. Negative controls were incubated in diluent 
consisting of Tris-buffered saline with carrier protein and homologous nonimmune sera.  All 
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sequential steps of the immunostaining procedure were performed on negative controls following 
incubation. Expression of phosphorylated AKT was evaluated using the rabbit monoclonal 
phosph-AKT antibody (Ser473, D9E, XP, Cell Signaling Technology, Danvers, MA) at 1:50 
dilution with the mouse and rabbit specific HRP/DAB (ABC) detection IHC kit (ab64264, 
abcam, Cambridge, United Kingdom).   
Western Blot 
CD4+ PTCL and T-zone lymphoma cases were identified based on flow cytometry. CD4+ 
PTCL was characterized by a uniform expansion of CD45+CD3+CD5+/-CD4+CD8-CD21- T-cells.  
Cases of T-zone lymphoma were selected based on CD45-CD3+CD4+CD5+CD21hi 
immunophenotype.160,174 Protein was extracted from fine needle aspirations of affected lymph 
nodes using Invitrogen cell extraction buffer (FNN0011, ThermoFisher Scientific, Waltham, 
MA) supplemented with 1mM PMSF and Halt protease/phosphatase inhibitor cocktail  
(ThermoFisher Scientific, Waltham, MA). Total protein concentrations were measured using 
Pierce BCA protein assay kit (ThermoFisher Scientific, Waltham, MA). Samples were 
resuspended to an equal total protein per sample using deionized water. NuPAGE LDS sample 
buffer (ThermoFisher Scientific, Waltham, MA) and NuPAGE reducing agent (ThermoFisher 
Scientific, Waltham, MA) were added to the samples and they were subsequently heated at 70°C 
for ten minutes. Gel electrophoresis was performed using NuPAGE Novex 12% Bis-Tris 
MiniGel (ThermoFisher Scientific, Waltham, MA). A Novex sharp pre-stained protein standard 
(ThermoFisher Scientific, Waltham, MA) and MagicMark XP western protein standard 
(ThermoFisher Scientific, Waltham, MA) were used as protein standards. The iBlot 2 dry 
blotting system (ThermoFisher Scientific, Waltham, MA) was used for membrane transfer. The 
protein-bound membrane was blocked with 5% non-fat dried milk for 1 hour and subsequently 
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washed in tris-buffered saline and polysorbate 20 (TBST) buffer. The membrane was exposed to 
the primary antibodies PDGFRB (28E1, 3169, rabbit monoclonal, diluted 1:1000, Cell Signaling 
Technologies, Danvers, MA) or B-actin (4967L, rabbit monoclonal, diluted 1:1000, Cell 
Signaling Technologies, Danvers, MA) at 4°C overnight. Membranes were then washed with 
TBST and incubated for 30 minutes at room temperature with the secondary antibody (goat anti-
rabbit HRP, diluted 1:5000, ab6721, abcam, Cambridge, United Kingdom). The membrane was 
washed again with TBST and visualized using a chemiluminescent visualizer. 
Cell Culture 
 
The canine T-cell lymphoma cell line, OSW188, and primary CD4+ PTCL cells obtained 
from fine-needle aspirations of peripheral lymph nodes were grown under standard conditions 
(37 °C, 5% carbon dioxide) in RPMI1640 medium supplemented with 10% fetal bovine serum, 
0.05μmol/ml 2-mercaptoethanol (Milipore Sigma, St. Louis MO), 1 x minimum essential 
medium (MEM), 78 non-essential amino acids (Milipore Sigma, St. Louis MO), 100U/mL 
penicillin and 100μg/mL streptomycin (Milipore Sigma, St. Louis MO), 1 x Glutamax (Gibco, 
Waltham MA), 10mM Corning HEPES (Media Tech Inc, Manassas VA) and 1mM sodium 
pyruvate (Gibco, Waltham MA). CD4+ PTCL cases were selected as described above.  
Proliferation Assays 
 
Neoplastic cells were washed with HBSS (Milipore Sigma, St. Louis, MO) and then 
labelled for carboxyfluorscein succinimidyl ester (CFSE, 5μM, Invitrogen, Waltham, MA) for 5 
minutes and washed as previously described.189 Cells were then resuspended in RPMI-10 
supplemented as described above. Cells were incubated in 96-well round bottom cell culture 
plates at a concentration of 5 X 105 cells per well for primary neoplastic lymphocytes or in a 48-
well round bottom cell culture plate at a concentration of 2 X 105 cells per well for OSW cell 
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line. To determine the total cell count, a known amount of CountBrite beads were added prior to 
sample acquisition, and cells were enumerated based on bead recovery and amount of sample 
remaining at the time of harvest. Cells were harvested at 6 or 24 hour time points over a total 
time frame of 48hrs to 7 days. Harvested cells were washed twice with 150µL of flow buffer 
(PBS-2% FBS-0.1%NaAZ) and resuspended in 25µL of flow buffer with or without 25µL of a 
cocktail of antibodies in flow buffer. For primary patient samples, surface antigens used 
included: CD5-APC (rat anti-dog T cell, clone YKIX322.2, Bio-Rad, Hercules CA), CD4-
pacblue (rat anti-dog CD4 T-cell, clone YKIX302.9, Bio-Rad, Hercules CA) and CD8-A700 (rat 
anti-dog CD8 T cell, clone YCATE 55.9, Bio-Rad, Hercules CA). OSW cell line was not stained 
with surface antigens. Samples were incubated for 15 minutes in the dark at room temperature 
and resuspended in 100µL of flow buffer and 100µL of 10µg/mL of propidium iodide (PI) for 
identification of dead cells. Samples were acquired on a 3-laser Coulter Gallios and analyzed 
with Kaluza software (Beckman Coulter, Brea, CA). 
Cell Death Assays 
Cell death was measured by annexin V expression and PI measured by flow cytometry. 
An Annexin V:FITC assay kit (ANNEX100F, Bio Rad, Hercules CA) was used according to 
manufacturer’s instructions. Briefly, cells were washed in cold PBS and resuspended in binding 
buffer. Cells were stained with the Annexin V: FITC antibody for 15 minutes in the dark at room 
temperature. Following staining, cells were washed with binding buffer and resuspended in 
binding buffer (0.01M Hepes (pH 7.4), 0.14M NaCl, and 2.5 mM CaCl2 solution) and PI. 
Samples were acquired on a 3-laser Coulter Gallios and analyzed with Kaluza software 
(Beckman Coulter, Brea, CA). 
Cellular stimulation or inhibition assays 
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Neoplastic T-cells were stimulated with 2.5 µg/mL phytohaemagglutinin (PHA) 
(Milipore Sigma, St. Louis MO) or 1ng/mL, 2 ng/mL, or 4ng/mL human recombinant platelet 
derived growth factor-BB (PDGF-BB) (Sigma-Aldrich, St. Louis MO). For PI3K inhibition 
assays, neoplastic T-cells were treated with 50 µM LY294002 (Cell Signaling Technology, 
Danvers MA) or equivalent volume of DMSO. 
Statistical analysis 
Statistical analyses were performed in GraphPad Prism 8.0. Evaluation of changes in total 
cell number and CFSE median fluorescence intensity (MFI) over short term culture was 
performed using multiple t-test analysis, resulting in an individual comparison per timepoint. 
Total cell death in short term cultures was compared using a Wilcoxon matched-pairs signed 
rank test.  
Results 
 
Canine patient demographics 
Fine-needle tissue aspirates from thirty-three canine patients diagnosed with PTCL by 
flow cytometry were selected for RNA-seq. Patient demographics are described in Table 3.1. 
The mean age at the time of flow cytometry diagnosis was 8 years (range 3-14 years) and the 
majority of patients were castrated males (70%). The most common breeds were mixed breed 
(24%), Boxer (18%), and golden retriever (15%), consistent with the previous reports of 
increased incidence of aggressive PTCLs in the Boxer and golden retriever breeds.153,158,163,164 
The majority of samples were obtained from fine-needle aspirates of the lymph node. Few 
















Cases fell into three immunophenotypic categories: CD4+CD8-, CD4-CD8+, and CD4-
CD8- (Figure 3.1 A-C). The majority of cases (26 individuals, 79%) were CD4+CD8- PTCLs. 
Eight of those 26 total CD4+CD8- PTCLs exhibited loss of the T-cell marker CD5. Fewer cases 
were CD4-CD8+ PTCLs (4 individuals, 12%) or CD4-CD8- PTCLs (3 individuals, 9%). A single 
CD4-CD8- exhibited loss of CD5. All cases expressed the pan-leukocyte marker CD45, thereby 





Table 3.1 Demographics of patients selected for RNA-seq  
 
Immunophenotype Breed Sex Age (years) Site Sampled 
CD4+CD8-CD3+CD5+ Mixed Male castrated 6 Lymph node 
CD4+CD8-CD3+CD5+ Boxer Female spayed 4 Mediastinum 
CD4+CD8-CD3+CD5+ German Shephard Female spayed 6 Bone 
CD4+CD8-CD3+CD5+ Labrador Retriever Male castrated 7 Pleura 
CD4+CD8-CD3+CD5+ Chesapeake Bay Retriever Male castrated 6 Lymph node 
CD4+CD8-CD3+CD5+ Rhodesian Ridgeback Male castrated 3 Mediastinum 
CD4+CD8-CD3+CD5+ Boxer Male castrated 9 Lymph node 
CD4+CD8-CD3+CD5+ Boxer Female spayed 10 Lymph node 
CD4+CD8-CD3+CD5+ Goldendoodle Male castrated 11 Lymph node 
CD4+CD8-CD3+CD5+ Golden Retriever Male castrated 7 Lymph node 
CD4+CD8-CD3+CD5+ Mixed Male castrated 11 Lymph node 
CD4+CD8-CD3+CD5+ Golden Retriever Male castrated 5 Lymph node 
CD4+CD8-CD3+CD5+ Shetland Sheepdog Male castrated 8 Lymph node 
CD4+CD8-CD3+CD5+ Presa Canario Female spayed 6 Lymph node 
CD4+CD8-CD3+CD5+ Miniature Australian Shephard Male castrated 5 Lymph node 
CD4+CD8-CD3+CD5+ Shiatzu Male castrated 11 Lymph node 
CD4+CD8-CD3+CD5+ Boxer Female spayed 9 Lymph node 
CD4+CD8-CD3+CD5+ Mixed breed Male castrated 12 Lymph node 
CD4+CD8-CD3+CD5- Boxer Male castrated 5 Lymph node 
CD4+CD8-CD3+CD5- Golden retriever Male castrated 10 Lymph node 
CD4+CD8-CD3+CD5- Golden retriever Male castrated 4 Lymph node 
CD4+CD8-CD3+CD5- Dogue de Bordeaux Male castrated 5 Lymph node 
CD4+CD8-CD3+CD5- Mixed breed Male castrated 6 Lymph node 
CD4+CD8-CD3+CD5- Boxer Male castrated 7 Lymph node 
CD4+CD8-CD3+CD5- Australian Shephard Male castrated 10 Lymph node 
CD4+CD8-CD3+CD5- Golden Retriever Female spayed 10 Lymph node 
CD4-CD8-CD3+CD5+ Cavalier King Charles Spaniel Female spayed 4 Lymph node 
CD4-CD8-CD3+CD5+ Mixed  Female spayed 4 Lymph node 
CD4-CD8-CD3+CD5- Pomeranian Male castrated 11 Lymph node 
CD4-CD8+CD3+CD5+ Mixed  Female spayed 12 Lymph node 
CD4-CD8+CD3+CD5+ Mixed Male castrated 6 Lymph node 
CD4-CD8+CD3+CD5+ Mixed Female spayed 14 Lymph node 
CD4-CD8+CD3+CD5+ Lhasa Apso Male castrated Unknown Lymph node 
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Gene expression profile of canine PTCL 
 The surface protein expression of T-cell subset markers CD4 and CD8 used to classify 
the PTCL cases and sort the control T-cells correlated strongly with the gene expression levels of 







Figure 3.1. Correlation between surface molecule expression and gene expression. The flow cytometry plots 
used to classify CD4+ TCL (A), CD8+ TCL (B), and CD4-CD8- TCL (C). Corresponding gene expression of 
CD4 and CD8a (D) demonstrate correlation to the surface protein level. Red denotes relative increased 
expression levels and blue denotes decreased expression levels. SS=side scatter; FS=forward scatter; DN=double 
negative, CD4-CD8-.  
 
 71 
 Hierarchical clustering and principle component analysis were performed to evaluate 
clustering of neoplastic and control samples using significantly differentially expressed genes 
(Figure 3.2). Control CD4+ and CD8+ T-cells clustered separately from neoplastic samples. 
Control cells further exhibited distinct CD4+ and CD8+ subgroups. The CD4+ PTCL and CD8+ 
PTCL appear to form two distinct molecular groups, with the CD8+ PTCLs clustering more 
closely with the control T-cells. Two of the 3 CD4-CD8- PTCLs clustered with the CD8+ PTCLs 
and 1 CD4-CD8- PTCL clustered with the CD4+ PTCLs. Distinct clinical features were not 
identified to differentiate between the CD4-CD8- PTCL that clustered with the CD4+ PTCLs 




Figure 3.2 Hierarchical clustering of canine PTCL and control T-cells. Heatmap showing hierarchical 
clustering with red denoting upregulated genes and blue denoting downregulated genes(A) and principle 
component analysis (PCA) (B). Control T-cells and PTCL samples formed distinct groups in both the heatmap 
and PCA plot, with CD4+ and CD8+ T-cell subgroups. The CD4+ and CD8+ PTCL cases clustered separately, as 
two distinct groups. Two CD4-CD8- (DN) PTCL cases clustered with the CD8+ PTCL subgroup and one DN 
PTCL clustered with the CD4+ PTCL subgroup. CD8+ PTCL cases clustered more closely with control samples 
than the CD4+ PTCL subgroup.  
 72 
Comparison of human and canine gene expression profiles 
 We next sought to evaluate the molecular similarity between human and canine PTCL-
NOS. Given the uniform clustering pattern and relative increased incidence within the canine 
population, subsequent studies focused on the CD4+ PTCL subgroup in the dog.  The top 200 
upregulated and 200 downregulated genes in human PTCL-NOS cases compared to sorted 
human CD4+ control T-cells were identified using a previous microarray study by Piccaluga et 
Figure 3.3 Canine PTCL is molecularly similar to the human counterpart. The top 200 upregulated and 200 
downregulated genes in human PTCL-NOS cases compared to sorted human CD4+ control T-cells were 
identified using a previous microarray study by Piccaluga et al. (2007) and GEO2R analysis. (A) A heatmap in 
which each vertical line indicates a human gene ranked in increasing order of differential expression compared 
to normal CD4 T-cells (left) and the relative expression levels of the equivalent dog genes (right) (B) The 
acquired list of differentially expressed genes in human PTCL-NOS was compared to canine PTCL using Gene 
Set Enrichment Analysis (GSEA). GSEA assesses how the genes of each gene set are distributed across a ranked 
list by walking down a ranked list of genes and increasing the running-sum statistic when a gene belongs to the 
set and decreasing it when the gene does not. The enrichment score (top) reflects the degree to which the genes 
in a gene set are overrepresented at the top or bottom of the entire ranked list of genes. The hits (middle) are 
shown as vertical lines that represent the location of the canine genes in the ranked set of all genes. The ranking 
metric scores (bottom) is the signal to noise ratio for each gene used to position the gene in the ranked list. A 
statistically significant enrichment was identified (P-value <0.001; FDR q-value<0.001). 
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al.128 This study was chosen because it included a control and experimental group analogous to 
the canine samples in our current study. The log2FC of the identified genes were compared 
between human and canine samples (Figure 3.3). The most significantly upregulated genes in the 
human PTCL-NOS cases were similarly upregulated in the canine samples. Upregulated genes in 
both human and canine samples were enriched for extracellular matrix organization, vesicle-
mediated transport, signaling by receptor tyrosine kinases, regulation of insulin-like growth 
factor, and platelet activation signaling and aggregation using the gene set enrichment analysis 
(GSEA)186 REACTOME pathway analysis (FDR<0.05).190–192 Using GSEA, the canine GEP was 
significantly enriched for the top 200 upregulated and 200 downregulated genes in human 
PTCL-NOS (p-value <0.001; FDR q-value<0.001) (Figure 3.3 B).  
CD30 expression in canine PTCL 
 CD30 is a useful cell-surface marker that is expressed by a number of 
lymphoproliferative diseases including neoplastic B-cells in classical Hodgkin’s lymphoma and 
neoplastic T-cells in anaplastic large cell lymphoma.20 A subset of PTCL-NOS is human patients 
has also been shown to express CD30, and stratification of PTCL-NOS based on CD30 
expression has been proposed.142  CD30 expression was therefore evaluated in canine PTCL. 
CD4+ PTCL cases exhibited significant down-regulation of CD30 compared to control CD4+ T-
cells (log2FC=-2.9605, FDR q-value=8.21 X 10-7). A single CD4+ PTCL case had increased 
expression of CD30 (Figure 3.4 A). Interestingly, this case clustered as an outlier from the other 
CD4+ PTCLs using hierarchical clustering (Figure 3.2 A, far right). All evaluated cases (n=6) of 
PTCL did not exhibit CD30 expression by immunohistochemistry (Figure 3.4 D).  Within a non-
neoplastic control lymph node, few individual lymphocyte exhibited positive immunoreactivity 
to CD30 (Figure 3.4 C) and a canine mast cell tumor, which have been previously shown to 
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express CD30193,  exhibit diffuse positive immunoreactivity to the CD30 antibody, serving as 







Platelet-derived growth factors in canine PTCL 
 Human PTCL-NOS has been previously shown to express platelet-derived growth factor 
alpha (PDGFRA) and PDGFR activation is thought to play a role in proliferation of the 
neoplastic T-cells.129 PDGFR expression and activation were subsequently evaluated in canine 
CD4+ PTCL cases (Figure 3.5). Canine CD4+ PTCL cases upregulate PDGFRA and PDGRB 
compared to control CD4+ T-cells and canine PTCL cases were enriched for the activation of the 
PDGF pathway190–192 using GSEA pathway enrichment analysis (FDR q-value<0.001). Protein 
expression of PDGRFA and PDGRB was confirmed by immunohistochemistry and western blot, 
respectively.  
Primary CD4+ TCL cells isolated from fine-needle aspiration of affected lymph nodes 
were grown in short term culture with the addition of exogenous PDGF, 
phytohemagglutinin (PHA), or no stimulation. Cellular proliferation was assessed by 
quantification of CFSE over a 7-day time-course. CFSE was measured by flow cytometry. 
Addition of exogenous PDGF did not stimulate proliferation in short-term culture of primary 
Figure 3.4. Most canine PTCLs do not express CD30. Normalized gene expression of canine CD4+ PTCL 
cases compared to sorted control CD4+ T-cells. The majority of cases exhibit down-regulation of the CD30 gene. 
One case exhibited upregulation of CD30 (A). Neoplastic mast cells in a canine cutaneous mast cell tumor 
demonstrate diffuse positive cytoplasmic staining (positive control) (B). In a normal lymph node there are few 
scattered cells with positive cytoplasmic staining (D). All six PTCL cases tested were negative for CD30 
expression. A representative photomicrograph of one of the six tested cases is presented (D). 400x magnification 
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CD4+ PTCL cells. PHA non-specifically binds sugars on glycosylated surface proteins, including 







Canine CD4+ PTCL is molecularly similar to PTCL-GATA3 
 Molecular characterization of PTCL-NOS has recently identified distinct subgroups 
named PTCL-GATA3 and PTCL-TBX21. Differentiation of these molecular subgroups is 
determined by respective expression of GATA3 and TBX21, as well as their associated genes.117 
Additional genes included within the GATA3 group include CCR4, IL18RA, CXCR7, IK, 
MSH6, EGR1, CAT, and SEPTIN6  and target genes within the TBX21 group include EOMES, 
Figure 3.5. Canine PTCL expresses platelet-derived growth factor receptors alpha and beta. (A,B) 
Normalized gene expression of PDGFRB (A) and PDGFRA (B) in canine CD4+ PTCL cases compared to sorted 
control CD4+ T-cells. The majority of cases exhibit upregulation of PDGFRA and PDGFRB. (C) There is 
significant (FDR q-value<0.001) enrichment of PDGF signaling pathways in canine PTCL. Pathway enrichment 
was performed using GSEA. Two out of four evaluated canine CD4+ PTCLs strongly expressed PDGFRB 
protein using western blot analysis compared to cases of indolent T-zone lymphoma. Canine PTCL cases (n=6) 
(F) exhibited strong, diffuse, expression of PDGFRA compared to control lymph node (E). The germinal center 
of the control lymph node exhibits increased PDGFRA expression. Primary CD4+ TCL cells were stimulated 
with PHA and PDGF in short-term (7-day) cell culture (G). TCL cells stimulated with PHA underwent 
proliferation, exhibited by loss of CFSE expression over time. TCL cells stimulated with PDGF, however, did 
not proliferate.  
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CXCR3, IL2RB, CCL3, and IFNG.117 Expression of these key markers within canine PTCL is 
illustrated in Figure 3.6. CD4+ canine PTCL samples exhibited upregulation of genes associated 
with the GATA3 subgroup, as well as diffuse, strong, positivity for GATA3 via 
immunohistochemistry. CD8 + and CD4-CD8- PTCL cases were more variable in their expression 




Figure 3.6. Canine CD4+ PTCL exhibits a gene expression pattern similar to that of PTCL-GATA3. (A) 
Expression levels of genes associated with the GATA3 and TBX21 subgroups of PTCL-NOS as defined by 
Iqbal et al. (2014). CD4+ PTCL cases exhibited upregulation of GATA3 and variable expression of the 
associated genes. CD8+ and CD4-CD8- (DN) cases have more variable expression patterns. A proportion of these 
cases appear to upregulate several genes associated with the TBX21 subgroup. CD4+ PTCL cases (n=6) exhibit 
strong upregulation of GATA3 by immunohistochemistry (C) compared to control lymph node tissue (B).  
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PI3K-AKT-MTOR pathway activation in canine PTCL 
 Human PTCL-GATA3 is enriched for the PI3K-AKT pathway and exhibits frequent 
mutations of PTEN,  a negative regulator of PI3K and tumor suppressor gene.117,119 Canine CD4+ 
PTCL was significantly enriched for gene signatures associated with downregulation of PTEN 
(FDR q-value=0.0266) and upregulation of MTOR (FDR q-value=0.0203) (Figure 3.7 A,B). 
CD4+ PTCL additionally exhibited diffuse expression of phosphorylated AKT compared to 
lymphocytes within a control lymph node (Figure 3.7 C, D).  
An inhibitor of PI3K, LY249002, was then used to evaluate the role of PI3K-AKT 
signaling in canine PTCL proliferation and survival. OSW, a canine TCL cell line, was treated 
with LY249002 or DMSO control and grown in a 4-day culture. Cell proliferation was evaluated 
by loss of CFSE quantified by flow cytometry. Total cell number was also evaluated using 
counting beads quantified by flow cytometry. Inhibition of PI3K by LY249002 resulted in 
impaired loss of CFSE and decreased total cell numbers compared to DMSO-treated controls 
(Figure 3.7 E, F). These findings indicate that inhibition of PI3K results in impaired proliferation 
of the canine TCL cell line, OSW.  
 The effects of PI3K inhibition were then evaluated in primary canine CD4+ T-cell 
lymphoma cells obtained from lymph node fine-needle aspirations. Cells from 8 separate patients 
were cultured for 48 hours following treatment with LY249002 or DMSO control. Annexin V 
and PI were quantified by flow-cytometry to measure total cell death. Total cell death was 
significantly increased in cells treated with LY249002 compared to DMSO controls (p-value 
0.0078) (Figure 3.7 G, H).  These results support the conclusion that PI3K plays an important 





Oncogene and tumor suppressor expression in canine PTCL 
  
 Differential expression of known cancer associated genes identified using the COSMIC 
cancer gene census194 were evaluated in CD4+ PTCL compared to combined CD4+ and CD8+ 
control T-cells. Genes were classified as oncogene, tumor suppressor gene, or cancer-associated 
gene based on the classification provided by the Network of Cancer Genes (NCG6.0).195 To 
focus on possible tumor drivers, significantly upregulated oncogenes and significantly 
downregulated tumor suppressor genes were identified and presented in Table 3.2. Specifically, 
Figure 3.7. Canine PTCL utilizes the PI3K-AKT-MTOR pathway for cell survival and proliferation. (A,B) 
CD4+ PTCL is significantly enriched for gene signatures associated with downregulation of PTEN (FDR q-
value=0.0266) and upregulation of MTOR (FDR q-value=0.0203) using GSEA enrichment analysis. CD4+ 
PTCL is diffusely and strongly positive for phosphorylated-AKT (D) compared to a non-neoplastic control 
lymph node (C). OSW, a canine TCL cell line, was treated with LY249002 (green bars in E and F) and a DMSO 
control (red bars in E and F) and grown in culture over a four-day time period. Cellular proliferation was 
measured by CFSE loss (E) and changes in total cell number determined by counting beads (F). Both CFSE and 
counting beads were evaluated using flow cytometry. Treatment with LY249002 resulted in decreased cellular 
proliferation and well as decreased total cell numbers compared to DMSO treated controls. Primary CD4+ PTCL 
cells were treated with LY249002 or DMSO control and grown in culture over 48 hours. Cellular death was 
evaluated by annexin V and PI, measured by flow cytometry. Significantly increased cell death was observed 
following treatment with LY294002. A representative flow cytometry plot from one individual (G) and the 
summary of 8 total CD4+ primary patient samples (H). ***=p-value<0.05 
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oncogenes that were upregulated and previously associated with T-cell neoplasms include: STIL, 
LMO1, LMO2, SET, TAL1 (T-ALL), ALK (ALCL), TNFRSF17 (intestinal T-cell lymphoma), 
CCR4 (ATLL), and FGFR3 (T-cell lymphoma). Tumor suppressor genes that were 
downregulated and associated with T-cell neoplasms include: PTPRC, KDM6A (T-ALL), ATM 
(T-PLL), and FAS (NK/T lymphoma).  
Table 3.2 Differentially expressed oncogenes and tumor suppressor genes in CD4+ PTCL 
Gene Symbol Log2FC Gene Characterization Tumor Types 
FOXA1 7.5954 Oncogene breast, prostate 
TNC 7.3082 Oncogene SCC, melanoma 
SMO 7.0253 Oncogene skin basal cell 
EGFR 6.827 Oncogene glioma, NSCLC 
ETV5 6.509 Oncogene prostate 
MLLT4 6.4 Oncogene AL 
NTRK3 6.3712 Oncogene congenital fibrosarcoma, secretory breast 
PLAG1 6.0526 Oncogene salivary adenoma, lipoblastoma 
FGFR2 5.9778 Oncogene gastric, NSCLC, endometrial 
ERBB2 5.8715 Oncogene breast, ovarian, other tumour types, NSCLC, gastric 
ERG 5.6479 Oncogene Ewing sarcoma, prostate, AML 
MECOM 5.6257 Oncogene AML, CML, MDS 
TCF7L2 5.4784 Oncogene colorectal 
PDGFRA 5.3187 Oncogene GIST, idiopathic hypereosinophilic syndrome, paediatric glioblastoma 
CSF1R 5.0788 Oncogene MDS, CML, AML, hemangioblastoma, CCRCC 
ZNF521 4.8523 Oncogene ALL 
SALL4 4.7209 Oncogene colorectal cancer, breast cancer, prostate cancer, glioblastoma, melanoma 
ACVR1 4.605 Oncogene DIPG 
TAL1 4.5629 Oncogene lymphoblastic leukaemia/biphasic 
MITF 4.5324 Oncogene melanoma 
PREX2 4.4162 Oncogene melanoma, pancreatic ductal adenocarcinoma 
MET 4.4043 Oncogene papillary renal, head-neck squamous cell 
PDGFRB 4.2167 Oncogene MPN, AML, CMML, CML 
SRC 4.2137 Oncogene colorectal cancer, endometrial carcinoma 
CDH17 4.1235 Oncogene melanoma 
PBX1 4.0008 Oncogene pre B-ALL, myoepithelioma 
DDR2 3.9118 Oncogene squamous cell carcinoma, NSCLC 
KIT 3.8839 Oncogene GIST, AML, TGCT, mastocytosis, mucosal melanoma 
ETV1 3.7066 Oncogene Ewing sarcoma, prostate 
CSF3R 3.5277 Oncogene 
aCML, CNL,  leukaemia lymphoma and MDS associated with severe congenital neutropenia, CMML, de novo 
AML, MDS 
MN1 3.3141 Oncogene AML, MDS 
SIX1 3.2392 Oncogene Wilms tumour 
ALK 3.0931 Oncogene ALCL, NSCLC, neuroblastoma, inflammatory myofibroblastic tumour, Spitzoid tumour 
MYB 2.7905 oncogene adenoid cystic carcinoma 
GATA2 2.7095 Oncogene AML (CML blast transformation) 
KNSTRN 2.7014 Oncogene SCC 
ETV4 2.681 Oncogene Ewing sarcoma, prostate carcinoma 
STIL 2.6465 Oncogene T-ALL 
PDCD1LG2 2.5546 Oncogene PMBL, Hodgkin lymphoma 
LMO1 2.5158 Oncogene T-ALL, neuroblastoma 
TFEB 2.3992 Oncogene renal cell carcinoma (childhood epithelioid) 
PRDM16 2.2653 Oncogene MDS, AML 
CCNE1 2.2578 Oncogene serous ovarian 
MAFB 2.2225 Oncogene MM 
EZH2 2.1319 Oncogene DLBCL 
WHSC1 1.9967 Oncogene MM 
TNFRSF17 1.9482 Oncogene intestinal T-cell lymphoma 
GNAQ 1.9053 Oncogene uveal melanoma, primary central nervous system melanocytic neoplasms 
NUTM1 1.8373 Oncogene lethal midline carcinoma 
CCND2 1.8124 Oncogene NHL,CLL 
CACNA1D 1.7827 Oncogene adrenal aldosterone producing adenoma 
CCR4 1.7119 Oncogene adult T-cell leukaemia/lymphoma 
SGK1 1.5619 Oncogene Nodular lymphocyte predominant Hodgkin lymphoma 
IDH1 1.5286 Oncogene glioblastoma 
SETBP1 1.4985 Oncogene aCML, sAML, MDS/MPN-U, CMML, JMML 
CDK4 1.4638 Oncogene N.A. 
DDIT3 1.4521 Oncogene liposarcoma 
RET 1.4335 Oncogene medullary thyroid, papillary thyroid, pheochromocytoma, NSCLC, Spitzoid tumour 
LMO2 1.3813 Oncogene T-ALL 
FGFR3 1.2785 Oncogene bladder, MM, T-cell lymphoma 
GNAS 1.2276 Oncogene pituitary adenoma, pancreatic intraductal papillary mucinous neoplasm, fibrous dysplasia 
U2AF1 1.0633 Oncogene CLL, MDS 
CALR 1.0376 Oncogene MPN, MDS 
SET 0.90317 Oncogene T-ALL 
NFE2L2 0.90091 Oncogene NSCLC, HNSCC 
 80 
HMGA1 0.82618 Oncogene microfollicular thyroid adenoma, various benign mesenchymal tumours 
IDH2 0.8096 Oncogene glioblastoma 
CDK6 0.78141 Oncogene ALL 
RAC1 0.77346 Oncogene melanoma, carcinoma 
RARA 0.72524 Oncogene APL 
IL6ST 0.67061 Oncogene hepatocellular carcinoma 
DEK 0.65948 Oncogene AML 
MTOR 0.55217 Oncogene 
endometrial carcinoma, head and neck, clear cell renal cell carcinoma, anaplastic thyroid cancer, urothelial cell 
carcinoma, central nervous system tumours, testicular germ cell tumours and other tumour types 
CTNNB1 0.54209 Oncogene colorectal, ovarian,  hepatoblastoma, pleomorphic salivary gland adenoma, other tumour types 
MAP2K1 0.52129 Oncogene NSCLC, melanoma, colorectal 
CRTC1 0.51746 Oncogene salivary gland mucoepidermoid 
HNRNPA2B1 0.46451 Oncogene prostate 
PRKACA 0.42949 Oncogene fibrolamellar hepatocellular carcinoma, cortisol secreting adrenal adenoma 
PTPN11 0.37755 Oncogene JMML, AML, MDS 
BRD3 0.37541 Oncogene lethal midline carcinoma of young people 
SRSF3 0.30357 Oncogene follicular lymphoma 
CDK12 -0.39846 TSG serous ovarian 
STAG2 -0.41288 TSG bladder carcinoma, glioblastoma, melanoma, Ewing's sarcoma, myeloid neoplasms 
ZRSR2 -0.49738 TSG MDS, CLL 
SMAD2 -0.56791 TSG colorectal carcinoma, hepatocellular carcinoma 
RPL22 -0.57979 TSG AML, CML 
KMT2C -0.61299 TSG medulloblastoma 
ASXL1 -0.61624 TSG MDS, CMML 
POT1 -0.66858 TSG CLL 
WRN -0.6841 TSG N.A. 
MYH9 -0.71494 TSG ALCL 
PTPRC -0.72314 TSG T-ALL 
ATM -0.72502 TSG T-PLL 
XPA -0.7296 TSG N.A. 
PIK3R1 -0.79664 TSG glioblastoma, ovarian, colorectal 
CYLD -0.81559 TSG cylindroma 
DDX3X -0.8222 TSG CLL, medulloblastoma 
FBXO11 -0.84687 TSG DLBCL 
PTEN -0.8523 TSG glioma, prostate, endometrial 
TRIM33 -0.87116 TSG papillary thyroid 
TNFRSF14 -0.8967 TSG follicular lymphoma 
BTG1 -0.89939 TSG B-CLL 
CHD2 -0.94338 TSG melanoma, large intestine, CLL, monoclonal B lymphocytosis 
PML -0.96579 TSG APL, ALL 
FANCG -0.99985 TSG N.A. 
SETD1B -1.0196 TSG CRC, endometrium 
KAT6B -1.1178 TSG AML, leiomyoma 
CASP8 -1.1565 TSG hepatocellular, oral squamous cell, breast 
ASXL2 -1.1771 TSG melanoma, CCRCC, AML 
ETNK1 -1.2706 TSG aCML, CMML, SM-AHD, HES 
CIITA -1.4001 TSG PMBL, Hodgkin lymphoma 
KDM6A -1.4596 TSG renal cell carcinoma, bladder carcinoma, oesophageal SCC, MM, medulloblastoma, T-ALL, other tumour types 
ZNF331 -1.6499 TSG follicular thyroid adenoma 
MGMT -1.7333 TSG glioma 
CDKN1B -1.9996 TSG breast, small intestine neuroendocrine tumours 
BAZ1A -2.2376 TSG uterine carcinosarcoma, colon cancer 
LRIG3 -2.2729 TSG NSCLC 
PRDM1 -2.3221 TSG DLBCL 
CBLB -2.3262 TSG AML 
FAS -3.1527 TSG TGCT, nasal NK/T lymphoma, skin squamous cell carcinoma-burn scar related 
+Abbreviations: AEL: Acute eosinophilic leukemia, AL: Acute leukemia, ALCL: Anaplastic large-cell lymphoma, ALL: Acute lymphocytic leukemia, AML: Acute myelogenous leukemia, 
AML*: Acute myelogenous leukemia (primarily treatment associated), APL: Acute promyelocytic leukemia, B-ALL: B-cell acute lymphocytic leukaemia, B-CLL: B-cell Lymphocytic leukemia, 
B-NHL: B-cell Non-Hodgkin Lymphoma, CLL: Chronic lymphatic leukemia, CML: Chronic myeloid leukemia, CMML: Chronic myelomonocytic leukemia, CNS: Central nervous system, 
DFSP: Dermatofibrosarcoma protuberans, DLBL: Diffuse large B-cell lymphoma, DLCL: Diffuse large-cell lymphoma, GIST: Gastrointestinal stromal tumour, JMML: Juvenile 
myelomonocytic leukemia, L: Leukaemia/lymphoma, MALT: Mucosa-associated lymphoid tissue lymphoma, MDS: Myelodysplastic syndrome, MLCLS: Mediastinal large cell lymphoma with 
sclerosis, MM: Multiple myeloma, MPD: Myeloproliferative disorder, NHL: Non-Hodgkin lymphoma, NSCLC: Non-small cell lung cancer, PMBL: Primary mediastinal B-cell lymphoma, pre-B 
All: Pre-B-cell acute lymphoblastic leukaemia, T-ALL: T-cell acute lymphoblastic leukemia. T-CLL: T-cell chronic lymphocytic leukaemia, TGCT: Testicular germ cell tumour, T-PLL: T cell 
prolymphocytic leukaemia, TSG: Tumor suppressor gene 
 
Discussion 
   We demonstrate molecular similarity between canine PTCL and human PTCL-NOS. 
Using RNA-seq, we show that canine CD4+ PTCL has a similar gene expression pattern as 
human PTCL-NOS. We created a list of the top 200 up-regulated and down-regulated genes in 
human PTCL-NOS using a previously published microarray study.128 This study contained 
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samples from human patients diagnosed with PTCL-NOS, as well as sorted control CD4+ T-
cells. The groups in that study were analogous to the samples obtained in our canine study, and 
therefore served as the optimal group for comparison. A statistically significant enrichment was 
identified for the list of differentially expressed genes in human PTCL-NOS when compared to 
control CD4+ T-cells.  
 We next evaluated the expression of key molecules previously shown to be important in 
the classification and pathogenesis of PTCL-NOS. CD30 is a TNF-receptor superfamily member 
and can be expressed on normal and neoplastic lymphocytes.140,141 Anaplastic large cell 
lymphoma, a subtype of PTCL, characteristically expresses CD30.20,196 A proportion of PTCL-
NOS cases have been shown to also express CD30, and separation of PTCL-NOS into CD30+ 
and CD30- subgroups has been proposed.142 CD30 is a particularly interesting molecule to 
evaluate because it can be targeted by the antibody-drug conjugate brentuximab vedotin and has 
shown promising therapeutic results in treating patients with relapsed or refractory ALCL.144,145 
The majority of canine PTCL cases did not exhibit upregulation of CD30 gene expression 
and did not express CD30 using immunohistochemistry. A single PTCL case did have high 
CD30 expression compared to control lymphocytes. It is therefore possible that a small 
proportion of PTCL cases in dogs may express CD30. Using hierarchical clustering, this case 
clustered as an outlier to the other PTCL cases, suggesting it may represent a different T-cell 
tumor such as anaplastic large cell lymphoma. Nevertheless, CD30 is likely not a valuable 
therapeutic target in the majority of canine PTCL cases.  
 PDGFs have been shown to be upregulated in human PTCL-NOS.128,129 Activation 
through PDGFRA has been shown to contribute to cellular proliferation and this process is 
mediated in part by STAT1 and STAT5.129 Similarly, we demonstrate that PTCL in dogs 
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expresses PDGFRA and PDGFRB both by gene expression and protein expression. Primary 
canine PTCL cells, however, were not stimulated to proliferation following exposure to 
exogenous PDGF. This finding may suggest that constitutive activation of the PDGFR signaling 
independent of growth factor stimulation, may be driving cellular proliferation. Alternatively, 
PDGFR signaling may not be a primary oncogenic driver in this tumor. A small clinical trial 
evaluating the efficacy of imatinib, a RTK inhibitor targeting PDGFRs, in patients with 
refractory or relapsed PTCL showed no significant improvement in overall survival or 
progression-free survival.130 Because of the lack of response to therapy targeting PDGFR, this 
pathway is not considered a primary therapeutic target. Nevertheless, shared expression of 
PDGFRs in human and canine PTCLs further supports a similar molecular profile.  
 A landmark study by Iqbal et al. characterized the GEP of PTCL-NOS and identified two 
major subgroups, PTCL-GATA3 and PTCL-TBX21.117 In this study PTCL-GATA3 was 
characterized by expression of GATA3 and its target genes CCR4, IL18RA, CXCR7, IK, MSH6, 
EGR1, CAT, and SEPTIN6 and was enriched for MTOR, MYC, and PI3K induced gene 
signatures. PTCL-TBX21 was characterized by expression of TBX21, EOMES, CXCR3, IL2RB, 
CCL3, and IFN-ß and was enriched for INFY and NFkB gene signatures. PTCL-GATA3 is 
associated with a worse prognosis. Expression of GATA3, TBX21 and their downstream targets 
was evaluated in canine PTCL. All of the evaluated canine CD4+ PTCL cases upregulated 
GATA3 and variably express the associated genes, suggesting that CD4+ PTCL in dogs exhibits 
molecular similarity to the PTCL-GATA3 subgroup identified in humans. Canine CD8+ and 
CD4-CD8- PTCL cases had more variable expression of the evaluated markers. A proportion of 
CD8+ cases express molecules associated with the PTCL-TBX21 subgroup. This finding is 
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consistent with human PTCL-NOS cases in which the majority of PTCL-GATA3 cases are 
CD4+CD8-, while a higher proportion of PTCL-TBX21 cases are CD4-CD8+.120 
 The PI3K-AKT-MTOR signaling pathway is an important cellular pathway that 
stimulates cell growth and survival in health. PI3K molecules can phosphorylate and activate 
AKT which subsequently phosphorylates MTOR. MTOR is a key regulator of proliferation, 
motility, survival, protein synthesis, autophagy, and cellular transcription. PTEN is a well-known 
tumor suppressor gene that functions to dephosphorylate and thereby inhibit PI3K.197 The 
importance of PTEN in regulating cell growth and survival is highlighted by Cowden syndrome. 
This is a genetic disease defined by autosomal dominant mutation in PTEN resulting in the 
presence of multiple hamartomas and increased risk of developing breast, thyroid, and uterine 
cancers.197,198 CD4+ PTCL in dogs was significantly enriched for gene signatures associated with 
upregulation of MTOR and downregulation of PTEN. Activation of this pathway in canine 
PTCL was further supported by diffuse expression of p-AKT by neoplastic cells. Inhibition of 
PI3K, using the pan-PI3K inhibitor LY294002 resulted in impaired proliferation of the canine 
TCL cell line, OSW, as well as increased cell death in primary canine CD4+ TCL cells.  
Altogether, these results demonstrate a central role of the PI3K-AKT-MTOR pathway in the 
proliferation and survival of PTCL in dogs. The PI3K-AKT-MTOR pathway has been shown to 
be enriched in human PTCL-GATA3.117,119 Furthermore, clinical trials using the PI3K inhibitor 
duvelisib in patients with refractory or relapsed PTCL have been promising, with reported 
overall response rate of 50% and complete response rate of 18.8%.138  
Activation of the PI3K-AKT-MTOR pathway is thought to be at least in part driven by 
loss of the negative regulator PTEN. PTEN-PI3K and CDKN2A-TP53 pathways have been 
shown to be frequently mutated in human PTCL-GATA3.119 Similarly, whole-exome sequencing 
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of Boxer dogs with T-cell lymphoma identified approximately 25% of cases have mutations in 
PTEN.167 A recent study using a Human Cancer Hotspot Panel to identify potential tumor-
associated mutations in canine PTCL also identified frequent mutations in MET, KDR, STK11, 
and BRAF and missense mutations in MYC, TP53, and MET.36 Loss of central tumor-suppressor 
genes including PTEN and TP53 appear to be key to the oncogenesis of PTCL in both humans 
and dogs. Loss of these negative regulators is likely to allow uncontrolled cellular proliferation, 
in part through the PI3K-ATK-MTOR pathway.  
In this study, we demonstrate molecular similarities between canine and human PTCL. 
Canine CD4+ PTCL exhibits significant enrichment for the differentially expressed genes in 
human PTCL-NOS, including PDGFRs. Furthermore, we show that canine CD4+ PTCL 
upregulates genes associated with the PTCL-GATA3 gene signature, including strong expression 
of GATA3. Similar to human PTCL-GATA3, canine CD4+ PTCL is enriched for the PI3K-
AKT-MTOR pathway, exhibits constitutive phosphorylation of AKT, and is at least in part 
dependent upon PI3K for cellular survival and proliferation. Combined, these features suggest 
that canine CD4+ PTCL has the potential to serve as a valuable model to study PTCL-GATA3. 
CD4+ PTCL is one of the more common subtypes of NHL in dogs, and therefore provides a 
unique opportunity to easily accumulate patient-derived tissue for evaluation. The lack of gold-
standard veterinary treatments also allows for the design of canine clinical trials which may 
include the early implementation of novel therapies. Early implementation of novel therapeutics 
not only aids in more efficient identification of promising new treatments for translation into 
human patients but also provides therapeutic options to pet dogs and their owners who otherwise 
would not pursue treatment. 
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 Hematopoietic neoplasms arise from immunological cells at various stages of 
development and differentiation. Classification of these neoplasms is in part reliant upon 
identification and characterization of the normal immune counterpart. Identification of the cell of 
origin provides insights into the underlying pathogenesis and can have prognostic and 
therapeutic impact. Within the field of B-cell neoplasia, cell of origin has been well studied and 
characterized. Tumors derived from T-cells, however, are less well-understood and identification 
of cellular origin is in part complicated by plasticity between normal T-cell subgroups. In this 
chapter we aim to characterize the cell of origin of canine PTCL. We use flow cytometry to 
evaluate surface marker expression as well as RNA-seq to evaluate changes in gene expression 
in PTCL compared to combined control CD4+ and CD8+ T-cells. We specifically evaluate 
markers of precursor phenotypes, T-cell activation, TCR signaling, and mature CD8+ cytotoxic 
and CD4+ T-helper subsets. We demonstrate that CD4+ PTCL appears to be derived from a naïve 
single positive T-cell. This conclusion is supported by lack of expression of markers of 
activation (MHC class II, CD25, and TCR signaling molecules) as well as lack of upregulation 
of markers associated with T helper subsets. A portion of CD4+ PTCL cases upregulate markers 
of immaturity including CD34 and TdT on a gene expression level, however surface CD34 
expression is not identified on neoplastic cells. The significance of this finding is therefore 
undetermined, but may suggest that a portion of these neoplasms are derived from a more 
immature thymic precursor cell. CD4-CD8- tumors are enriched for gene expression profiles 
associated with a more immature T-cell phenotype, and are therefore thought to most likely 
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develop from an immature, double negative, thymic precursor cell.  CD8+ TCL upregulate 
molecules associated with activated cytotoxic T-cells, suggesting that at least a subset of CD8+ 
TCLs may originate from a mature CD8+ effector cell.  
Introduction 
 Identification of the neoplastic cell of origin is a useful way to classify and subtype 
cancer phenotypes. This is particularly true in hematopoietic tumors which have potential to arise 
from a wide variety of stages of development and functional capabilities. Identification of the 
cell of origin has important implications on our understanding of oncogenesis, biologic behavior, 
epidemiology, and the development of targeted therapies in hematopoietic neoplasms.20,117,199,200 
Tumors derived from B-lymphocytes have been well-studied and a detailed classification system 
rooted in identification of the normal counterpart has been developed.199 T-cell lymphomas, on 
the other hand, are less well characterized and peripheral T-cell lymphomas (PTCLs), in 
particular, often lack defining diagnostic or cytogenetic markers that allow for definitive 
identification of the cell of origin.  
In humans, PTCL encompasses a heterogenous group of diseases with variable clinical 
presentations, biologic behaviors, and diagnostic criteria. Angioimmunoblastic T-cell lymphoma 
(AITL), anaplastic large cell lymphoma (ALCL), extranodal NK/T-cell of nasal type and adult 
T-cell leukemia/lymphoma (ATLL) are well-described entities that fall within the PTCL 
classification. Approximately 30-50% of PTCL cases, however, do not fall within specific 
defined subtypes and are named PTCL-not otherwise specified (PTCL-NOS).20,110 AITL is the 
most common PTCL subtype and is characterized by polyclonal hypergammaglobulinemia and 
autoimmune manifestations.201 AITL is thought to be derived from T-follicular helper 
lymphocytes and expresses key Tfh markers including BCL6, CXCR5, CD10, and CXCL13.95–98 
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Adult T-cell leukemia/lymphoma (ATLL) is thought to originate from CD4+ CD25+ FoxP3+ 
Tregs104 and patients with ATLL characteristically exhibit T-cell immunodeficiency and frequent 
opportunistic infections.20,105 
Recent studies have identified molecular subgroups of PTCL-NOS including PTCL-
GATA3 and PTCL-TBX21.117–120,202 These subgroups appear to be derived from different 
normal T-cell counterparts with unique oncogenic transcriptional signatures, clinical outcomes, 
and genetic alterations.117–119 GATA3 is the master transcriptional regulator to the T-helper 2 
(Th2) T-cell subset and T-box 21 (TBX21) is the master regulator of Th-helper 1 (Th1) and 
cytotoxic T-cell differentiation.203,204 Given these findings, it has been postulated that these 
PTCL subgroups are derived from Th2 or Th1 T-cells, respectively. These findings however, are 
interpreted cautiously due to the plasticity of T-cell differentiation and multiple roles that these 
key transcriptional regulators play in T-cell development and function.205 
The cell of origin of canine PTCL has not been previously characterized. In this chapter 
we seek to determine the normal counterpart for canine PTCL using surface protein expression 
evaluated by flow cytometry as well as transcriptomic profiling and pathway enrichment 
analysis.  
Materials and Methods 
Flow Cytometry 
Flow cytometry was performed by the Colorado State University Clinical Immunology 
Laboratory (CSU-CI) on all cases as previously described.160 TCL cases were identified by 
uniform expansion of T-cells characterized by expression of the pan-leukocyte marker CD45, the 
T-cell markers CD3 with or without CD5, and lack of expression of the B-cell marker CD21. 
Cases exhibited variable expression of T-cell subset antigens, CD4 and CD8. 
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Case selection for RNA Sequencing 
Fine needle tissue aspirates from 33 dogs submitted to the Colorado State University-
Clinical Immunology laboratory for routine diagnostics and diagnosed with CD4+, CD4-CD8-, or 
CD8+ TCL by flow cytometry were selected for RNA-seq. TCL cases were identified by uniform 
expansion of T-cells characterized by expression of the pan-leukocyte marker CD45, the T-cell 
markers CD3 with or without CD5, and lack of expression of the B-cell marker CD21. Cases 
exhibited variable expression of T-cell subset antigens, CD4 and CD8. Median purity of 
neoplastic cells was 91.5% (range 63-99%).  
Control CD4+ and CD8+ T lymphocytes were harvested from lymph nodes of healthy 
dogs utilized for IACUC approved surgical continuing education courses. T-cell subsets were 
sorted by a MoFlo cell sorter (Beckman Coulter, Brea, CA) using positive selection with anti-
CD4 (clone YKIX302.9) or anti-CD8 (clone YCATE55.9). Sorted populations were re-analyzed 
for purity and were used if greater than 90% of the cells were the desired population. 
RNA Extraction and Sequencing 
RNA extraction was performed using the Purelink RNA mini Kit (Thermo Fisher 
Scientific, Waltham, MA) and quality was measured with an Agilent 2100 Bioanalyzer System. 
All samples had a RIN value greater than 6.3 (median RIN 8.45; range 6.3-9.8). RNA was 
shipped to Novogene Corporation Inc (Sacramento, CA) where the libraries were constructed 
and sequenced using an Illumina Hiseq PE150 platform.  
Differential Gene Expression 
Sequences were aligned to CanFam3.1 genome using HISAT2.182 HTseq183 and 
DESeq2184 were then used to quantify reads, normalize gene expression, and evaluate 
differentially expressed genes between tumor samples and controls. P-values were determined 
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using a negative binomial distribution.  A Benjamini-Hochberg procedure was used to correct p-
values and padj<0.05 was considered the differentially expressed gene screening standard.  
Pathway Enrichment Analysis 
 Gene set enrichment analysis (GSEA)186 was used to compare canine PTCL gene 
expression profiles to various T-cell subset gene signatures. The list of significantly differentially 
expressed genes for CD4+, CD8+, and CD4-CD8- compared to combined control CD4+ and CD8+ 
T-cells was ranked based on log2foldchange. The pre-ranked gene list was then compared to 
gene sets identified in the molecular signature database (MSigDB) v7.0.187 Gene sets with an 
FDR q-value <0.05 were considered significantly enriched.  
Results 
Canine PTCL does not express markers of T-cell activation 
 Canine CD4+, CD8+, and CD4-CD8- PTCL are identified as T-cell neoplasms based on 
expression of the T-cell cell marker CD3. These neoplasms have variable expression of CD5 and 
can be classified based on their patterns of expression of the T-cell subset markers CD4 and 
CD8. These neoplasms does not express surface CD34, a hematopoietic stem cell marker that is 
often used to identify hematopoietic neoplasms of precursor origin (Figures 4.1-4.3).20,206–208 
Neoplastic cells typically exhibit low expression of CD25 and MHC class II (Figures 4.1-4.3). 
CD25 (IL-2 receptor alpha-chain) is expressed by antigen-exposed, activated T-cells209,210 and is 
constitutively expressed by CD4+ regulatory T-cell (Tregs).211 Similarly, MHC class II is 
expressed by activated T-cells in multiple species, including dogs.212–217 This immunophenotypic 








Figure 4.1 CD4+ PTCL immunophenotype. CD4+ PTCL is characterized by a uniform expansion of 
intermediate to large cells (A) which express the T-cell markers CD3, CD5 and the T-cell subset marker CD4 
(B-C). Neoplastic cells do not express CD8 (D), CD34 (E), and have low expression of CD25 (F) and MHC 
Class II (G).  
Figure 4.2 CD4-CD8- PTCL immunophenotype. CD4-CD8- PTCL is characterized by a uniform expansion of 
intermediate to large cells (A) which express the T-cell markers CD3 and CD5 (B). Neoplastic cells do not 
express the T-cell subset antigens CD4 or CD8 (C-D), CD34 (E), and have low expression of CD25 (F) and 
MHC Class II (G).  
Figure 4.3 CD8+ PTCL immunophenotype. CD8+ PTCL is characterized by a uniform expansion of 
intermediate to large cells (A) which express the T-cell markers CD3 (B). This case exhibits loss of CD5 (B,C). 
Neoplastic lymphocytes express the T-cell subset marker CD8 (D). Cells do not express CD4 (C), CD34 (E), and 
have low expression of CD25 (F) and MHC Class II (G).  
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To further determine if canine PTCL exhibits a naïve or activated T-cell phenotype, the 
gene expression profiles of canine PTCL subsets were compared to gene signatures specific to 
naïve and activated T-cells using GSEA. Gene signatures of naïve and activated T-cell 
phenotypes were derived from a previous microarray study performed on isolated human 
immune cell subsets.218  Evaluated gene sets are listed in table 4.1. 
 
Table 4.1 Naïve and Activated T-
cell Subset Gene Lists Used for 
GSEA Pathway analysis 
 
T-cell activation Subset Gene Sets 
Naïve CD4 T-cell vs Memory T-cell_DN 
Naïve CD4 T-cell vs Memory T-cell_UP 
Naïve CD4 T-cell vs 12h activated Th1_DN 
Naïve CD4 T-cell vs 12h activated Th1_UP 
Naïve CD4 T-cell vs 12h activated Th2_DN 
Naïve CD4 T-cell vs 12h activated Th2_UP 
Naïve CD4 T-cell vs 48h activated Th1_DN 
Naïve CD4 T-cell vs 48h activated Th1_UP 
Naïve CD4 T-cell vs 48h activated Th2_DN 
Naïve CD4 T-cell vs 48h activated Th2_UP 
Naïve CD8 T-cell vs Memory T-cell_DN 
Naïve CD8 T-cell vs Memory T-cell_UP 
Naïve vs Memory T-cell_DN 
Naïve vs Memory T-cell_UP 
Th1 vs Th2_12h activated_DN 
Th1 vs Th2_12h activated_UP 
Th1 vs Th2_48h activated_DN 
Th1 vs Th2_48h activated_UP 
The lists of differentially expressed genes in canine CD4+, CD8+, and CD4-CD8- PTCL 
compared to normal CD4+/CD8+ T-cells were compared to the gene lists defining activated and 
naïve T-cell subsets. The signature for genes upregulated in naïve CD4 T-cells compared to 
memory T-cells was significantly upregulated in CD4+ PTCL (FDR q-value=0.035). No gene 
signatures were enriched at an FDR q-value<0.05 in CD8+ or CD4-CD8- PTCL. CD8+ did have 
moderate enrichment for the gene signatures representing genes upregulated in naïve CD4 or 
naïve CD8 T-cells compared to memory T-cells (p-value 0.015 and 0.027, respectively), as well 
as the gene signature representing genes upregulated in Th1 cells compared to Th2 cells 
following 48 hours of activation (p-value 0.031). (Figure 4.4). Together, the flow cytometry 
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immunophenotype and gene enrichment analysis focused on signatures of naïve and activated T-
cells suggest that these neoplasms originate from a naïve, late thymic or post-thymic T-cells.  
To further test our hypothesis that canine PTCL is derived from a naïve T-cell, we sought 
to evaluate if canine PTCL upregulates genes associated the T-cell receptor (TCR) signal 
transduction. A simplified schematic of TCR signaling is presented in Figure 4.5.  
Figure 4.4. Gene set enrichment analysis (GSEA) of canine PTCL subgroups compared to naïve and 
activated T-cells. CD4+ PTCL was significantly enriched (FDR q-value<0.05) for the gene set that representing 
genes upregulated in naïve CD4 T-cells compared to memory T-cells. CD8+ PTCL was moderately enriched (p-
value <0.05) for signatures associated genes upregulated in naïve CD4 and CD8 T-cells compared to memory T-
cells as well as genes upregulated in Th1 cells compared to Th2 cells following 48 hours of activation. GSEA 
was performed on the list of differentially expressed genes when comparing PTCL cases to combined CD4 and 
CD8 control T-cells. 
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Differential gene expression of key molecules associated with TCR activation including 
FYN, LCK, ZAP70, CD3 molecules (CD3G, CD3E, CD3D), CD28, and IL-2 receptor molecules 
(IL2RG, IL2RB, IL2RA) were evaluated in canine PTCL cases compared to combined CD4+ and 
CD8+ control T-cells. (Figure 4.6, Table 4.2). The majority of CD3 molecules had significantly 
lower expression levels or not differentially expressed in PTCL. CD3D expression was modestly 
elevated in CD4+ PTCL. Similarly, FYN, LCK, ZAP70, CD28, and IL-2 receptor molecules 
were either significantly downregulated or not differentially expressed in PTCL compared to 
combined CD4+ and CD8+ control T-cells. IL2RB expression is moderately elevated in CD8+ 
PTCL and IL2RG expression is modestly elevated in CD4+ PTCL. Taken together, these results 
suggest that PTCL is not proliferating through enhanced or constitutive TCR signaling and 
support the hypothesis that in dogs, this neoplasm is derived from naïve-T-cells.   
Figure 4.5 Schematic of T-cell signaling adapted from Gaud et al. The TCR signal transduction is initiated 
by binding of the TCR to antigen-MHC complexes expressed on the surface of antigen-presenting cells (APCs). 
Upon TCR engagement, the tyrosine kinases LCK and FYN binds to the cytoplasmic domains of the CD4/CD8 
co-receptors or CD3, respectively. LCK and FYN phosphorylate immunoreceptor tyrosine-based activation 
motifs (ITAMs) in the CD3 chains, which allows docking and activation of ZAP70. ZAP70 phosphorylates the 
transmembrane protein linker for activation of T-cells (LAT), which subsequently recruits a number of adaptor 
and effector proteins that form the LAT signalosome. The LAT signalosome propagates three major signaling 
systems including the Ca2+-calcineurin, mitogen-activated protein kinase (MAPK) and nuclear factor-kB (NF-
kB). Activation of the T-cell co-receptor CD28 or cytokine receptors additionally results in activation of PI3K-




Table 4.2. Summary of differential gene expression of genes associated with TCR signaling 
 
Gene Name Immunophenotype Log2(FC) p-value padj 
CD3E CD4+ -0.22796 0.089892 0.15403 
CD4-CD8- (DN) -0.78457 0.024223 0.066383 
CD8+ -0.66027 1.38E-05 0.00010555 
CD3D CD4+ 0.46635 0.0032487 0.0092189 
CD4-CD8- (DN) 0.20665 0.5088 0.648 
CD8+ -0.61891 0.12739 0.22579 
CD3G CD4+ 0.41689 0.023476 0.050206 
CD4-CD8- (DN) -0.17474 0.74096 0.83353 
CD8+ 0.065206 0.79926 0.86438 
CD28 CD4+ 0.47452 0.1484 0.23099 
CD4-CD8- (DN) -1.7991 0.03644 0.091337 
CD8+ -3.3698 2.51E-08 4.04E-07 
ZAP70 CD4+ -1.0296 1.06E-08 1.13E-07 
CD4-CD8- (DN) -1.4846 4.36E-06 4.47E-05 
CD8+ -0.59737 0.0082548 0.024958 
LCK CD4+ -0.75767 4.58E-06 2.77E-05 
CD4-CD8- (DN) -1.4095 0.00076012 0.0038747 
CD8+ -0.83077 5.03E-08 7.50E-07 
FYN CD4+ 0.43756 0.13271 0.21081 
CD4-CD8- (DN) -1.2691 0.0071247 0.02469 
CD8+ 0.25548 0.18938 0.30502 
IL2RA CD4+ -3.3953 5.33E-09 5.94E-08 
CD4-CD8- (DN) -2.68 0.0037583 0.014588 
CD8+ -1.5585 0.034454 0.080649 
IL2RB CD4+ -1.8204 0.0023388 0.0069277 
CD4-CD8- (DN) -0.071857 NA NA 
CD8+ 1.8689 4.55E-07 5.25E-06 
IL2RG CD4+ 0.39352 0.0076045 0.019282 
CD4-CD8- (DN) -0.17803 0.68608 0.79088 
CD8+ 0.36824 0.23623 0.36233 
*Bold and red highlighting indicates significantly upregulated genes and bold and blue highlighting indicates 
significantly downregulated genes (padj<0.05) 
Figure 4.6 Differential gene expression of key molecules associated with TCR signaling. Normalized gene 
expression for CD3E (A), CD3D (B), CD3G (C), CD28 (D), ZAP70 (E), Lck (F), Fyn (G), IL2RA (H), IL2RB 
(I), IL2RG (J). Normalized gene expression is derived from DESeq2. ***FDR q-value<0.05  
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Evaluation of Markers of Immaturity and Thymic Development 
Given the suggested naïve cell phenotype, and presence of mediastinal mass in a portion 
of canine PTCL patients, we next aimed to evaluate if this neoplasm could originate from 
immature thymic precursor cells. Gene expression levels of markers of immaturity including 
CD34, TdT, and CD117 (c-KIT) were evaluated (Figure 4.7, Table 4.3). Expression of CD34, 
TdT, and CD117 were variable among all evaluated cases. Differential gene expression 
evaluation revealed significantly increased expression of CD34 and CD117 in CD4+ PTCL and 
CD8+ PTCL. TdT expression was significantly elevated in CD4+ PTCL. Of the seven CD4+ 
PTCL cases with the highest expression levels of CD34, four of those also expressed high levels 








Figure 4.7 Gene expression of markers of immaturity. Normalized gene expression derived from DESeq2 for 
each PTCL immunophenotype compared to combined CD4+ and CD8+ controls. CD34 and CD117 expression is 
variable amongst evaluated cases and is significantly increased in CD4+ and CD8+ PTCL (A,C). TdT expression 
is significantly increased in CD4+ PTCL (B). ***FDR q-value<0.05 
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Table 4.3 Summary of differential gene expression of precursor markers 
Gene Name Immunophenotype Log2(FC) p-value padj 
CD34 
CD4+ 5.5983 3.26E-13 8.10E-12 
CD4-CD8- (DN) 2.2542 0.071822 0.15502 
CD8+ 4.8003 2.49E-08 4.02E-07 
TdT 
 
CD4+ 3.6338 0.0015856 0.0049431 
CD4-CD8- (DN) 0.87449 NA NA 
CD8+ -1.3869 0.11169 0.20409 
CD117 
CD4+ 3.8839 3.05E-10 4.38E-09 
CD4-CD8- (DN) 3.9348 NA NA 
CD8+ 6.5239 1.10E-18 1.47E-16 
*Bold and red highlighting indicates significantly upregulated genes (padj<0.05) 
 
Table 4.4 Thymic T-cell Subset 
Gene Lists Used for GSEA 
Pathway analysis 
 
Thymic Subset Gene Sets 
CD4 SP vs CD8 SP Thymocyte_DN 
CD4 SP vs CD8 SP Thymocyte_UP 
DN vs CD4 SP Thymocyte_DN 
DN vs CD4 SP Thymocyte_UP 
DN vs CD8 SP Thymocyte_DN 
DN vs CD8 SP Thymocyte_UP 
DN vs DP Thymocyte_DN 
DN vs DP Thymocyte_UP 
DN vs immature CD4 SP Thymocyte_DN 
DN vs immature CD4 SP Thymocyte_UP 
DP vs CD4 SP Thymocyte_DN 
DP vs CD4 SP Thymocyte_UP 
DP vs CD8 SP Thymocyte_DN 
DP vs CD8 SP Thymocyte_UP 
Immature CD4 SP vs CD4 SP Thymocyte_DN 
Immature CD4 SP vs CD4 SP Thymocyte_UP 
Immature CD4 SP vs CD8 SP Thymocyte_DN 
Immature CD4 SP vs CD8 SP Thymocyte_UP 
Immature CD4 SP vs DN Thymocyte_DN 
Immature CD4 SP vs DN Thymocyte_UP 
+ Abbreviations: SP: Single positive, DN: 
Double negative, DP: double positive 
 GSEA was then utilized to compare the GEP of canine PTCL to gene sets that define 
stages of thymic development. Gene sets were derived from a previous microarray study that 
evaluated consecutive T-cell developmental stages in human samples.219 CD34+CD38− CD1a−, 
CD34+CD38+CD1a−, CD34+CD38+CD1a+, immature single positive (ISP) CD4+, double positive 
(DP) CD3−, DP CD3+, single positive (SP) CD4+, and SP CD8+ T-cell subgroups were isolated 
from human thymi and gene expression was evaluated using Affymetrix microarray analysis. 
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Results of this microarray study provided 20 gene sets for comparison to PTCL samples (Table 
4.4).  
The lists of differentially expressed genes in canine CD4+, CD8+, and CD4-CD8- PTCL 
samples were compared to the gene lists defining thymic T-cell subsets. CD4+ PTCL was 
significantly enriched for two gene sets (FDR q-value <0.05), DN PTCL was significantly 
enriched for one gene set, and CD8+ PTCL was not enriched for any of the evaluated gene sets. 
Both CD4+ and DN PTCL were significantly enriched for the genes upregulated in immature 
CD4 single positive thymocytes compared to double positive thymocytes (CD4+ FDR q-value 
0.002; DN FDR q-value 0.005 ) (Figure 4.8). Immature CD4 single positive thymocytes 
represent an intermediary thymocyte stage between double negative and double positive 
thymocytes. CD4+ PTCL was also significantly enriched for the genes upregulated in double 
positive thymocytes when compared to CD4 single positive thymocytes (FDR q-value 0.027). 
The gene set enrichment analysis of thymic subsets, as well as upregulation of several markers of 
immaturity on a gene expression level, suggests that at least a portion of canine PTCL may arise 
from an immature thymic precursor cell.  
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Expression of T-cell subset markers in canine PTCL 
During thymic T-cell development T-cells commit to the CD4 or CD8 lineage upon 
interaction with MHC class II or MHC class I molecules, respectively. CD8+ T-cells are 
cytotoxic and act to directly target and destroy virus-infected or tumor cells. CD4+ T-cells 
perform a variety of functions that aid in propagating an appropriate immune response to the 
inciting stimulus.  Upon antigen exposure, naïve CD4+ T-cells differentiate into T-helper subsets 
including T helper 1 (Th1), T helper 2 (Th2), T regulatory (Treg), T helper (Th17), and T 
follicular helper (Tfh) cells. T-cell subsets are defined by major regulatory transcription factor 
expression and associated secreted cytokines.220 Differential gene expression analysis of key 
markers and pathway enrichment analysis for gene signatures associated with the cytotoxic CD8 
Figure 4.8. Gene set enrichment analysis (GSEA) of canine PTCL subgroups compared to stages of thymic 
development. Both CD4+ and CD4-CD8- PTCL were significantly enriched for the gene set that representing 
genes upregulated in immature CD4 single positive (SP) thymocytes compared to double positive (DP) 
thymocytes. CD4+ PTCL was also significantly enriched for the gene set representing genes upregulated in 
double positive thymocytes versus CD4 single-positive thymocytes.  
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T-cell as well as the T-helper subsets Th1, Th2, Th17, Treg, and Tfh were performed in canine 
PTCL groups.  
Cytotoxic CD8 T-cells are characterized by the transcription factor EOMES221–223 and 
expression of effector molecules TNF, IFNG, perforin, and granzyme-B.58 CD8+ PTCL 
significantly upregulates IFNG, TNF, and GZMA (Figure 4.9, Table 4.5). CD4+ PTCL 
significantly downregulates EOMES, INFG, and GZMB. CD4-CD8- PTCL significantly 
downregulates TNF. GSEA was performed on PTCL subgroups compared to gene sets 
comparing naïve to activated CD8+ T-cells in mice.224,225 Significant enrichment for activated 








Figure 4.9 Differential gene expression of cytotoxic CD8+ T-cell associated genes. Normalized gene 
expression for key cytotoxic CD8+ T-cells genes EOMES, INF-G, TNF, PRF1, GZMB, and GZMA. Normalized 
gene expression is derived from DESeq2.  
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Table 4.5 Summary of differential gene expression of genes associated with CD8+ 
phenotype 
Gene Name Immunophenotype Log2(FC) p-value padj 
EOMES 
CD4+ -3.0752 6.67E-06 3.88E-05 
CD4-CD8- (DN) 0.042822 0.97137 0.98263 
CD8+ 0.28436 0.78892 0.85699 
IFN-G 
CD4+ -2.9877 1.60E-05 8.41E-05 
CD4-CD8- (DN) 2.8702 NA NA 
CD8+ 1.761 0.0033631 0.011743 
TNF 
CD4+ 0.80452 0.035721 0.071781 
CD4-CD8- (DN) -1.0483 0.0020806 0.0089965 
CD8+ 1.3218 0.00020926 0.0011074 
PRF1 CD4+ -1.1285 0.091264 0.15586 
CD4-CD8- (DN) 0.056902 0.95142 0.97053 
CD8+ 1.3756 0.10275 0.19112 
GZMB CD4+ -2.3626 1.40E-05 7.49E-05 
CD4-CD8- (DN) -0.46672 0.60128 0.72287 
CD8+ 3.2925 NA NA 
GZMA CD4+ -1.5062 0.068423 0.12325 
CD4-CD8- (DN) 2.5417 NA NA 
CD8+ 3.0572 0.0058024 0.018599 
*Bold and red highlighting indicates significantly upregulated genes and bold and blue highlighting indicates 
significantly downregulated genes (padj<0.05) 
 
 The Th1 phenotype is characterized by expression of the master transcription factor 
TBX21 and downstream molecules INF-" and TNF.226 TBX21 and IFN-" were significantly 
downregulated in CD4+ PTCL. TNF was significantly downregulated in CD4-CD8- PTCL. 
Effector molecules IFN-" and TNF were significantly upregulated in CD8+ PTCL (Figure 4.10, 
Table 4.6). The differentially expressed gene lists from canine CD4+, CD8+, or CD4-CD8- 
PTCLs were compared to a gene signature associated with Th1 cells using GSEA. The Th1 gene 
signature was derived from a previous study that compared gene expression profiles of untreated 
CD4+ T-cell from mice to CD4+ T-cell cultured in Th1 conditions (anti-IL-4, IL-12, and IL-2). 




Table 4.6 Summary of differential gene expression of genes associated with Th1 phenotype 
Gene Name Immunophenotype Log2(FC) p-value padj 
TBX21 
CD4+ -1.8445 0.0050847 0.01361 
CD4-CD8- (DN) 0.60217 NA NA 
CD8+ 0.65439 0.22201 0.34526 
IFNG 
CD4+ -2.9877 1.60E-05 8.41E-05 
CD4-CD8- (DN) 2.8702 NA NA 
CD8+ 1.761 0.0033631 0.011743 
TNF 
CD4+ 0.80452 0.035721 0.071781 
CD4-CD8- (DN) -1.0483 0.0020806 0.0089965 
CD8+ 1.3218 0.00020926 0.0011074 
*Bold and red highlighting indicates significantly upregulated genes and bold and blue highlighting indicates 
significantly downregulated genes (padj<0.05) 
 
 The Th2 phenotype is characterized by expression of the master transcription factor 
GATA3 and downstream effectors IL4, IL5, and IL13.227 GATA3 expression was significantly 
upregulated in CD4+ PTCL. IL4R, IL5, and IL13 were not differentially expressed in PTCL 
groups compared to control T-cells (Figure 4.11, Table 4.7). GSEA was then used to compare 
the differentially expressed gene lists from canine CD4+, CD8+, or CD4-CD8- PTCLs to the gene 
Figure 4.10 Differential gene expression of Th1 associated genes. Normalized gene expression for key Th1-
associated molecules TBX21, IFNG, and TNF. Normalized gene expression is derived from DESeq2.  
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signature associated with Th2 cells. The Th2 gene signature was identified using a previous 
murine study that compared gene expression profiles of untreated CD4+ T-cells to CD4+ T-cell 
cultured in Th2 conditions (anti-IFN-", anti-IL-12, IL-4, and IL-2). Significant enrichment for 
the Th2 gene signature was not identified an any subset of canine PTCL. 
 
Table 4.7 Summary of differential gene expression of genes associated with Th2 phenotype 
Gene Name Immunophenotype Log2(FC) p-value padj 
GATA3 
CD4+ 2.4208 1.31E-15 4.73E-14 
CD4-CD8- (DN) 0.11384 0.85535 0.91415 
CD8+ 0.26511 0.57297 0.69066 
IL4R 
CD4+ 0.30586 0.29803 0.40099 
CD4-CD8- (DN) 0.69255 0.23268 0.37333 
CD8+ 1.0865 0.024985 0.061946 
IL5 
CD4+ -0.83084 0.17792 0.26751 
CD4-CD8- (DN) 0.42228 0.51964 0.65752 
CD8+ 0.31264 0.69167 0.78623 
IL13 CD4+ -0.71623 0.43155 0.5341 
CD4-CD8- (DN) 0.20327 0.87546 0.92607 
CD8+ 0.11264 0.91861 0.94755 
*Bold and red highlighting indicates significantly upregulated genes and bold and blue highlighting indicates 
significantly downregulated genes (padj<0.05) 
 
 The Th17 phenotype is characterized by expression of the master transcription factor 
ROR"T and downstream effector IL17. RORC (ROR"T), IL17C and IL17F gene expression 
Figure 4.11 Differential gene expression of Th2 associated genes. Normalized gene expression for key Th2-
associated molecules GATA3, ILR4, IL5 and IL13. Normalized gene expression is derived from DESeq2.  
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levels were compared between canine PTCL and combined CD4+ and CD8+ control T-cells 
(Figure 4.12, Table 4.8). RORC is significantly downregulated in CD4+, CD4-CD8-, and CD8+ 
PTCL. IL17C and IL17F are not differentially expressed in any PTCL subgroup.  
 GSEA was used to compare the differentially expressed gene lists from canine CD4+, 
CD8+, or CD4-CD8- PTCLs to the gene signature associated with Th17 cells. The Th17 gene 
signature was derived from a previous study that compared gene expression profiles of untreated 
CD4+ T-cell from mice to CD4+ T-cell cultured in Th17 conditions (anti-IL-4, inti IFN-", anti-
IL-12, TGF-B, IL-6, and IL-1B). Significant enrichment was not identified an any subset of 










Figure 4.12 Differential gene expression of Th17 associated genes. Normalized gene expression for key 
Th17-associated molecules RORC, IL17C, IL17F. Normalized gene expression is derived from DESeq2.  
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Table 4.8 Summary of differential gene expression of genes associated with Th17 
phenotype 
Gene Name Immunophenotype Log2(FC) p-value padj 
RORC 
CD4+ -4.8387 2.52E-08 2.48E-07 
CD4-CD8- (DN) -3.5621 0.00035528 0.0020239 
CD8+ -2.9855 0.0013551 0.0054625 
IL17C 
CD4+ -0.30732 0.64238 0.72229 
CD4-CD8- (DN) 0.92834 0.37797 0.52651 
CD8+ 0.31176 0.76809 0.84342 
IL17F 
CD4+ -1.7978 0.057487 0.10675 
CD4-CD8- (DN) 1.2193 0.332 0.4821 
CD8+ -0.97185 0.37404 0.50759 
*Bold and red highlighting indicates significantly upregulated genes and bold and blue highlighting indicates 
significantly downregulated genes (padj<0.05) 
 
The Treg phenotype is characterized by expression of the master transcription factor 
FOXP3 and downstream effectors IL-10, and TGF-!. FOXP3, IL10, and TGF!1 gene 
expression levels were compared between canine PTCL and combined CD4+ and CD8+ control 
T-cells (Figure 4.13, Table 4.9). FoxP3 was significantly downregulated in CD8+ and CD4-CD8- 
PTCL. IL-10 was significantly downregulated in CD4+ PTCL. The differentially expressed gene 
lists of canine PTCL subgroups were compared to Treg gene signatures using GSEA. Treg gene 
signatures were derived from a previous murine microarray study which compared naïve CD4+ 
T-cells to both CD4+CD25hi natural Tregs or cells cultured under Treg (anti-IL4, anti IFN-", 
TGF-!, and IL-2) conditions.228 Canine PTCL was not significantly enriched for the induced or 




Table 4.9 Summary of differential gene expression of genes associated with Treg phenotype 
Gene Name Immunophenotype Log2(FC) p-value padj 
FOXP3 
CD4+ -1.1157 0.21624 0.31199 
CD4-CD8- (DN) -4.6035 6.76E-08 1.12E-06 
CD8+ -2.4332 0.0033481 0.011704 
IL10 
CD4+ -1.6448 0.0069544 0.017856 
CD4-CD8- (DN) -2.0471 0.044487 0.10652 
CD8+ -0.18754 0.82702 0.88451 
TGFB1 
CD4+ 0.093982 0.70194 0.77324 
CD4-CD8- (DN) 0.415 0.24123 0.38279 
CD8+ -0.19164 0.57158 0.68976 
*Bold and red highlighting indicates significantly upregulated genes and bold and blue highlighting indicates 
significantly downregulated genes (padj<0.05) 
 
The Tfh phenotype is characterized by expression of the master transcription factor 
BCL6, downstream effector IL21, as well as CXCL13 and CXCR5. Gene expression levels of 
BCL6, CXCL13, and CXCR5, and IL21R were compared between canine PTCL and combined 
CD4+ and CD8+ control T-cells (Figure 4.14, Table 4.10). BCL6 was significantly overexpressed 
by CD4-CD8- PTCL and downregulated in CD8+ PTCL. CXCR5 was significantly 
downregulated in CD4+ and CD8+ PTCL. GSEA pathway analysis was also performed to 
Figure 4.13 Differential gene expression of Treg associated genes. Normalized gene expression for key Treg-
associated molecules FOXP3, IL10, and TGFB1. Normalized gene expression is derived from DESeq2.  
 106 
compare the differentially expressed gene lists of canine PTCL subgroups to Tfh gene signatures. 
Tfh gene signatures were derived from a gene expression microarray study that compared virus-
specific Tfh and non-Tfh effector CD4+ T-cells in mice.88 Canine PTCL was not significantly 
enriched for the Tfh signature.    
 
Table 4.10 Summary of differential gene expression of genes associated with Tfh phenotype 
Gene Name Immunophenotype Log2(FC) p-value padj 
BCL6 
CD4+ 0.20706 0.50664 0.60425 
CD4-CD8- (DN) 2.4693 0.0011378 0.0054287 
CD8+ -0.99223 0.0050851 0.016638 
IL21R 
CD4+ -0.38801 0.30516 0.40861 
CD4-CD8- (DN) -1.0651 0.16676 0.29298 
CD8+ -0.8549 0.1274 0.22579 
CXCL13 
CD4+ 0.88009 0.31165 0.41556 
CD4-CD8- (DN) -2.5195 0.023422 0.064633 
CD8+ -0.53066 0.56512 0.6838 
CXCR5 
CD4+ -3.6176 1.31E-07 1.12E-06 
CD4-CD8- (DN) -2.8713 0.017946 0.052229 




Figure 4.14 Differential gene expression of Tfh associated genes. Normalized gene expression for key Tfh-
associated molecules BCL6 and IL21R. Normalized gene expression is derived from DESeq2.  
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Discussion 
 In this chapter we aim to better understand the normal immunological counterpart of 
canine PTCL. PTCL expresses T-cell markers CD3 and variably expresses CD5. In thymic 
development, T-cells gain expression of CD3 following productive rearrangement of the TCR !-
chain. Low levels of CD5 are expressed on immature double negative (DN) CD4-CD8- 
thymocytes. CD5 surface expression increases in both the double positive (DP) CD4+CD8+ and 
single positive (CD4+ or CD8+) thymocytes. CD5 expression is then maintained on circulating 
single positive T-cells.229,230  
Canine PTCL expresses low levels of surface MHC class II and CD25. MHC class II has 
been shown to be expressed on activated T-cells in a number of species including humans, dogs, 
horses, and cows. 212–217 CD25 (IL-2 receptor alpha-chain) is expressed by antigen-exposed, 
activated T-cells209,210 and is constitutively expressed by CD4+ Tregs.211 Upon antigen-exposure, 
naïve T-cells become activated and are able to proliferate through TCR-mediated signaling 
pathways. CD25, along with other genes associated with TCR signaling, were expressed at lower 
levels in canine PTCL compared to controls. Lower expression levels of molecules associated 
with antigen-exposure and T-cell activation in canine PTCL supports a naïve T-cell phenotype. 
Further supporting a naive T-cell origin, GSEA analysis identified significant enrichment for a 
gene signature representing genes upregulated in naïve T-cells compared to memory T-cells.  
 Canine PTCL does not express the surface CD34 molecule. CD34 is a marker of 
hematopoietic stem cells and hematopoietic progenitor cells. 20,206–208 Evaluation of the canine 
gene expression profiles, however, identified significant upregulation of several markers of 
precursor phenotypes including CD34 and TdT. The significance of this upregulation is 
undetermined. PTCL cases were compared to normal control lymphocytes and a precursor 
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control was not included in this study. Comparison of CD34 and TdT expression by PTCL to 
acute leukemia or bone-marrow derived stem cells would provide further insights into the 
observed upregulation. Based on our gene expression results, a subset of PTCL cases may 
exhibit a precursor phenotype. Stratification of PTCL cases based on CD34 and TdT gene 
expression levels and comparison of clinical features, clinical outcome, and gene expression 
compared to isolated hematopoietic stem cells or acute leukemia cells would be interesting future 
study directions. TdT protein quantification has been attempted by us and others, however, 
antibodies that react with canine TdT have yet to be successfully optimized.  
Canine CD4+ and CD4-CD8- PTCL can present with mediastinal involvement, suggesting 
that in a portion of cases, neoplastic T-cells may be derived from thymic T-cells. GSEA analysis 
identified significant enrichment for immature CD4 single positive and double positive 
thymocytes. Together, these findings imply that canine PTCL may originate from thymic 
precursors and naïve CD4+ T-cells in various stages of development, a subset of which may be 
early precursors that maintain expression of CD34 and TdT.   
  CD117 (c-kit) expression was also evaluated in canine PTCL. CD117 is expressed in 
several cell types including normal and neoplastic hematopoietic cells.231 CD117 expression can 
be seen in both non-neoplastic myeloid and lymphoid lineages, although within the lymphoid 
lineage expression appears to be restricted to NK-cell and early T-cell precursor subsets.231 
CD117 has also be shown to be expressed in Hodgkin’s lymphoma, CD30+ anaplastic large cell 
lymphoma,232 multiple myeloma,233 as well as precursor neoplasms including acute myeloid 
leukemia,231 and T-cell acute lymphoblastic leukemia.234 It is undetermined if CD117 
upregulation in canine PTCL is a primary oncogenic pathway or supports derivation from a 
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precursor lymphocyte. Nevertheless, this finding suggests that receptor tyrosine kinase inhibitors 
targeting CD117 have potential to be therapeutically beneficial in canine PTCL.235 
 We also assessed expression of key transcription factors and signaling molecules 
associated with CD4+ T-helper lymphocyte subsets. CD4+ PTCL significantly upregulated the 
Th2 master regulator GATA3, but did not upregulate downstream effector molecules IL4R, IL5, 
or IL13. While, GATA3 is best known as the primary transcription factor that directs Th2 
differentiation, it has also been shown to have essential roles in early T-cell commitment, !-
selection, and CD4+ T-cell development.236 GATA3 is detectable in hematopoietic stem cells and 
mRNA levels increase as development proceeds through the lymphoid progenitor, double 
negative, double positive and single positive stages.237,238 GATA3 has been shown to be critical 
for commitment to the CD4+ single positive phenotype. Mice that were conditionally ablated for 
GATA3 at the double-positive stage result in decreased numbers of CD4 SP thymocytes and 
increased numbers of CD8 SP thymocytes.47 Furthermore, enforced expression of GATA3 
throughout T-cell development, resulted in reduced numbers of peripheral CD8+ T-cells as well 
as development of thymic lymphoblastoid neoplasms.53 These findings support a critical role for 
GATA3 in the commitment to the CD4+ T-cell lineage and suggest that overexpression of this 
transcription factor could contribute to oncogenesis of this T-cell subset within the thymus. 
Canine PTCL gene expression did not appear to correlate to key molecules associated 
with Th17, Treg, or Tfh phenotypes. Furthermore, significant enrichment for gene signatures 
associated with these effector subgroups was not identified. BCL6 was significantly upregulated 
in CD4-CD8- PTCL. The significance of this finding is interpreted with caution, given the low 
sample number in this group.  
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 CD8+ cytotoxic T-cell molecules, INF-", TNF, and granzyme A were upregulated by 
CD8+ PTCL, indicating that CD8+ PTCL may originate for a more mature, activated cytotoxic T-
cell. This finding is in contrast to significant upregulation of markers of immaturity including 
CD34 and downregulation of TCR signaling associated molecules in CD8+ PTCL. These 
contradictory findings could imply that the CD8+ PTCL encompasses a heterogenous group of 
tumors, some of which arise from an immature naïve T-cell while others originate from a mature 
effector T-cell. Alternatively, upregulation of these effector molecules could represent a more 
inflammatory microenvironment in the CD8+ PTCL phenotype compared to the more common 
CD4+ PTCL group. In human PTCL-NOS, the PTCL-TBX21 subgroup is associated with an 
enhanced mixed inflammatory background compared to PTCL-GATA3.120 
 Based on the findings of this study, we propose that CD4+ PTCL originates from a naïve 
single positive T-cell that does not signal through the TCR and does not represent an activated T-
helper phenotype. At least a proportion of CD4+ PTCL appear to upregulate markers of 
immaturity, including CD34 and TdT, and are enriched for gene signatures of early thymic 
development. Based on these findings, it is possible that a subset of these neoplasms are 
consistent with a lymphoblastic lymphoma derived from precursor cells. Further stratification of 
canine PTCL based on markers of immaturity may be helpful to better characterize the biologic 
significance of these findings. Evaluation of the origin of CD4-CD8- and CD8+ PTCL is limited 
by the low sample numbers in this study. We hypothesize that CD4-CD8- PTCL originates from 
a double negative thymic precursor, prior to commitment to a single-positive lineage. Our results 
also imply that CD8+ PTCL may encompass a more heterogenous tumor group, some of which 
may be derived from naïve CD8+ T-cells and other from activated cytotoxic CD8+ T-cells. 
Characterization of the cellular origin of PTCL gives us insights into underlying pathogenesis of 
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these neoplasms and helps to direct further studies focused on more advanced classification of 





























 Chromosome aberrations and rearrangements are common in a wide variety of cancers. 
One of the consequences of chromosomal rearrangements is the formation of gene fusions. 
Fusion genes are particularly common drivers of hematologic malignancies and serve as useful 
diagnostic markers, as well as therapeutic targets. Identification of novel driving chromosomal 
translocations and fusion genes offers new targets to investigate disease pathogenesis and 
treatment. In this chapter we aim to discover fusion gene candidates in 26 canine PTCL cases 
using an RNA-seq based discovery pipeline. We utilized FusionCatcher to identify fusion 
transcripts in PTCL cases and control canine lymphocytes. We specifically focused on recurrent 
fusion genes in which the 3’ fusion partner was identified in more than one candidate. Following 
strict filtering criteria, a total of 591 fusion transcripts were identified in the 26 cases. Recurrent 
fusion genes involving 11 different 3’ fusion partners were chosen for further evaluation of the 
genome structure and fusion event. Recurrent fusion genes involving DGKZ-MDK and LMO4 
with several 5’ fusion partners were particularly interesting due to the 3’ gene partners’ potential 
roles in driving oncogenesis.   This study identifies a list of potential fusion gene candidates in 











Chromosomal rearrangements that juxtapose two different genes can result in a fusion 
gene that has potential to drive uncontrolled cellular proliferation and survival. Structural 
chromosomal rearrangements that yield fusion genes include translocations, inversions, 
amplifications and deletions. Fusion genes can also form by non-structural aberrations including 
cis- and trans- splicing or transcriptional read-through.239,240 Fusion genes and chromosomal 
translocations are valuable molecular diagnostic markers for tumor identification and 
classification, particularly in tumors that lack useful cell surface markers. Oncogenic 
translocations also represent potential therapeutic targets.  
Fusion genes can alter cell biology through a number of mechanisms. Among the most 
common mechanisms is overexpression of an oncogene due to promoter exchange. In this case, a 
chromosomal rearrangement brings the 3’ gene’s expression under control of the 5’ gene’s 
promoter. The IGH-MYC fusions identified in Burkitt lymphoma is an example in which the 
promoter of immunoglobulin heavy locus is fused with the MYC proto-oncogene.241  
Fusion events can also alter oncogene expression by replacing the 3’UTR. The 3’ UTR is 
a regulatory domain that influences the localization, export, stability, and translation efficiency 
of mRNA. The 3’ UTR also contains various sequences that are involved in gene expression, 
including microRNA (miRNA) response elements, AU-rich elements, and the poly-A tail. MYB-
NFIB fusion identified in adenoid cystic carcinoma results in elevated MYB protein levels due to 
loss of miRNA binding sites as a result of the fusion event.242  
Chimeric proteins can also form during a fusion gene event. Alterations in the protein 
structure may result in constitutive activation, altered signaling mechanisms to change 
downstream signaling events, or inhibition of normal cellular function. BCR-ABL1 is a 
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canonical example and is identified in greater than 90% of human patients with chronic 
myelogenous leukemia (CML).243 BCR-ABL1 fusions result in constitutively active ABL1 
kinase by enabling BCR-ALB1 oligomerization via the coiled-coil domain present in BCR.244 
Fusion genes are frequent drivers of human hematopoietic malignancies. Studies focused 
on PTCL in humans have identified several recurrent fusion proteins. Anaplastic large cell 
lymphoma (ALCL) is one of the more common PTCL subtypes and encompasses several distinct 
entities based on the presence or absence of ALK (anaplastic lymphoma kinase) gene 
rearrangements. ALK-positive ALCL generally affects a younger patient population than ALK-
negative ALCL or other PTCL subtypes.20 The most common rearrangement involves a 
t(2;5)(p23;q35) translocation that results in the fusion of nucleophosmin (NPM1) to ALK.245 
This translocation and fusion protein is identified in approximately 75-85% of ALK-positive 
ALCLs. Fewer ALK-positive ALCLs involve more than 20 other ALK fusion partners.20,246 
ALK fusion proteins result in constitutive ALK tyrosine kinase activity which promotes cancer 
cell proliferation and survival.247 Pharmacologic ALK inhibition is an effective therapeutic 
strategy for patients with ALK-positive ALCL, including patients with relapsed/refractory 
disease.248–251 With conventional cytotoxic therapy or ALK targeted therapy, ALK-positive 
ALCL has a better prognosis than ALK-negative ALCL, as well as most other PTCL subtypes, 
with 5-year overall survival rates of 70-85%.251,252 
Recurrent chromosomal translocations appear to occur within a smaller proportion of 
individuals with other types of PTCL. CTLA4-CD28 fusion genes have been identified in 
variable numbers of angioimmunoblastic T-cell lymphomas (AITL), PTCL-NOS, and extranodal 
NK/T cell lymphomas.253–255 Additionally, a recurrent t(5;9)(q33;q22) translocation resulting in 
ITK-SYK fusion has been identified in a subset of PTCLs with a follicular growth pattern and 
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Tfh phenotype, and rarely in AITL. This fusion results in overexpression and activation of spleen 
tyrosine kinase (SYK).256–259 The identification of this recurrent fusion gene has contributed to 
the development of the Tfh-derived PTCL categories, previously discussed.  
Recurrent fusions involving VAV1 with varying partners have been identified in 7% of 
PTCL, including  PTCL-NOS as well as ALK-negative ALCL.260 In vitro ectopic expression of 
VAV1 fusion was shown to promote cell proliferation and migration in a RAC1-dependent 
manner. RAC1 inhibitors are clinically available and potentially useful therapeutics for patients 
with VAV1 fusion proteins.260  
While fusion genes have been well-characterized in a wide-range of human tumors, the 
roles of chromosomal translocations and functional fusion genes in canine malignancies are not 
well understood. There have been few reported oncogenic fusion genes in canine tumors 
including: IGK-CCND3 in B-cell lymphoma, MPB-BRAF in glioma, COL3A1-PDGFRB in 
dermatofibrosarcoma protuberans-like, BCR-ABL in chronic lymphocytic leukemia, and IGH-
MYC translocation in Burkitt lymphoma.261,262   
RNA-seq offers a powerful tool for the discovery of fusion genes. A number of 
algorithms and programs have been developed for fusion detection using RNA-Seq data. These 
programs generally work by identifying the split reads in discordant read pairs that map to two 
distinct genes. The exact fusion point is then determined from the split reads where a single mate 
reads overlap the fusion junction, with the fusion-encompassing reads used as supporting 
evidence (summarized in Figure 5.1).263,264  
In this chapter, we aim to identify fusion genes that may be driving canine PTCL using 
RNA-seq derived transcriptomic data. After applying strict filtering criteria, 591 fusion 
transcripts were identified in the 26 cases. Recurrent fusion genes involving 11 different 3’ 
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fusion partners were chosen for further evaluation. The structural features of these proposed 
chromosomal rearrangements and subsequent fusion transcripts were subsequently modeled.  
This study identifies a list of potential fusion gene candidates in canine PTCL, and lays the 







Figure 5.1 Summary of RNA-seq gene fusion detection from paired-end mapping. The reference sequence 
includes two chromosomes with four different genes represented by colored boxes. Reads are first mapped to the 
reference sequence and reads that map concordantly are discarded. Reads that map to the reference sequence are 
colored with the region to which they are aligned to. Unmapped reads are colored black. Reads that map 
discordantly are used to determine approximate fusion boundaries. In cases with reads in which at least one end 
is unaligned to the reference sequence, the unmapped read is cut into multiple segments (curved lined) to be 
aligned independently to the approximate fusion boundaries. Fusion junctions are identified through these ‘split-
reads’ in which the two segments are mapped to two different chromosomes or genes. The sequences of the 
fusion candidates are then assembled and those with the highest likelihood to be real fusions are selected as final 
outputs (adapted from Zhoa et al. 2013).   
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Materials and Methods 
 
Case selection for RNA-Seq 
Fine needle tissue aspirates from 26 dogs submitted to the Colorado State University-
Clinical Immunology laboratory for routine diagnostics and diagnosed with CD4+ PTCL by flow 
cytometry were selected for RNA-seq. PTCL cases were identified by uniform expansion of T-
cells characterized by expression of the pan-leukocyte marker CD45, the T-cell markers CD3 
with or without CD5, the T-cell subset marker CD4, and lack of expression of the B-cell marker 
CD21.  
Control CD4+ and CD8+ T lymphocytes were harvested from lymph nodes of healthy 
dogs utilized for IACUC approved surgical continuing education courses. T-cell subsets were 
sorted by a MoFlo cell sorter (Beckman Coulter, Brea, CA) using positive selection with anti-
CD4 (clone YKIX302.9). Sorted populations were re-analyzed for purity and were used if 
greater than 90% of the cells were the desired population.  
RNA Extraction and Sequencing 
RNA extraction was performed using the Purelink RNA mini Kit (Thermo Fisher 
Scientific, Waltham, MA) and quality was measured with an Agilent 2100 Bioanalyzer System. 
RNA was shipped to Novogene Corporation Inc (Sacramento, CA) where the unstranded 
libraries were constructed and sequenced using an Illumina Hiseq PE150 platform. Quality 
parameters of the sequencing are summarized in Table 5.1. The median number of raw reads of 
samples used for fusion discovery was 57,422,874 (range: 46,655,240-71,686,242 reads). The 








Fusion Gene Discovery 
 Candidate fusion genes in CD4+ PTCL cases as well as control sorted CD4+ and CD8+ 
lymphocytes were identified using FusionCatcher265 v1.10 with default parameters. Strict 
filtering criteria was applied to identify the most biologically-relevant fusion genes in tumor 
samples. To identify tumor-specific fusion candidates, fusion pairs found in the control 
lymphocyte groups were excluded from tumor samples. A total of 697 unique fusion pairs were 
Table 5.1. RNA-seq Quality Control Summary  
Sample 










rate(%) Q20(%) Q30(%) 
GC 
content(%) 
107029 CD4 Control 71686242 69323150 10.8G 10.4G 0.03 97.79 94.01 51.21 
63500 CD4 Control 49892460 48111496 7.5G 7.2G 0.03 97.78 93.97 51.04 
77877 CD4 Control 68020740 65801830 10.2G 9.9G 0.03 97.92 94.25 51.61 
80398 CD4 Control 70986464 68679512 10.6G 10.3G 0.03 97.73 93.81 51.3 
100641 CD4 PTCL 49548966 47959446 7.4G 7.2G 0.03 97.68 93.62 50.23 
100850 CD4 PTCL 48707294 47190500 7.3G 7.1G 0.03 97.52 93.31 50.58 
100993 CD4 PTCL 52926966 51138812 7.9G 7.7G 0.03 97.73 93.85 49.89 
101786 CD4 PTCL 64708040 63022640 9.7G 9.5G 0.03 97.7 93.8 49.92 
104029 CD4 PTCL 54004842 52430952 8.1G 7.9G 0.03 97.76 93.97 50.53 
60342 CD4 PTCL 46655240 45027580 7G 6.8G 0.03 97.75 93.88 51.37 
65026 CD4 PTCL 49907106 48214140 7.5G 7.2G 0.03 97.77 93.94 49.84 
67283 CD4 PTCL 56817058 55231380 8.5G 8.3G 0.03 97.91 94.22 50.87 
67308 CD4 PTCL 64997916 62882384 9.7G 9.4G 0.03 97.8 94.03 51.06 
69996 CD4 PTCL 50074724 48315878 7.5G 7.2G 0.03 97.87 94.16 50.61 
71175 CD4 PTCL 62740124 60789720 9.4G 9.1G 0.03 97.78 93.95 51.31 
71312 CD4 PTCL 55758818 53882748 8.4G 8.1G 0.03 97.83 94.03 51.14 
71508 CD4 PTCL 55384306 53636026 8.3G 8G 0.03 97.64 93.65 51.57 
71605 CD4 PTCL 59408924 57461946 8.9G 8.6G 0.03 97.8 94.03 50.51 
71779 CD4 PTCL 60828100 58535460 9.1G 8.8G 0.03 97.25 92.59 50.49 
76055 CD4 PTCL 67319066 65041220 10.1G 9.8G 0.03 97.75 93.88 50.62 
76392 CD4 PTCL 57422874 55688672 8.6G 8.4G 0.03 97.78 93.95 50.82 
95512 CD4 PTCL 60838638 58502090 9.1G 8.8G 0.03 97.85 94.1 50.9 
95591 CD4 PTCL 67189882 65277158 10.1G 9.8G 0.03 97.61 93.57 51.67 
95593 CD4 PTCL 47484046 46006612 7.1G 6.9G 0.03 97.82 94.14 51.42 
96300 CD4 PTCL 58334394 56604978 8.8G 8.5G 0.03 97.86 94.12 50.4 
97074 CD4 PTCL 66146888 62293732 9.9G 9.3G 0.03 97.78 93.96 50.99 
97336 CD4 PTCL 64768664 62833840 9.7G 9.4G 0.03 97.72 93.86 51.73 
97568 CD4 PTCL 62849258 60771456 9.4G 9.1G 0.03 97.77 93.95 50.46 
97578 CD4 PTCL 50640402 49050588 7.6G 7.4G 0.03 97.83 94.11 50.57 
98458 CD4 PTCL 57844072 55828494 8.7G 8.4G 0.03 97.72 93.85 51.18 
107031 CD8 Control 55899102 54070548 8.4G 8.1G 0.03 97.74 93.88 51.05 
107032 CD8 Control 56832496 55029784 8.5G 8.3G 0.03 97.82 94.05 50.77 
63491 CD8 Control 51380682 49598884 7.7G 7.4G 0.02 97.94 94.36 51.14 
Abbreviations: PTCL-peripheral T-cell lymphoma, DN-Double negative (CD4-CD8-) 
Definitions: (1) Raw reads: read counts from the raw data. 
                    (2) Clean reads: read counts filtered from raw data (removed reads containing N, low quality reads, reads containing adapter) 
                    (3) Raw bases: # of raw reads X sequence length 
                    (4) Clean bases: # of clean bases X sequence length 
                    (5) Error rate (%): base error rate of whole sequencing 
                    (6) Q20 (%): (Base number of Phred values > 20) / (Total base number) *100 
                    (7) Q30 (%): (Base number of Phred values > 30) / (Total base number) *100 
                    (8) GC content (%): (G&C base number) / (Total base number)*100 
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identified in the control group. Having removed fusion transcripts present in control tissues, a 
total of 2,399 fusion candidates were identified in the 26 PTCL samples. In a given tumor, 
fusions with multiple predicted breakpoints involving the same gene partners were considered a 
single event, as previously described.266  
 Next, fusion genes were filtered on two criteria: fusion description and predicted effect. 
The fusion description is an output of FusionCatcher that describes the type of fusion event. 
Fusion candidates that were described as having a high probability of being a false positive were 
excluded from the candidate list. A list of the fusion descriptions that are associated with a high 
likelihood of false positivity and were used to excluded cases is provided in Table 5.2.  
Candidate fusion genes were further selected to include only those involving exonic, 
coding sequence (CDS), and/or untranslated regions (UTR). Fusions that are considered in-frame 
have persevered reading frames for both partners, and are therefore potentially functional if 
translated. UTR’s often contain regulatory elements that can alter the expression of genes they 
are positioned next to and therefore, a fusion event involving a UTR and protein-coding 
sequence also has potential to form a functional protein. Candidate fusions in which one of the 
gene partners was intergenic or intronic were removed from evaluation.  
Fusion candidates that were recurrent or involved at least one cancer-associated gene 
were selected for further evaluation. Fusions were considered recurrent if the 3’ fusion partner 
was identified in two or more tumor samples.  To identify fusions in which one or both partners 
were cancer-associated genes, candidates were screened using the COSMIC cancer-gene 





Differential Gene Expression 
Sequences were aligned to CanFam3.1 genome using HISAT2.182 HTseq183 and 
DESeq2184 were then used to quantify reads, normalize gene expression, and evaluate 
differentially expressed genes between tumor samples and controls. P-values were determined 
using a negative binomial distribution.  A Benjamini-Hochberg procedure was used to correct p-
values and padj<0.05 was considered the differentially expressed gene screening standard. 
Normalized gene expression of cancer-associated fusion partners was compared between cases 






Table 5.2 Description of fusion events with high probability of being a false positive 
Fusion Description Title Description 
Adjacent/Readthrough Both genes forming the fusion are on the same strand and there are no other genes 
situated between them 
Short_repeats The sequence of the fusion junction contains a highly repetitive region containing 
repeating short sequences or polyA/C/G/T 
 
Long_repeats The sequence of the fusion junction contains a highly repetitive region containing 
repeating long sequences or polyA/C/G/T  
 
Mt One or both genes are situated on mitochondrion 
 




The genes forming the fusion gene are partially overlapping (on same strand or on 
different strands) according the Ensembl database. 
 
Rt_circ_RNA Reciprocal fusion genes which are also readthrough 




Fusion gene candidates were identified using FusionCatcher.265 After applying the strict 
filtering criteria, 591 fusion candidates were identified in the 26 tumor samples.  
  Recurrent fusion events in which the 3’fusion partner was identified in more than one 
fusion candidate are summarized in Table 5.3. Fusion candidates with one gene partner encoding 
long non-coding RNA (lncRNA), retrotransposable elements, or fusions between two genes from 
similar gene families with similar functions were considered unlikely to be biologically 
significant, and removed from the analysis. Forty-three genes were identified as recurrent 3’ 
fusion partners.  The most commonly identified 3’ fusion partners were MDK, PTMA, GNAS, 
EEF2, GATD3A, HMGB1, and MYH9. 
The counts of common mapping reads, spanning pairs, spanning unique reads, and 
longest anchor found are listed for each fusion candidate in Table 5.3.  The counts of common 
mapping reads identify the number of reads mapping simultaneously on both genes which form 
the fusion gene. This metric indicates the similarity of the DNA/RNA sequences of the two 
fusion gene partners. If the two genes forming the fusion have completely different sequences, 
this value should be zero, indicating a higher chance of being a true fusion event. All selected 
recurrent fusions have a count of common mapping reads of zero.  
The spanning pairs metric counts the pairs of reads that support the fusion, including the 
multimapping reads. These reads map to the gene partners involved in the proposed fusion. The 
spanning unique reads is a count of the unique reads that map to the fusion junction. The longest 
anchor found indicates the longest sequence hangover found among the unique reads mapping on 
the fusion junction. Higher values for the spanning pairs, spanning unique reads, and longest 




Normalized gene expression of the recurrent 3’ fusion genes was subsequently evaluated 
in cases in which the fusion gene was identified compared to cases without the candidate fusion 
gene and control lymphocytes (Figure 5.3). Genes which exhibited aberrant expression in the 
cases with the fusion identified were considered more likely to produce possible driver fusion 
proteins. LSP1, TRIM8, GATD3A, and PTMA all exhibited increased expression in at least one 
of the patient samples with a fusion candidate involving the respective gene. Other fusion 
candidates of interest include 3’ cancer-associated genes: GNAS, MYH9, XPO1, IKZF1, LMO4, 
JUN, and MDK (Table 5.4).  
Table 5.3 Recurrent fusion genes identified in canine CD4+ PTCL 
CN Fusion Candidate 5' Gene 3' Gene CM SP SU LA 5’ Fusion_point 3’ Fusion_point 
76055 ENSCAFG00000000661-ENSCAFG00000000336 EZR HNRNPH1 0 8 3 32 1:48176970:- 11:2059687:+ 
71779 ENSCAFG00000016306-ENSCAFG00000000336 ARAP2 HNRNPH1 0 3 3 29 3:75657733:+ 11:2055916:+ 
71175 ENSCAFG00000006794-ENSCAFG00000000458 GTF3A RAB21 0 6 2 34 25:12183372:- 10:13325416:+ 
71779 ENSCAFG00000017975-ENSCAFG00000000458 FAM219B RAB21 0 3 2 40 30:37947583:- 10:13216897:+ 
60342 ENSCAFG00000013633-ENSCAFG00000010077 B2M LSP1 0 9 3 27 30:11331865:+ 18:46126859:+ 
69996 ENSCAFG00000014396-ENSCAFG00000010077 PPY LSP1 0 10 2 34 9:19395171:+ 18:46087948:+ 
71508 ENSCAFG00000000638-ENSCAFG00000000580 KLF10 YWHAZ 0 8 2 24 13:4223542:- 13:2760450:- 
97578 ENSCAFG00000000638-ENSCAFG00000000580 KLF10 YWHAZ 0 13 3 29 13:4223542:- 13:2760450:- 
71508 ENSCAFG00000000580-ENSCAFG00000000638 YWHAZ KLF10 0 8 7 30 13:2763430:- 13:4220105:- 
97578 ENSCAFG00000000580-ENSCAFG00000000638 YWHAZ KLF10 0 13 3 26 13:2763430:- 13:4220105:- 
71508 ENSCAFG00000000689-ENSCAFG00000000718 TUBGCP6 BRD1 0 11 3 25 10:17008020:+ 10:17393422:+ 
71779 ENSCAFG00000000689-ENSCAFG00000000718 TUBGCP6 BRD1 0 9 3 22 10:17008020:+ 10:17393422:+ 
100850 ENSCAFG00000014172-ENSCAFG00000000718 ZDHHC8 BRD1 0 7 2 30 26:29207807:- 10:17393422:+ 
69996 ENSCAFG00000018898-ENSCAFG00000001324 TAOK1 ATF4 0 6 2 32 9:43631429:+ 10:25529195:- 
100850 ENSCAFG00000019288-ENSCAFG00000001324 SSR4 ATF4 0 3 2 39 X:121613669:+ 10:25530976:- 
95512 ENSCAFG00000012315-ENSCAFG00000001630 TFAM MYH9 0 6 4 34 4:10597916:+ 10:28110256:+ 
71779 ENSCAFG00000016150-ENSCAFG00000001630 NR1D1 MYH9 0 4 2 35 9:22468461:+ 10:28116611:+ 
104029 ENSCAFG00000017416-ENSCAFG00000001630 DENND4B MYH9 0 5 2 31 7:43194960:+ 10:28122813:+ 
95512 ENSCAFG00000017809-ENSCAFG00000001630 BCL11B MYH9 0 8 3 34 8:67622861:- 10:28122190:+ 
71779 ENSCAFG00000003374-ENSCAFG00000023756 IKZF1 GNAS 0 6 2 30 18:1683965:+ 24:43643409:+ 
100850 ENSCAFG00000016589-ENSCAFG00000023756 SRSF5 GNAS 0 7 3 36 8:43514223:+ 24:43643409:+ 
100993 ENSCAFG00000016589-ENSCAFG00000023756 SRSF5 GNAS 0 6 3 37 8:43514223:+ 24:43643409:+ 
97568 ENSCAFG00000013633-ENSCAFG00000023756 B2M GNAS 0 6 6 40 30:11331865:+ 24:43643409:+ 
97578 ENSCAFG00000019693-ENSCAFG00000023756 PTBP1 GNAS 0 6 2 37 20:57811498:- 24:43643409:+ 
67283 ENSCAFG00000024818-ENSCAFG00000023756 RACK1 GNAS 0 10 3 32 11:430867:- 24:43643409:+ 
100993 ENSCAFG00000005428-ENSCAFG00000002656 DYRK1B EEF1A1 0 4 2 30 1:113798304:+ 12:35577281:- 
100993 ENSCAFG00000000336-ENSCAFG00000002656 HNRNPH1 EEF1A1 0 12 2 37 11:2059763:+ 12:35579054:- 
95591 ENSCAFG00000014413-ENSCAFG00000003050 SPOCK2 XPO1 0 4 3 37 4:22752884:- 10:61542482:- 
100850 ENSCAFG00000028707-ENSCAFG00000003050 ITM2C XPO1 0 5 3 24 25:42830052:+ 10:61585054:- 
65026 ENSCAFG00000032596-ENSCAFG00000006597 PTMA HMGB1 0 10 9 29 25:43563385:+ 25:9554184:+ 
97568 ENSCAFG00000032596-ENSCAFG00000006597 PTMA HMGB1 0 5 2 27 25:43563385:+ 25:9554184:+ 
100993 ENSCAFG00000032596-ENSCAFG00000006597 PTMA HMGB1 0 16 10 29 25:43563385:+ 25:9554184:+ 
101786 ENSCAFG00000032596-ENSCAFG00000006597 PTMA HMGB1 0 10 4 28 25:43563385:+ 25:9554184:+ 
100850 ENSCAFG00000003422-ENSCAFG00000003374 GRB10 IKZF1 0 38 3 28 18:1970944:- 18:1676646:+ 
100850 ENSCAFG00000016762-ENSCAFG00000003374 PCGF3 IKZF1 0 3 2 36 3:91676726:- 18:1732840:+ 
65026 ENSCAFG00000003374-ENSCAFG00000006889 IKZF1 CD44 0 9 3 28 18:1683965:+ 18:32789707:- 
Figure 5.2 Schematics illustrating metrics used to characterize fusion candidates including spanning pairs, 
spanning unique reads, and longest anchor found. Adapted from Liu et al. 2016.  
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97336 ENSCAFG00000003422-ENSCAFG00000006889 GRB10 CD44 0 6 2 30 18:1970944:- 18:32751720:- 
100993 ENSCAFG00000016589-ENSCAFG00000031003 SRSF5 PTTG1IP 0 6 3 37 8:43514223:+ 31:38503255:- 
100993 ENSCAFG00000011049-ENSCAFG00000031003 FAM207A PTTG1IP 0 19 2 29 31:38591996:+ 31:38506663:- 
71508 ENSCAFG00000005312-ENSCAFG00000005190 PGS1 SEPTIN9 0 6 2 21 9:2812326:- 9:3506846:- 
60342 ENSCAFG00000009917-ENSCAFG00000005190 ABHD14A SEPTIN9 0 4 2 23 20:37744387:- 9:3506846:- 
69996 ENSCAFG00000001345-ENSCAFG00000013165 MATR3 PRPF6 0 3 2 34 11:26789895:+ 24:47450709:+ 
71779 ENSCAFG00000011777-ENSCAFG00000013165 APH1A PRPF6 0 4 2 39 17:59511020:- 24:47477399:+ 
71508 ENSCAFG00000010627-ENSCAFG00000006413 RASSF1 NCKAP1L 0 4 2 29 20:39016878:+ 27:805784:- 
69996 ENSCAFG00000009248-ENSCAFG00000006413 DGKZ NCKAP1L 0 4 2 27 18:43088545:- 27:805656:- 
60342 ENSCAFG00000009248-ENSCAFG00000020060 DGKZ MDK 0 10 5 37 18:43088838:- 9:55100533:+ 
67308 ENSCAFG00000009248-ENSCAFG00000020060 DGKZ MDK 0 18 2 40 18:43088833:- 9:55100533:+ 
97074 ENSCAFG00000009248-ENSCAFG00000020060 DGKZ MDK 0 11 3 41 18:43088723:- 9:55100533:+ 
97336 ENSCAFG00000009248-ENSCAFG00000020060 DGKZ MDK 0 8 2 31 18:43088838:- 9:55100533:+ 
100850 ENSCAFG00000009248-ENSCAFG00000020060 DGKZ MDK 0 14 9 34 18:43088838:- 9:55100533:+ 
95591 ENSCAFG00000010551-ENSCAFG00000008933 CHEK1 NLRC5 0 4 2 40 5:8879255:- 2:59285583:- 
95512 ENSCAFG00000023756-ENSCAFG00000008933 GNAS NLRC5 0 6 2 34 24:43651280:+ 2:59280850:- 
97568 ENSCAFG00000009354-ENSCAFG00000020233 TOX2 LMO4 0 5 3 28 24:31523443:+ 6:60906444:- 
65026 ENSCAFG00000016589-ENSCAFG00000020233 SRSF5 LMO4 0 8 3 25 8:43514227:+ 6:60906444:- 
71779 ENSCAFG00000032596-ENSCAFG00000020233 PTMA LMO4 0 7 4 28 25:43563385:+ 6:60906444:- 
69996 ENSCAFG00000010155-ENSCAFG00000010232 NFKB2 TRIM8 0 457 26 33 28:14910267:+ 28:15136432:+ 
76055 ENSCAFG00000017764-ENSCAFG00000010232 KRI1 TRIM8 0 3 2 37 20:50613993:+ 28:15135460:+ 
100850 ENSCAFG00000010899-ENSCAFG00000010865 HSPE1-MOB4 HSPD1 0 12 4 29 37:7035913:+ 37:7020338:- 
100993 ENSCAFG00000010899-ENSCAFG00000010865 HSPE1-MOB4 HSPD1 0 9 4 27 37:7035913:+ 37:7020338:- 
71508 ENSCAFG00000016034-ENSCAFG00000016010 TNRC18 FSCN1 0 9 3 28 6:12521202:+ 6:12363346:- 
95512 ENSCAFG00000048528-ENSCAFG00000016010 STAT1 FSCN1 0 4 2 34 37:1514448:- 6:12370804:- 
76055 ENSCAFG00000005876-ENSCAFG00000012143 TACC1 NPEPL1 0 6 3 36 16:26710648:- 24:43470151:+ 
101786 ENSCAFG00000001546-ENSCAFG00000012143 MROH1 NPEPL1 0 9 2 21 13:37647046:+ 24:43467691:+ 
100850 ENSCAFG00000001546-ENSCAFG00000041383 MROH1 GATD3A 0 8 3 27 13:37690507:+ 31:38035219:+ 
97578 ENSCAFG00000004722-ENSCAFG00000041383 JPT1 GATD3A 0 6 3 29 9:5321847:+ 31:38035219:+ 
100850 ENSCAFG00000013072-ENSCAFG00000041383 TPD52L2 GATD3A 0 8 4 30 24:47363544:+ 31:38035219:+ 
101786 ENSCAFG00000019693-ENSCAFG00000041383 PTBP1 GATD3A 0 9 2 30 20:57818279:- 31:38035219:+ 
65026 ENSCAFG00000013054-ENSCAFG00000032596 ATG4B PTMA 0 14 2 29 25:51514673:+ 25:43566003:+ 
65026 ENSCAFG00000011037-ENSCAFG00000032596 NCL PTMA 0 10 2 26 25:43340008:- 25:43566003:+ 
100993 ENSCAFG00000011037-ENSCAFG00000032596 NCL PTMA 0 20 9 28 25:43340008:- 25:43566003:+ 
97568 ENSCAFG00000006597-ENSCAFG00000032596 HMGB1 PTMA 0 5 2 28 25:9552010:+ 25:43566003:+ 
100993 ENSCAFG00000006597-ENSCAFG00000032596 HMGB1 PTMA 0 16 2 21 25:9556607:+ 25:43566390:+ 
100993 ENSCAFG00000009885-ENSCAFG00000032596 JARID2 PTMA 0 7 2 24 35:14477306:+ 25:43566003:+ 
95512 ENSCAFG00000031204-ENSCAFG00000032596 RGS10 PTMA 0 5 4 35 28:29688064:- 25:43563253:+ 
100993 ENSCAFG00000013689-ENSCAFG00000032596 RFC4 PTMA 0 3 2 40 34:19374779:- 25:43563189:+ 
97074 ENSCAFG00000001709-ENSCAFG00000032596 MCM5 PTMA 0 4 2 35 10:28722768:- 25:43567242:+ 
100993 ENSCAFG00000016589-ENSCAFG00000032596 SRSF5 PTMA 0 13 3 35 8:43514223:+ 25:43566003:+ 
97074 ENSCAFG00000005437-ENSCAFG00000013054 SLCO2B1 ATG4B 0 3 2 37 21:23372107:- 25:51517290:+ 
100850 ENSCAFG00000032596-ENSCAFG00000013054 PTMA ATG4B 0 6 2 35 25:43563385:+ 25:51504539:+ 
60342 ENSCAFG00000007137-ENSCAFG00000014309 TOX RASGRP2 0 6 2 29 29:9841497:- 18:52414263:+ 
71779 ENSCAFG00000032596-ENSCAFG00000014309 PTMA RASGRP2 0 9 3 26 25:43563385:+ 18:52414263:+ 
100850 ENSCAFG00000032596-ENSCAFG00000014309 PTMA RASGRP2 0 9 2 27 25:43563385:+ 18:52414263:+ 
71779 ENSCAFG00000013013-ENSCAFG00000014309 RNF168 RASGRP2 0 6 2 21 33:29627903:- 18:52414263:+ 
100850 ENSCAFG00000019517-ENSCAFG00000014309 MAN1B1 RASGRP2 0 7 2 26 9:48540410:+ 18:52414263:+ 
100850 ENSCAFG00000016628-ENSCAFG00000016129 EIF4A1 EIF5A  0 6 2 28 5:32492527:+ 5:32270433:+ 
71508 ENSCAFG00000016984-ENSCAFG00000016129 PER1 EIF5A  0 7 2 24 5:32968315:- 5:32270433:+ 
100993 ENSCAFG00000018147-ENSCAFG00000016129 SS18 EIF5A  0 6 3 28 7:62491489:+ 5:32270433:+ 
67283 ENSCAFG00000012916-ENSCAFG00000016568 S100A11 ADAM10 0 6 3 38 17:61021556:- 30:23607379:- 
95512 ENSCAFG00000001399-ENSCAFG00000016568 HNRNPK ADAM10 0 5 3 35 1:75510496:+ 30:23635480:- 
97568 ENSCAFG00000011659-ENSCAFG00000016762 ATP9A PCGF3 0 4 2 25 24:37817969:- 3:91684117:- 
100850 ENSCAFG00000015152-ENSCAFG00000016762 CAPZB PCGF3 0 4 2 23 2:79296763:+ 3:91704666:- 
71508 ENSCAFG00000017516-ENSCAFG00000018285 CALM1 KLC1  0 9 3 23 8:61398437:+ 8:71443489:+ 
76392 ENSCAFG00000010450-ENSCAFG00000018285 SLC37A1 KLC1  0 3 2 28 31:36828738:+ 8:71443489:+ 
97568 ENSCAFG00000008921-ENSCAFG00000018437 NEK4 RAI1 0 4 2 37 20:37091735:+ 5:41699555:- 
97568 ENSCAFG00000043502-ENSCAFG00000018437 OBSCURIN RAI1 0 4 3 38 14:737566:- 5:41703579:- 
101786 ENSCAFG00000007215-ENSCAFG00000018897 YTHDF3 JUN 0 3 3 36 29:13240194:+ 5:50967308:- 
67283 ENSCAFG00000019639-ENSCAFG00000018897 VBP1 JUN 0 9 4 40 X:123216276:+ 5:50968371:- 
100993 ENSCAFG00000032596-ENSCAFG00000019158 PTMA EEF2 0 5 2 34 25:43567427:+ 20:55581740:+ 
98458 ENSCAFG00000012687-ENSCAFG00000019158 EIF4G1 EEF2 0 8 3 39 34:17204102:+ 20:55585972:+ 
71508 ENSCAFG00000015532-ENSCAFG00000019158 MYO9B EEF2 0 6 2 33 20:45525613:- 20:55580985:+ 
71312 ENSCAFG00000016522-ENSCAFG00000019158 PLOD1 EEF2 0 8 2 33 2:84326004:- 20:55578680:+ 
95591 ENSCAFG00000032222-ENSCAFG00000019158 DLA-12 EEF2 0 10 2 35 12:935460:+ 20:55578635:+ 
71175 ENSCAFG00000042696-ENSCAFG00000019158 
THYMOSIN 
BETA 4 EEF2 0 7 2 40 20:6016910:- 20:55583511:+ 
60342 ENSCAFG00000005204-ENSCAFG00000019346 CTNNB1 SRRM2 0 4 2 41 23:10572354:+ 6:38306369:+ 
97336 ENSCAFG00000007875-ENSCAFG00000019346 TMSB10 SRRM2 0 6 2 36 17:40048895:- 6:38301717:+ 
101786 ENSCAFG00000012045-ENSCAFG00000019448 PCNT ABHD17A 0 3 2 30 31:39626139:+ 20:57086800:+ 
65026 ENSCAFG00000019648-ENSCAFG00000019448 TMEM259 ABHD17A 0 3 2 24 20:57695359:+ 20:57086800:+ 
71175 ENSCAFG00000013589-ENSCAFG00000025045 IVNS1ABP HNRNPD 0 6 2 27 7:18443461:- 32:6323770:- 
69996 ENSCAFG00000001704-ENSCAFG00000025045 APOL6 HNRNPD 0 8 3 39 10:28535182:- 32:6340742:- 
95512 ENSCAFG00000009389-ENSCAFG00000025145 NISCH ZNF777 0 3 2 29 20:37312413:- 16:14388958:- 
97568 ENSCAFG00000010958-ENSCAFG00000025145 RIN3 ZNF777 0 5 2 30 8:1746136:+ 16:14388958:- 
100993 ENSCAFG00000001181-ENSCAFG00000025145 TRAPPC9 ZNF777 0 4 2 22 13:34686848:- 16:14388958:- 
95591 ENSCAFG00000029183-ENSCAFG00000029191 EIF1B STMN1 0 6 2 36 23:9800563:+ 2:74042893:+ 
96300 ENSCAFG00000001618-ENSCAFG00000029191 CCND3 STMN1 0 6 2 28 12:10599352:- 2:74042952:+ 
100850 ENSCAFG00000005692-ENSCAFG00000031449 RPTOR UBE2I 0 5 2 25 9:1028499:- 6:39447817:- 
100993 ENSCAFG00000019581-ENSCAFG00000031449 UNKL UBE2I 0 24 9 41 6:39394207:+ 6:39447817:- 
98458 ENSCAFG00000029086-ENSCAFG00000032222 ARF4 DLA-12 0 4 2 40 20:32870570:+ 12:935192:+ 
69996 ENSCAFG00000049487-ENSCAFG00000032222 NRM DLA-12 0 6 2 35 12:490872:- 12:983548:+ 







Figure 5.3 Expression of recurrent 3’ fusion partners. 43 recurrent 3’ fusion partners were identified. 
Normalized gene expression levels (DESeq2) were compared between cases in which the fusion was identified 




Table 5.4. Selected recurrent candidate fusion genes  
CN 5' Gene 3' Gene 5’ Fusion_point 3’ Fusion_point Fusion Sequence 
101786 YTHDF3 JUN 29:13240194:+ 5:50967308:- 
CTGCTGTGAGTGCTCGGGGAGAGGCCCAGGCGGCGGCGGCGGCGGCGGCG*G
AGCTTTGCAAAAGTTCGCTCCGGGACCCGGGCCACTCGTCCCCTGTGCT 
67283 VBP1 JUN X:123216276:+ 5:50968371:- 
GATACAGTGCTGAAGAAGCTGGATGAACAGTACCAGAAGTACAAGTTTAT*C
CGCTGCTCAGCGCGCCCGGGTTGAAGTTGCTGAGGTTGGCGTAGACCGG 
65026 ATG4B PTMA 25:51514673:+ 25:43566003:+ 
CAGCAGGATGAGCATCGGGGAGCTCGACCCGTCCATTGCCGTG*GACTTAAA
GGAGAAGAAGGAAGTTGTGGAGGAGGCAGAGAATG 
65026 NCL PTMA 25:43340008:- 25:43566003:+ 
CACTCCGCCGGCATAAGCCGCCATCATGGTGAAGCTCGCAAAG*GACTTAAA
GGAGAAGAAGGAAGTTGTGGAGGAGGCAGAGAATG 
100993 NCL PTMA 25:43340008:- 25:43566003:+ 
CACTCCGCCGGCATAAGCCGCCATCATGGTGAAGCTCGCAAAG*GACTTAAA
GGAGAAGAAGGAAGTTGTGGAGGAGGCAGAGAATG 
97568 HMGB1 PTMA 25:9552010:+ 25:43566003:+ 
TGAGAGCCAGACGGGCACTGGGCGACTCTGTGCCTCGCTGAGG*GACTTAAA
GGAGAAGAAGGAAGTTGTGGAGGAGGCAGAGAATG 
100993 HMGB1 PTMA 25:9556607:+ 25:43566390:+ 
AAGACGAGGAGGATGAAGAGGATGAGGAGGAGGAAGAAGATGAAGAAGAT*
GAAGAAGAGGAGGAGGAGGAAGGTGATGGTGAGTAGCCTTGTTTGTCTCC 
100993 JARID2 PTMA 35:14477306:+ 25:43566003:+ 
GAGCAAGGAAAGACCCAAGAGGAATATCATTCAGAAGAAATAC*GACTTAAA
GGAGAAGAAGGAAGTTGTGGAGGAGGCAGAGAATG 
95512 RGS10 PTMA 28:29688064:- 25:43563253:+ 
ACAAGTCAACGTCGAGGGGCAGTCCCGGCTCAATGAGAAGATACTGGAAG*C
CGCGGACTCCGGCAGCTCCCTCGCCAGAGTCCTCGAACTCTTGCTCTCT 
100993 RFC4 PTMA 34:19374779:- 25:43563189:+ 
AAACCACCACTGAAGGATCGAGGAATAGCTGCCACAGCTGGAAGCAGTGG*G
CATTGTTCCTGTGTCCGGCTCCCCGTTCGCCGCAACCACCTCCGCCGCG 
97074 MCM5 PTMA 10:28722768:- 25:43567242:+ 
GCTTTACCAGCCAGGAGGACCAGGAGCTTCTGAGCCGCATCGAGAAGCAG*G
ACGTCGACACCAAGAAGCAGAAGACTGATGAGGATGACTAGACAGCAAA 
100993 SRSF5 PTMA 8:43514223:+ 25:43566003:+ 
CGTCGCAGACTACGGACCTCTCTGGTCTCAGCTGCCAAAGATCCTGTCCG*GA
CTTAAAGGAGAAGAAGGAAGTTGTGGAGGAGGCAGAGAATGGAAGAGA 
97568 TOX2 LMO4 24:31523443:+ 6:60906444:- 
GCCGGCCGGCCTGGCGCACCTGGACTATTACCACTGCGGCAAG*ACCATGGTG
AATCCGGGCAGCAGCTCACAGCCGCCCCCCGTGA 
65026 SRSF5 LMO4 8:43514227:+ 6:60906444:- 
ACGGACCTCTCTGGTCTCAGCTGCCAAAGATCCTGTCCGGTAG*ACCATGGTG
AATCCGGGCAGCAGCTCACAGCCGCCCCCCGTGA 
71779 PTMA LMO4 25:43563385:+ 6:60906444:- 
GTCAGACGCGGCCGTGGACACCAGCTCCGAGATCACCACCAAG*ACCATGGT
GAATCCGGGCAGCAGCTCACAGCCGCCCCCCGTGA 
69996 NFKB2 TRIM8 28:14910267:+ 28:15136432:+ 
CCCCCTGAGCCACCAGGAGGGCTCTGCCATGGGCACCCCCAGCCTCAG*AAC
ACCAAGTCTGTGAAAATCCTAATGGACAGGTGAGCAGATGACCACTG 
76055 KRI1 TRIM8 20:50613993:+ 28:15135460:+ 
ATCCTCCGTGCGCCGCAAGGATGAGCGCAGGAAGGAGAAGAGAGAGGAGA*
TGCTGGATGAGGACCTGCGGCAGACGGTTGAGGTCCTGGACAAGGCCCAG 
60342 DGKZ MDK 18:43088838:- 9:55100533:+ 
AGCACTACCAGATGATCCAGCGGGAGGACCAAGAGACGGCCGTGTAGCTG*A
TGCAGCTCCGAGGCTTCCTCCTCCTCGCCCTCCCCACCCTGCTGGCGCT 
67308 DGKZ MDK 18:43088833:- 9:55100533:+ 
TACCAGATGATCCAGCGGGAGGACCAAGAGACGGCCGTGTAGCTGTGAGG*A
TGCAGCTCCGAGGCTTCCTCCTCCTCGCCCTCCCCACCCTGCTGGCGCT 
97074 DGKZ MDK 18:43088723:- 9:55100533:+ 
TGCACTGCCACATTCCAGTCGGACTGCCACGGGGGGACCCAGGCCCCAGG*A
TGCAGCTCCGAGGCTTCCTCCTCCTCGCCCTCCCCACCCTGCTGGCGCT 
97336 DGKZ MDK 18:43088838:- 9:55100533:+ 
AGCACTACCAGATGATCCAGCGGGAGGACCAAGAGACGGCCGTGTAGCTG*A
TGCAGCTCCGAGGCTTCCTCCTCCTCGCCCTCCCCACCCTGCTGGCGCT 
100850 DGKZ MDK 18:43088838:- 9:55100533:+ 
AGCACTACCAGATGATCCAGCGGGAGGACCAAGAGACGGCCGTGTAGCTG*A
TGCAGCTCCGAGGCTTCCTCCTCCTCGCCCTCCCCACCCTGCTGGCGCT 
100850 GRB10 IKZF1 18:1970944:- 18:1676646:+ 
CCAGGCTTCCCGGCGCCGGCCGACCGGCTCACAGGCCACCAGG*ATAACCTG
AGGACAATGGATGCTGATGAGGGTCAAGACATGTC 
100850 PCGF3 IKZF1 3:91676726:- 18:1732840:+ 
AACACTTCACAGTCTCAGCGGCCGGAGAGGCGCCTCTCGCAGACTAGATG*G
GGAGCGGCCCTTCCAGTGCAACCAGTGCGGCGCCTCCTTCACGCAGAAG 
95591 SPOCK2 XPO1 4:22752884:- 10:61542482:- 
TGGTTCCAGCTCCTTCATGAGAACGCCAAGCAGAATGGCTCGGCCGGCAG*G
GATATTTGTCGACCAAAATGATGCCAATTTGTAAATTAAAATGTCACCT 
100850 ITM2C XPO1 25:42830052:+ 10:61585054:- 
GGCCCCGGCTCCGGCCGCTGAGATCCTGCTGACGCCGGCTCGG*TAATCTATG
CCAGCAATTATGACAATGTTAGCAGACCATGCAG 
71779 IKZF1 GNAS 18:1683965:+ 24:43643409:+ 
TTCCACCACATCTGGCGGACAGCAGACCTCCAAGAATGAGAGAGGCGTGG*G
TGCCGGAGAATCTGGTAAAAGCACCATTGTGAAGCAGATGAGGATCCTG 
100850 SRSF5 GNAS 8:43514223:+ 24:43643409:+ 
CGTCGCAGACTACGGACCTCTCTGGTCTCAGCTGCCAAAGATCCTGTCCG*GT
GCCGGAGAATCTGGTAAAAGCACCATTGTGAAGCAGATGAGGATCCTG 
100993 SRSF5 GNAS 8:43514223:+ 24:43643409:+ 
CGTCGCAGACTACGGACCTCTCTGGTCTCAGCTGCCAAAGATCCTGTCCG*GT
GCCGGAGAATCTGGTAAAAGCACCATTGTGAAGCAGATGAGGATCCTG 
97568 B2M GNAS 30:11331865:+ 24:43643409:+ 
GGCCTTGCTCCTCATCCTCCTCGCTGCGTGCCGCCTGGATGCCGTGCAGC*GTG
CCGGAGAATCTGGTAAAAGCACCATTGTGAAGCAGATGAGGATCCTG 
97578 PTBP1 GNAS 20:57811498:- 24:43643409:+ 
CTCTGGCGACAGCCAGCCCTCGCTGGACCAGACCATGGCTGCTGCCTTCG*GT
GCCGGAGAATCTGGTAAAAGCACCATTGTGAAGCAGATGAGGATCCTG 
67283 RACK1 GNAS 11:430867:- 24:43643409:+ 
GATCGCCACCACTCCCCAATTCCCAGACATGATACTGTCTGCTTCTCGAG*GT
GCCGGAGAATCTGGTAAAAGCACCATTGTGAAGCAGATGAGGATCCTG 
95512 TFAM MYH9 4:10597916:+ 10:28110256:+ 
GTTATTATAATGAAATGAAATCTTGGGAAGAACAGATGATGGAAGTCGGA*G
GGGACTCCACCGACCTCAATGACCAGATCGCCGAGCTGCAGGCTCAGAT 
71779 NR1D1 MYH9 9:22468461:+ 10:28116611:+ 
GGGAGCCTGGACGTGTGTGGCCTGTTCGGGGAAGGAGAATGGCCCTGTGG*G
ATGGAGGCTGAGCTGGAGGACGAGAAGAAGCAGCGCTCGATGGCTGTGG 
104029 DENND4B MYH9 7:43194960:+ 10:28122813:+ 
TCCTTCCCGCCGCTCCCCCGCCTCTCATGTTCCCCCACCTGAGCTGCCCC*CCA
GTTGCTGTCACAAAGGAGTGAACGGAGCTCCCAGCCCCACCCCTTTT 
95512 BCL11B MYH9 8:67622861:- 10:28122190:+ 
TGTGCAACTACGCGTGCGCGCAGAGCAGCAAGCTCACGCGCCACATGAAG*G
CGCCACTGTCCCCTCCTGTTTCTAAAGTGTCTCAAGTGCAATGACGACC 
60342 B2M LSP1 30:11331865:+ 18:46126859:+ 
CTCCTCATCCTCCTCGCTGCGTGCCGCCTGGATGCCGTGCAGC*CTCTCCTGAG
ACTACAGGTGCCTCTGGCAGCAGCGTCCACGTC 
69996 PPY LSP1 9:19395171:+ 18:46087948:+ 
ACCAGAGCAGATGGCCCAGTACGCGGCTGAGCTCCGCAGATACATCAACA*C
GACGCCAGCCCAATGGCCGAGGCTCCGAGCCACCCCAGCTCCGAGGAGC 
100850 MROH1 GATD3A 13:37690507:+ 31:38035219:+ 
CGGTGGTCACCAGCCTCCTGGGAAGCCCCCTGCCCTTTGACAG*CTTGTGCTG
CATCGCGTCTGTCCTCGCAGCCAAAGTGCTCCAT 




100850 TPD52L2 GATD3A 24:47363544:+ 31:38035219:+ 
CCACCGTGGGCTCCGCCATTAGCAGGAAGCTCGGGGATATGAG*CTTGTGCTG
CATCGCGTCTGTCCTCGCAGCCAAAGTGCTCCAT 




Structural Analysis of Fusion Genes 
 The structural features of the selected fusion candidates from Table 5.3 were evaluated 
using Geneious Prime 2020.0.5 software. For each fusion partner, the fusion junction sequence 
was mapped to the reference genome (CanFam3.1). The chromosomal alignment and junction 
point were identified and junction sequences for both gene sequences were concatenated to 
create the complete fusion junction sequence.  
DGKZ-MDK, was identified in 5 of the 26 evaluated cases (19%). The predicted fusion 
sequence is illustrated in Figure 5.4. MDK is an oncogene that is highly expressed by a number 
of tumors.268,269 DGKZ is located on the reverse strand of chromosome 18 and MDK is located 
on the forward strand of chromosome 9.  Therefore, the formation of a functional fusion 
transcript would require an inversion event. Among the 5 cases, there were 3 different 
breakpoints for the DGKZ gene and a single, recurrent breakpoint for the MDK gene. The 
breakpoint involving MDK is at the beginning of the coding sequence of this protein. This gene 
has 1 exon and 1 splice variant and therefore, transcription of the entire coding sequence (CDS) 
of this gene is likely occur.  
Of the five total cases, three cases have a DGKZ breakpoint on chromosome 18 at 
43088838. The other two breakpoints are within the same region of the gene (18:43088833 and 
18:43088723). The fusion junction in all cases of DGKZ involves the 3’ UTR with or without 
the end of the CDS of this gene. Two of the five samples (60342 and 100850) have greater than 
or equal to 5 spanning unique reads, supportive of a higher likelihood of being a true positive. 
Because the fusion transcripts involve the entire DGKZ CDS and a portion of the 3’ UTR, the 
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DGKZ stop codon (TAG) is present within the fusion sequence. This finding has the potential to 
complicate effective translation of the fusion protein. 
 
PTMA (prothymosin-alpha) was identified as a 3’ fusion partner in 10 fusion candidates 
from 5 patients. PTMA is present in both lymphoid and non-lymphoid organs and has dual roles 
controlling the cell cycle and modulating immune responses.270 Eight different genes (ATG4B, 
HMGB1, JARID2, MCM5, NCL, SRSF5, RFC4, RGS10) were identified as fusion partners. The 
predicted fusion sequences are illustrated in Figure 5.5.  
 The predicted fusions involving ATG4B-PTMA, NCL-PTMA, JARID2-PTMA, and 
MCM5-PTMA are comprised of the 5’UTR and 5’ CDS of the first fusion partner joining with 
the truncated CDS and 3’ UTR of PTMA. This type of fusion construct could result in the 
regulatory elements of the 5’ gene driving expression of the 3’ gene. Alternatively, a chimeric 
protein could be formed. Because the PTMA CDS is truncated, evaluation of the open reading 
Figure 5.4. Structure of the DGKZ-MDK fusion gene. The gene structures of DGKZ and MDK are shown 
with the gene sequences in green, mRNA in red, and coding sequence in yellow. The alignment of the mRNA 
sequence identified by RNA-seq is shown in blue and the fusion junction points are shown on the top of the 
aligned sequences. DGKZ is on the reverse strand of chromosome 18 and MDK is on the forward strand of 
chromosome 9. An inversion of DGKZ is therefore necessary for the fusion gene to form. The predicted fusion 
junction sequence is shown for the three different junction points of the 5’ DGKZ fusion partner.  
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frame and alterations of the protein structure and function would need to be evaluated. The 
number of spanning unique reads of the NCL-PTMA fusion is greater than 5, supporting a higher 
likelihood of being a true positive. Additionally, 1 of the 5 individuals (97568) with the 
candidate fusion gene involving a 3’ PTMA partner exhibited concurrent upregulation of PTMA 
compared to other cases and control T-cells (Figure 5.3).  The 5’ fusion partner in this case was 
MCM5. 
The SRSF5-PTMA fusion involves only the 5’ UTR joining with the truncated PTMA 
CDS. This construct could also functionally enable PTMA expression to be driven by the SRSF5 
5’ regulatory units. The RGS10-PTMA and RFC4-PTMA fusion candidates involve the 5’ ends 
of RGS10 or RFC4 fusing to the 5’ UTR of PTMA. In these cases, the complete PTMA CDS has 
potential to be translated and form a complete PTMA protein, if the open-reading frame remains 
in-tact.  
One of the fusion transcripts involving HMGB1-PTMA (5’ fusion breakpoint 
25:9556607) involves the 5’ end of HMGB1 CDS fusing to the shortened PTMA CDS. The other 
HMGB1-PTMA fusion transcript (5’ fusion breakpoint 25:9552010) involves the fusion of the 
HMGB1 3’ UTR to the truncated PTMA CDS. This fusion would likely involve a fully 
transcribed HMGB1 gene with an intact stop codon. It is therefore, uncertain, if translation 













JUN, a well-established oncogenic transcription factor, and key regulator of cell cycle 
progression, was identified as a 3’ fusion partner in two cases. JUN was partnered with YTHDF3 
and VBP1, respectively (Figure 5.6). The fusion junction sequence identified by RNA-seq 
involves the reverse complement sequence, suggesting that an inversion event and complex 
chromosomal rearrangement likely took place. Alternatively, this finding could be an artifact of 
an unstranded library preparation. In the YTHDF3-JUN fusion, it is predicted that the 5’ UTR of 
YTHDF3 combines with the 5’UTR of JUN. In the VBP1-JUN fusion, it is predicted that the 5’ 
CDS and UTR of VBP1 would fuse with the truncated CDS of JUN.  In these fusions, JUN could 




Figure 5.5. Structure of the fusion genes involving PTMA as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes ATG4B-PTMA (A), NCL-
PTMA (B), HMGB1-PTMA (C), JARID2-PTMA (D), RGS10-PTMA (E), RFC4-PTMA (F), SRSF5-PTMA 
(G), MCM5-PTMA (H).  The gene structures of are shown with the gene sequences in green, mRNA in red, and 
coding sequence in yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in blue and 





LMO4 was identified as a recurrent 3’ fusion partner with 3 different 5’ genes (TOX2, 
SRSF5, and PTMA) in three different dogs. LMO4 is a member of the LIM domain-only genes 
and has been shown to be an oncogene in a number of malignancies, including breast cancer.271 
The structures of the proposed fusion genes are shown in Figure 5.7.  LMO4 is located on the 
reverse strand of chromosome 6 and the 5’ fusion partners are on the forward strands of 
Figure 5.6. Structure of the fusion genes involving JUN as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes YTHDF3-JUN(A), VBP1-JUN 
(B). The gene structures of are shown with the gene sequences in green, mRNA in red, and coding sequence in 
yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in blue and the fusion junction 
points are shown on the top of the aligned sequences. The fusion junction sequence is shown below.   
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chromosome 24, 8, and 25, respectively. An inversion event of the LMO4 gene is therefore 
required to form these predicted fusion genes. The fusion gene constructs would involve the 5’ 
UTR (SRSF5) and 5’ UTR and 5’ CDS (PTMA and TOX2) to juxtapose the beginning of the 
Figure 5.7. Structure of the fusion genes involving LMO4 as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes TOX2-LMO4(A), SRSF5-
LMO4 (B), and PTMA-LMO4 (C). The gene structures of are shown with the gene sequences in green, mRNA 
in red, and coding sequence in yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in 
blue and the fusion junction points are shown on the top of the aligned sequences. The fusion junction sequence 
is shown below.   
 134 
LMO4 CDS. These events have the potential for complete transcription and translation of 
LMO4, driven by the 5’ fusion partners regulatory elements, or the formation of a chimeric 
protein.  
TRIM8 was identified as the 3’ fusion partner in two different dogs (Figure 5.8). TRIM8 
was paired with either NFKB2 or KRI1 as 5’ gene partners. TRIM8 has been shown to work as 
an oncogene through positive regulation of the NF-#B pathway or as a tumor suppressor by 
regulating p53 activity.272 TRIM8 and NFKB2 are both located on the forward strand of 
chromosome 28 and KRI1 is located on the forward strand of chromosome 20. The 5’ UTR and 
5’ CDS of NFKB2 or KRI1 would be juxtaposed to the truncated CDS and 3’ UTR of TRIM8, 
allowing TRIM8 expression to be under the control of the 5’ gene partner. It is also possible that 
the 3’ UTR of TRIM8 allows for enhanced mRNA stability or altered translational regulation of 
the 5’ gene partner. One case (69996) exhibited increased expression of TRIM8 compared to 
other cases and control lymphocytes. The NFKB2-TRIM8 candidate fusion gene was identified 
in this individual. Additionally, the number of spanning unique reads in the NFKB2-TRIM8 








 IKZF1 was identified as a 3’ fusion partner with two separate 5’ partners (GRB10 and 
PCGF3) (Figure 5.9). Both of these candidate fusion genes were identified in the same individual 
patient (100850), suggesting multiple chromosomal alterations may have taken place at this site. 
An inversion event of the 5’ fusion partner is required for either of these fusion events to occur. 
The fusion transcripts predict that the 5’ UTR and 5’ CDS of GRB10 would juxtapose the CDS 
of IKZF1. The 3’ UTR of PCGF3 would juxtapose the CDS of IZKF1. A truncated IKZF1 CDS 
would result from the fusion event. Evaluation of the open reading frame would aid in 
determining if this fusion event would result in a potentially functional protein. IKZF1encodes 
the lymphoid transcription factor IKAROS, and genetic alterations involving this gene have been 
described in acute lymphoblastic leukemia in humans.273 
 
Figure 5.8. Structure of the fusion genes involving TRIM8 as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes NFKB2-TRIM8 (A), and KRI1-
TRIM8 (B). The gene structures of are shown with the gene sequences in green, mRNA in red, and coding 
sequence in yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in blue and the 
fusion junction points are shown on the top of the aligned sequences. The fusion junction sequence is shown 





 Two fusion candidates involving the 3’ partner of XPO1 were identified in two different 
dogs (Figure 5.10). XPO1 encodes a critical nuclear export protein, exportin-1, and plays a role 
in oncogenesis of several types of cancer, including B-cell malignancies.274–276 SPOCK2 and 
XPO1 are located on the reverse strands of chromosome 4 and 10, respectively. Inversions of 
both genes would be necessary to form the fusion junction sequence identified by RNA-seq. The 
fusion construct would involve the 5’ CDS of SPOCK2 juxtaposed to the 3’ UTR of XPO1. This 
fusion, therefore, does not contain the XPO1 CDS. Alternatively, regulatory elements within the 
3’ UTR of XPO1, including miRNA binding sites, may have an effect on expression of 
Figure 5.9. Structure of the fusion genes involving IKZF1 as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes GRB10-IKZF1 (A), and 
PCGF3-IKZF1 (B). The gene structures of are shown with the gene sequences in green, mRNA in red, and 
coding sequence in yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in blue and 
the fusion junction points are shown on the top of the aligned sequences. The fusion junction sequence is shown 
below.   
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SPOCK2. The ITM2C-XPO1 fusion event would result in the 5’ UTR and beginning of the 5’ 
CDS of ITM2C juxtaposed to the 5’ UTR and CDS of XPO1. In this case, complete translation 
of the XPO1 CDS could take place and XPO1 expression could be altered by the regulatory 




 Fusion genes involving GNAS as the 3’ partner were identified in 6 different dogs 
(Figure 5.11). The SRSF5-GNAS fusion gene was identified to two different patients, with 
consistent fusion junction sequences and fusion points. GNAS encodes the G protein G$s and 
has been shown to have oncogenic or tumor suppressor functions, depending on the 
microenvironmental context.277–279 The fusion candidate involving a B2M-GNAS fusion had 
Figure 5.10. Structure of the fusion genes involving XPO1 as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes SPOCK2-XPO1 (A), and 
ITM2C-XPO1 (B). The gene structures of are shown with the gene sequences in green, mRNA in red, and 
coding sequence in yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in blue and 
the fusion junction points are shown on the top of the aligned sequences. The fusion junction sequence is shown 
below.   
 138 
greater than 5 spanning unique reads, supporting a possible true fusion event. All predicted 
fusion events would involve the 5’ UTR or 5’ UTR and CDS of the 5’ gene partner juxtaposed to 
the beginning of the GNAS CDS. This model would predict that expression of GNAS could be 











 MYH9 was a 3’ fusion partner in 4 different fusion gene candidates in 4 different dogs 
(Figure 5.12).  MYH9 has been shown to play a role in cancer through modulating cytoskeletal 
reorganization and cellular migration.280,281 High expression levels of MYH9 have been 
identified in a number of human malignancies.282 The TFAM-MYH9 and NR1D1-MYH9 fusion 
events are predicted to result in the 5’ UTR and CDS of the 5’ fusion partner placed adjacent to a 
truncated MYH9 CDS. The DENND4B-MYH9 and BCL11B-MYH9 fusion candidates, on the 
other hand, involved the 5’ UTR and CDS of the 5’ fusion partner placed adjacent to the 3’ UTR 
of MYH9. It is possible that regulatory elements within the 3’ UTR of MYH9 may exert their 
effects on the upstream fusion partner, but transcription and translation of the MYH9 CDS is not 
expected in these cases.  
 
E 
Figure 5.11. Structure of the fusion genes involving GNAS as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes IKZF1-GNAS (A), SRSF5-
GNAS (B), B2M-GNAS (C), RACK1-GNAS (D), PTBP1-GNAS (E). The gene structures of are shown with the 
gene sequences in green, mRNA in red, and coding sequence in yellow. The alignment of the mRNA sequence 
identified by RNA-seq is shown in blue and the fusion junction points are shown on the top of the aligned 








 LSP1 was identified as the 3’ fusion partner in 2 different patients. The 5’ fusion partners 
were B2M and PPY (Figure 5.13). LSP1 encodes lymphocyte specific protein 1and LSP1 
Figure 5.12. Structure of the fusion genes involving MYH9 as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes TFAM-MYH9 (A), NR1D1-
MYH9 (B), DENND4B-MYH9 (C), and BCL11B-MYH9 (D). The gene structures of are shown with the gene 
sequences in green, mRNA in red, and coding sequence in yellow. The alignment of the mRNA sequence 
identified by RNA-seq is shown in blue and the fusion junction points are shown on the top of the aligned 
sequences. The fusion junction sequence is shown below.   
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downregulation, mutation, or deletion has been shown to play a role in multiple cancer types, 
including lymphomas, breast cancer, and hepatocellular carcinoma.283–285 The B2M-LSP1 fusion 
involves juxtaposition of the 5’ UTR and beginning of the B2M CDS to the 3’ UTR of LSP1. 
Therefore, a functional LSP1 protein is unlikely to result from this fusion event. It is also 
possible for the 3’ UTR regulatory elements to alter expression of B2M. Regardless of these 
structural features, LSP1 expression was markedly increased in the case (60342) with the B2M-
LSP1 fusion gene identified compared to other cases and control T-cells. The PPY-LSP1 fusion 
results in juxtaposition of the 5’ UTR and CDS of PPY and the 5’ UTR and complete CDS of 




 GATD3A (C31H21orf33) was the 3’ fusion partner in 4 fusion gene candidates from 3 
different dogs (Figure 5.14). Two fusion genes, MRPH1-GATD3A and TPD52L2-GATD3A, 
were identified in a single dog (100850). This patient (100850) and one other individual (97578) 
Figure 5.13. Structure of the fusion genes involving LSP1 as a 3’ fusion partner. The gene structures and 
predicted fusion junction sequence is illustrated from the following fusion genes B2M-LSP1 (A), and PPY-LSP1 
(B). The gene structures of are shown with the gene sequences in green, mRNA in red, and coding sequence in 
yellow. The alignment of the mRNA sequence identified by RNA-seq is shown in blue and the fusion junction 
points are shown on the top of the aligned sequences. The fusion junction sequence is shown below.   
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with a JPT1-GATD3A exhibited higher expression levels of GATD3A compared to other cases 
or control T-cells (Figure 5.3). The role of this gene as a potential genetic driver of cancer is not 
well explored. In all cases, the fusion breakpoint of GATD3A is conserved and results in 
truncation of the GATD3A CDS. This 3’ fusion partner is juxtaposed to the 5’ UTR and CDS of 












A recurrent fusion gene present in the majority of PTCL cases was not identified using 
our RNA-seq derived fusion gene discovery pipeline. This finding is not unique to canine PTCL. 
The prevalence of known fusion genes in different human malignancies varies greatly, with the 
majority of recurrent fusion genes occurring at low frequencies.240,286 
 We identified 43 genes that were recurrently identified as 3’ fusion partners from 26 
cases of canine PTCL. This list was subsequently narrowed to 11 target genes that have been 
previously described as cancer-associated and/or genes in which at least one of the patients with 
the fusion candidate exhibited aberrant expression of the 3’ fusion partner.  This list of fusion 
candidates warrants validation studies to confirm the presence of the fusion gene in the patient 
samples used for RNA-seq using PCR. Further screening of a larger cohort of new patients may 
also provide greater insights into the prevalence of identified fusion candidates within the 
population of canine patients with PTCL.  
Figure 5.14. Structure of the fusion genes involving GATD3A(C31H21orf33) as a 3’ fusion partner. The 
gene structures and predicted fusion junction sequence is illustrated from the following fusion genes MROH1-
GATD3A (A), JPT1-GATD3A (B), TPD52L2-GATD3A (C), and PTBP1-GATD3A (D).The gene structures of 
are shown with the gene sequences in green, mRNA in red, and coding sequence in yellow. The alignment of the 
mRNA sequence identified by RNA-seq is shown in blue and the fusion junction points are shown on the top of 
the aligned sequences. The fusion junction sequence is shown below.   
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The DGKZ-MDK fusion gene is of particular interest since it was among the most 
frequently encountered fusion candidates, identified in 19% of cases. This fusion gene was one 
of the few in which both the 5’ and 3’ partners occurred repetitively in different patients. 
Additionally, within 2 of the 5 evaluated cases the spanning unique read count was greater than 
5, further supporting the possibility that this is a true fusion event. Diacylglycerol kinase zeta 
(DGKZ) functions at the TCR complex following TCR/CD28 engagement and works as a 
negative regulator of DAG-mediated signals.287 Midkine (MDK) is heparin-binding growth 
factor that can act as an oncogene and promotes multiple hallmarks of cancer including cell 
growth, survival, metastasis, migration, and angiogenesis.269 
 The fusion breakpoint of the MDK partner occurred at the same location in all cases and 
was located at the start of the CDS, beginning with the start codon ATG. The MDK gene is 
simple with 1 exon and 1 splice variant. Therefore, the entire coding sequence of this protein 
would be expected to be translated. The 5’ UTR of MDK is lost, and consequently this gene is 
likely to regulated by of the 5’ UTR of DGKZ. Because DGKZ can be expressed downstream of 
the TCR, regulation under the DGKZ could result in subsequent upregulation of MDK in the 
neoplastic T-cells.  
Three different junction points were identified in the DGKZ gene, with 3 cases sharing 
the same junction point. The fusion breakpoint involves the 3’ end of the CDS and 3’ UTR in 
two of the junction breakpoints. One junction breakpoint involves only the 3’ UTR. Successful 
translation of this fusion transcript is challenged by the presence of a stop codon within the 
upstream DGKZ gene. Translation of this fusion protein would be dependent on uninterrupted 
translation of both proteins, despite the presence of the DGKZ stop codon or re-initiation of 
translation using the start codon for MDK. Interestingly, despite the presence of the stop codon 
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in this fusion transcript, non-sense mediated decay did not take place to remove the mRNA 
transcripts from the sequencing evaluation. It is possible the disruption of the DGKZ 3’ UTR 
alters RNA stability or normal regulation of translation.  In vitro validation of the presence of 
this fusion transcript and fusion protein is warranted to better understand if this transcript is a 
true potential driving fusion gene or a false positive result.  
 Another candidate of interest involves recurrent fusions to LMO4. Genes within the 
LMO family, particularly LMO1, LMO2, and LMO3,  have been shown to frequently participate 
in chromosomal translocations that drive T-acute lymphoblastic lymphoma (T-ALL).288 The role 
of LMO4 in T-cell development and function, however, is less well understood. LMO4 is widely 
expressed in mouse tissues, including T-cells within the embryonic and adult thymus.289 LMO4 
has been shown to drive cellular proliferation in other tumor types, including breast cancer, by 
working as a downstream target of ErbB2 and PI3K.271,290 In this study, three fusion gene 
candidates involving LMO4 were identified in three different dogs. The 5’ fusion partners in 
these cases were TOX2, SRSF5, and PTMA. The LMO4 fusion breakpoint was conserved in all 
cases and was located 3 nucleotides before the start codon of the LMO4 CDS. Therefore, the 
entire LMO4 CDS is predicted to be translated, increasing the likelihood of the formation of a 
functional LMO4 protein. The fusion breakpoint of TOX2 and PTMA involve the 5’ UTR and 
the beginning of the 5’ CDS. The fusion breakpoint of SRSF5 involves only the 5’ UTR. These 
fusion constructs are predicted to result in expression of LMO4 being driven by the 5’ UTR of 
the fusion partner.  
The 5’ fusion partner genes are expressed by T-cells and/or neoplastic cells. TOX2 is a 
transcription factor belonging to the thymocyte selection-associated high mobility group box 
protein family (TOX).291 TOX2 plays multiple roles in T-cell development and differentiation, 
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including transition from the double-positive to single-positive stage of thymic development.292–
295 TOX2 is also highly expressed in Tfh cells and is a key regulator of Tfh development.292,294 
PTMA encodes the protein thymosin $1. Thymosin $1 is a thymic peptide that primarily works 
to augment T-cell function.296 SRSF5 is a member of the serine/arginine-rich protein (SR) family 
and works to regulate pre-mRNA alternative splicing. SRSF5 has been shown to play a role in 
oncogenesis, and is upregulated by neoplastic cells in a number of cancers.297,298 Other members 
of SR family, including SRSF1, also play a role in regulating expression of the T-cell receptor-
associated CD3 signaling.299 Validation of the LMO4 fusion genes in patient samples using PCR 
is warranted to better understand if the identified fusion transcripts may be potential oncogenic 
drivers of canine PTCL.   
RNA-seq is considered the preferred methodology for oncologic fusion gene 
identification for several reasons including: 1) RNA-seq only sequences regions of the genome 
that are transcribed and spliced into mature mRNA, therefore rearrangements resulting in non-
sense mediated decay would not be included 2) RNA-seq is practical with relatively low cost, 
fast turnaround time, and computational efficiency and 3) RNA-seq fusion discovery identifies 
candidates based on the presence of a potential fusion transcript and allows for detection of 
multiple alternative splice variants resulting from a fusion event.  
Despite these advantages, there are several drawbacks to RNA-seq based fusion 
discovery. A major challenge of identifying fusion genes using RNA-seq derived fusion 
discovery are the high rates of false positivity. Differentiation between fusions of interest from 
artifacts is extremely challenging due to the high prevalence of gene readthrough events and 
other false-positive candidates.263. Therefore, stringent filtering techniques must be applied in an 
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attempt to identify the most biologically relevant fusion transcripts. In applying this technique, 
however, it is possible to filter-out potentially relevant candidates.  
Additionally, the tissue-specificity, dynamic range of expression, and variable 
transcription of genes in different tissues and cellular stages within the canine transcriptome 
complicates evaluation of fusion transcripts. RNA-seq is dependent upon alignment to the 
reference genome as well as reference transcriptome for gene annotation. Fusion gene discovery 
in the dog is exceptionally challenging due to poor annotation accuracy and incompleteness of 
the canine genome. In particular, the genes encoding the T-cell receptor (TCR) are not well 
annotated and incompletely identified in the dog. It is possible that fusion gene transcripts that 
involve TCR genes are not identified by our fusion gene discovery pipeline, which relies on the 
CanFam3.1 genome.  
The fusion discovery was performed on an unstranded library in this study. An 
unstranded library does not maintain the coding DNA strand (sense and antisense) for the 
transcript that is sequenced. An unstranded library may produce artifacts if there are small 
overlapping regions of isoforms of two genes located on opposite strands.   
In our study we identified several samples in which multiple fusions were detected with 
the same 3’ partner paired to different 5’ partners. Formation of fusion genes involving multiple 
fusion partners is possible in the event of massive chromosomal disruptions such as 
chromothripsis. Chromothripsis describes a process in which there are tens to thousands of 
clustered chromosomal rearrangements confined to a localized genomic region.300  
Additional studies using combined whole genome sequencing (WGS) and RNA-seq with 
paired somatic and germline tissues from a large number of canine PTCL cases may be helpful to 
better understand the chromosomal alterations that are driving this disease. In addition to 
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confirming the presence of RNA-seq identified fusion events, WGS may provide an opportunity 
to identify chromosomal translocations involving untranscribed regions and those that result in 
loss of tumor suppressor genes. Additionally, WGS would be helpful to characterize 
chromosomal deletions or amplification events that may be occurring in these tumors. 
 In this study we performed fusion gene discovery and identified a candidate list for 
further validation in canine PTCL. From an initial list of 591 fusion candidates, we selected 11 
recurrent fusions of interest for structural evaluation. This list was selected based on aberrant 
expression of the 3’ fusion partner and/or cancer-related 3’ gene partners. We specifically 
identified fusions involving DGKZ-MDK and LMO4 as potential oncogenic drivers. This work 
seeks to begin to understand that roles of chromosomal alterations and fusion genes as drivers of 





























 The overarching goals of this dissertation were to better understand the pathobiology 
underlying peripheral T-cell lymphomas in dogs, and to determine if the dog could serve as a 
naturally occurring translational model for this aggressive disease in people. Through this work 
we aimed to better establish a canine disease model to foster the concept of ‘One Health’ and 
promote the shared goals of veterinarians, medical physicians, and researchers to understand and 
treat diseases in a comparative and translational capacity. We were able to build a strong 
foundation to inform future studies focused on the molecular drivers of canine and human PTCL.  
Characterization of CD4+, CD8+, and CD4-CD8- subtypes of canine PTCL 
We began our investigation into canine PTCL by characterizing the histologic and 
clinical features of the CD4+, CD8+, and CD4-CD8- TCLs. Previous work focused on these tumor 
subtypes in dogs is scarce in the literature. Perhaps most importantly, we established that these 
neoplasms, regardless of immunophenotype appear to behave aggressively. This prognostic 
information can be used by veterinarians to treat and manage these patients. Prospective clinical 
studies in which patient treatment is standardized would be greatly beneficial in further 
evaluating potential differences in biologic behaviors within these tumor subgroups.  
By looking at the presenting clinical signs and expression of cell surface markers by flow 
cytometry, we show that CD4-CD8- TCLs share clinical and diagnostic features with the more 
common CD4+ TCLs, suggesting a common pathogenesis. CD8+ TCLs, on the other hand exhibit 
unique clinical features and prognostic indicators suggesting that these tumors may be have a 
different pathobiology.  This conclusion is further strengthened by hierarchical clustering of 
tumor samples based on RNA-seq derived gene expression profiles. CD8+ tumors clustered 
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separately from the CD4+ tumors whereas, CD4-CD8- tumors were split between the CD8+ and 
CD4+ groups. Histologic and cytologic morphologies of the CD8+ and CD4-CD8- tumor types 
were more variable than the CD4+ subtype, and therefore it is possible that different subgroups 
with unique pathogeneses may exist within these less common immunophenotypic subgroups. 
Using gene expression profiling and cell surface marker expression by flow cytometry we 
then attempted to better understand the cell of origin of these subtypes. We concluded that CD4+ 
PTCL appears to be derived from a naïve single positive T-cell and CD4-CD8- PTCL appears to 
be derived from a slightly more immature naïve double negative T-cell. A subset of these cases 
expressed markers of immaturity, suggesting that at least a portion of PTCL may originate from 
a more immature thymic precursor, consistent with lymphoblastic lymphoma. Additional studies, 
looking at protein expression of markers of immaturity, including TdT, in a large group of these 
tumors would be useful next steps. Because optimizing antibodies for protein expression in dogs 
can be challenging, evaluating mRNA levels of CD34 and TdT and correlating to any differences 
in histomorphology, clinical presentation, or outcome in those patients with higher expression 
levels may also provide further insights.  
CD8+ TCLs upregulated molecules associated with activated cytotoxic T-cells, 
suggesting that at least a subset of CD8+ TCLs may originate from a mature CD8+ effector cell. 
Additional gene expression profiling studies, including larger numbers of dogs with CD8+ and 
CD4-CD8-  tumors may provide further information about possible molecular subtypes within 
these groups.  
Interestingly, one CD4+ PTCL case exhibited increased gene expression of CD30 and this 
case clustered separately from the rest of the PTCL samples. This finding suggests that this 
individual tumor may represent an uncommon CD30+ subgroup of PTCL, or perhaps may 
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represent an anaplastic large cell lymphoma, which in humans are characteristically CD30+. 
Evaluation of CD30 expression in a large cohort of new patients may be helpful in better 
determining the significance of this finding.  
Molecular drivers of canine PTCL and development of a translational model 
 We were able to show molecular similarities between canine CD4+ PTCL and the human 
PTCL-GATA3 subtype. This finding lays the groundwork to use the dog as a naturally occurring 
model. The dog may be particularly useful in this capacity because studies in PTCL in people are 
limited by the scarcity of patients for enrollment in large clinical trials and difficulty in acquiring 
adequate patient material for molecular studies.  We show that like PTCL-GATA3, this 
neoplasm in dogs is driven in part by PI3K-AKT-MTOR signaling. Both human and canine 
PTCL exhibit frequent loss of the tumor suppressor gene PTEN, which likely contributes to the 
key oncogenic role of this pathway. PI3K inhibitors have already been used in human PTCL, 
with promising results. Implementation of clinical studies looking at the effects of various PI3K 
inhibitors in dogs diagnosed with CD4+ PTCL may provide further insights into therapeutic 
benefits of this targeted treatment.  
 To further understand the molecular drivers of this neoplasm, we sought to identify 
potential fusion genes using an RNA-seq discovery platform. Because many hematopoietic 
tumors are driven by chromosomal translocations and subsequent fusion genes, we hypothesized 
that a recurrent fusion gene would be discovered in the majority of cases. Fusion genes and 
driving chromosomal translocations are well described in human tumors and cytogenetic analysis 
of tumors is a routine diagnostic modality. Chromosomal translocation and fusion genes in 
canine cancers, however, are poorly described with only few individual cases referenced in the 
literature. We did not identify a recurrent fusion gene present in the majority of cases. 
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Nevertheless, we did identify a number of candidate fusion genes present in a minority of the 
PTCL samples. Of particular interest were DGKZ-MDK fusions and fusions involving LMO4 
with multiple partners. Next steps include validation of the presence of these fusion transcripts in 
the samples used for RNA-seq by conventional PCR and subsequent screening of a larger, 
independent patient cohort for the presence of the fusion genes of interest. Developing methods 
to identify canine fusion genes is a valuable endeavor and can lead to enhanced classification and 
diagnostic accuracy of canine tumors, development of targeted treatment options, and 
identification of novel fusions present in human tumors.  
 Future studies involving paired whole-genome sequencing and RNA-seq on a large group 
of tumors would facilitate better understanding of the molecular drivers of canine PTCL. Having 
both genomic and transcriptomic data would allow for detailed evaluation of the mutational 
profile and chromosomal aberrations which could be directly correlated to the mRNA transcript 
levels. Additionally, because PTCL in dogs exhibits strong breed predilections with Boxer dogs 
being overrepresented in the patient population, genome-wide association studies may provide 
useful insights into predisposing genetic factors that are novel to both dogs and humans.  
 In this dissertation we begin to understand the molecular and genetic drivers of PTCL and 
correlate these findings to the human counterpart. We contribute to the development of a 
naturally occurring canine cancer model, with the hopes of promoting collaborations between 
veterinarians, biomedical researchers, and physicians to enhance our understanding of cancer 
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